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Introduction: Childhood acute lymphoblastic leukaemia (ALL) is a disease that originates 
before birth and results from the proliferation of neoplastic lymphoid precursor cells in the 
bone marrow. In the majority of cases of B-ALL, “pre-leukaemic” cells, harbouring B-
ALL genetic mutations, can be retrospectively detected at birth, suggesting the prenatal 
origin of the disease. Previously, dense biallelic DNA methylation of the TES promoter 
was described in over 90% of B-ALL and 70% of T-ALL cases. By exploring publicly 
available datasets, hundreds of genes were found to be differentially methylated in ALL. 
The large number and consistency of the epigenetically modified genes raises the 
possibility that methylation-induced gene silencing in B-ALL may not be an acquired 
cancer-related phenomenon. I propose that B-ALL arises from normal “ALL-like” fetal 
cell lineage, comparable to murine fetal B-1 lymphocytes. 
Hypothesis: that there is a distinct population of normal fetal lymphocytes that have an 
epigenetic profile similar to that reported in ALL and that this population contains the fetal 
cell of origin for ALL. To test this hypothesis, this project has three aims: 1) identify a 
panel of methylation biomarkers by exploring publicly available datasets; 2) evaluate the 
panel of biomarkers by deep targeted methylation sequencing using leukaemia and normal 
DNA samples; and 3) use the panel of biomarkers to identify the ALL-like fetal cells in 
healthy newborns. 
Methods: The ABC.RAP package was developed to identify a panel of methylation 
biomarkers for ALL from publicly available 450k DNA methylation array datasets. The 
identified biomarker panel was validated by deep targeted methylation sequencing (MiSeq; 
Illumina) using blood samples from healthy adults, newborns, B-ALL and T-ALL 
xenograft samples and cell lines. Cord blood samples were either enriched into CD19+ B 
cells using MicroBeads or sorted into CD34+ progenitor cells, CD19+ B cells, CD3+ T 
cells and CD3-CD19- lymphocytes using fluorescence-activated cell sorting. 
Results: Analysis of nine leukaemia datasets revealed 36 genes that were consistently 
methylated across T- and B-ALL datasets. A panel of 11 genes was selected for validation 
by targeted sequencing and results showed dense DNA methylation in leukaemia cases 
compared to low level methylation in adult blood samples. The methylation biomarker 
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panel was used to identify the ALL-like fetal cells in enriched cell population from 34 cord 
blood samples. Remarkably, the ALL-like methylation profile was detected in 39% of the 
study population. The number of methylated epialleles was low in the sequenced samples 
(methylation level ranged between 0.1% to 13%). Methylated TES sequences were 
detected in CD19+ B cells of a preterm neonate (4-week-old, 28 week-gestation). In 
addition, methylated NEFM sequences were found at low levels in CD34+ progenitor cells 
and CD19+ B cells from healthy newborns (median methylation of 1.6% (n=4) and 1.4% 
(n=6), respectively). Furthermore, methylated TES and NEFM epialleles were detected at 
low level in CD3+ T cells and CD3-CD19- lymphocytes from newborns. Methylated 
KITLG and PAK7 sequences were also detected in neonatal CD19- mononuclear cells and 
CD3-CD19- lymphocytes, respectively. 
Conclusion: An ALL-like epigenotype is detectable in normal neonatal blood, suggesting 
the presence of a distinct fetal blood lineage from which ALL can arise. The identification 
of these cells will contribute hugely to our understanding of the development and 
pathogenesis of ALL.  
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Definition of Terms 
 
ALL-methylated genes List of differentially methylated genes in childhood acute 
lymphoblastic leukaemia that were identified from ABC.RAP 
analysis of publicly available 450k array methylation datasets. 
These genes contained at least two differentially methylated 
CpG sites in leukaemia cases compared to normal controls 
(Student’s t-test P-value < 1 x 10-7 and difference of DNA 
methylation ³ 50%). The methylation patterns of the 
identified genes/CpG sites were consistent across at least three 
cohorts. 
 
ALL-methylated gene panel List of 11 ALL-methylated genes that have been selected for 
experimental validation using targeted methylation 
sequencing (MiSeq; Illumina). These genes contained 
differentially methylated CpG sites at promoter regions and 
the methylation of control samples was < 10% while the 
methylation of ALL cases was > 50%. 
 
Methylated sequence reads These are sequence reads with DNA methylation > 50% (i.e., 
more than 50% of the CpG sites were methylated) across the 
sequenced amplicon. Methylated epialleles refers to the 
sequence reads with unique methylation patterns.  
 
ALL-like cells Neonatal cells which contain methylated sequence reads for 
some of the ALL-methylated gene panel similar to that seen in 
ALL cases. 

Chapter 1: Introduction  
Childhood acute lymphoblastic leukaemia (ALL) is the most common malignancy in 
children, representing about 26% of paediatric malignant tumours (Ward et al., 2014). 
Acute lymphoblastic leukaemia can be divided into two main groups based on the affected 
lineage: B-cells and T-cells. Childhood ALL represent about 80% of leukaemia cases and 
about 85% of childhood ALL cases are of the B-cell lineage (Downing et al., 2012; Ward 
et al., 2014). In children, the peak age onset is between 2 to 4 years of age (Ward et al., 
2014). In children with B-ALL, “pre-leukaemic” cells, harbouring B-ALL genetic 
mutations, were detected in the majority of cases at birth, indicating the prenatal origin of 
the disease. But, if B-ALL “pre-leukaemic” cells can be detected prenatally, why does B-
ALL develop at 2 to 4 years of age? In addition, cells containing the t(12;21) translocation 
that is specific to ALL have been detected in normal newborns at a very low frequency. 
Does this mean that normal children with “pre-leukaemic” cells are prone to develop B-
ALL later in their life? 
Is it possible that “pre-leukaemic” cells represent or arise from a normal fetal cell lineage 
that naturally disappears around birth in the majority of healthy newborns? The postnatal 
persistence of these “pre-leukaemic” cells may permit the occurrence of secondary genetic 
mutations that transforms them into B-ALL. If “pre-leukaemic” cells arise from a normal 
fetal cell lineage, then this most likely suggests that B-ALL has a fetal cell of origin. In 
addition, B-ALL cases were found to have a unique DNA methylation pattern, and it is 
possible that the unique B-ALL methylome reflects the epigenotype of B-ALL fetal cell of 
origin. Consequently, it may be possible to identify the B-ALL fetal cell of origin using a 
panel of specific B-ALL methylation biomarkers. To address these issues, this chapter 
reviews the literature and provides details regarding the debate about “pre-leukaemic” cells 
in healthy newborns; discusses the genetic and epigenetic features of B-ALL; reviews the 
available B-ALL methylation biomarkers; discusses the presence of fetal B cell lineage in 




1.1 Childhood B-ALL 
B-ALL is a proliferation of neoplastic B lymphoid precursor cells (Jabbour et al., 2005). 
The rapidly proliferating malignant leukaemic cells affect the proliferation and maturation 
of other blood lineages within the bone marrow. Clinically, the disease is characterised by 
pancytopenia (anaemia, neutropenia, and thrombocytopenia) and the presence of abnormal 
lymphoblasts in peripheral blood (Zhou et al., 2012). The diagnosis is based on the 
following criteria: 1) morphologic findings - the presence of blasts in the peripheral blood 
smear and a hypercellular bone marrow; 2) immunophenotypic features - three main types 
of patterns can be identified based on B-ALL stage: early pro-B, later pro-B, and pre-B; 
and 3) cytogenetic abnormalities including hyperdiploidy (51 to 65 chromosomes), 
t(12;21)(p13;q22) ETV6-RUNX1 fusion transcript, t(1;19) TCF3-PBX1 fusion transcript, 
del(9p13), del(9p21), and del(7q13) (Zhou et al., 2012). The ETV6-RUNX1 fusion 
transcript and hyperdiploidy are the most common genetic abnormalities in childhood B-
ALL, representing about 21% and 19%, respectively (Downing et al., 2012). It was widely 
accepted that these two genetic aberrations are generally associated with good prognosis.  
Following the discovery of the ETV6-RUNX1 fusion transcript in B-ALL in 1999, deletion 
of normal ETV6 allele was found in at least 50% of ETV6-RUNX1 B-ALL cases and was 
proposed to be subclonal to the chromosome translocations (Sood et al., 2017). In addition, 
ETV6-RUNX1 protein dimerises with the wild-type ETV6 protein and disrupts ETV6 
normal activity. Furthermore, ETV6-RUNX1 collaborates with other transcription factors to 
drive the expression of target genes such as ETS-1, PU.1 and C/EBPα and promote 
leukaemic transformation (Sood et al., 2017). ETV6/RUNX1 protein recruits 
NCOR/HDAC complexes to the ETV6 moiety of the fusion protein, following which 
NCOR1 and HDAC1 interact with a repression domain on ETV6 forming a stable 
repressor-corepressor complexes. It is widely accepted that ETV6-RUNX1 translocation is 
the initial hit for leukaemogenesis, producing a “pre-leukaemic” clone before birth; 
however, the secondary ALL mutations may occur postnatally (Sun et al., 2017) (see 
below for more details). 
Hyperdiploid B-ALL cases are characterised by chromosomal gains and about 70% of the 
cases gain of chromosomes X, 4, 6, 10, 14, 17, 18 and/or 21 (Paulsson, 2016). It was 
proposed that the chromosomal gain leads to increased expression of certain genes on the 
gained chromosomes and subsequently affects the activity of the corresponding genes on 
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the normal chromosomes (Paulsson, 2016). As a result, the upregulation of gene 
expression on the gained chromosomes affects the regulatory pathways and compromises 
the normal functions of the affected genes (Paulsson, 2016). Paulsson and colleagues 
sequenced 35 hyperdiploid B-ALL cases with matched controls and identified two groups 
of mutations: group one mutations were found in 50% of the cases and included mutations 
in the RAS signalling pathway, such as mutations in FLT3, KRAS, NRAS and PTPN11; 
while group two mutations were in the histone modifier genes such as CREBBP and 
WHSC1 and were identified in 20% of the cases. They proposed that gene mutations were 
unlikely to be the main driver event for leukaemogenesis in hyperdiploidy, and instead it 
was the chromosomal aneuploidy. This is because half of the hyperdiploid B-ALL cases 
did not contain mutations in the RAS pathway or histone modifier genes (Paulsson et al., 
2015). 
The majority of paediatric B-ALL cases have a good prognosis with four-year event-free 
survival at >90% and 46% for low- and very high-risk patient groups, respectively (Zhou 
et al., 2012). Low-risk groups included B-ALL cases with ETV6-RUNX1 fusion transcript 
or hyperdiploidy, whereas the very high-risk groups included cases with extreme 
hypodiploidy (<44 chromosomes), BCR-ABL1 fusion transcript and failure of remission-
induction chemotherapy (Zhou et al., 2012). Minimal residual disease is a measurable 
prognostic factor that is used to predict and monitor the risk of relapse in treated patients. 
Minimal/measurable residual disease (MRD), i.e., the number of detectable leukaemic 
cells, is often measured at the end of induction therapy. Five-year event-free survival is 
87% in cases with MRD less than 0.01% compared to 28% for cases with MRD more than 
1% (Borowitz et al., 2015). MRD can be measured using a multi-colour flow cytometry 
panel to evaluate the expression of surface markers or by sequencing techniques (Shaver et 
al., 2015). Recently, Wood and colleagues (2018) found that the use of next generation 
sequencing to detect IGH and TRG rearrangement enhanced the analytical sensitivity of 
MRD detection by about 20% and detected measurable disease in one-third of 619 patients 
who were missed by the flow cytometry protocol.  
1.1.1 B-ALL leukaemic cells  
In B-ALL, leukaemic cells contain B-ALL genetic mutations, such as ETV6-RUNX1 
fusion transcript, hyperdiploidy, BCR-ABL1 fusion transcript or KMT2A-AFF1 fusion 
transcript (Greaves, 2018). Twenty percent of B-ALL cases show leukaemic cells that 
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harbour the ETV6-RUNX1 fusion transcript which can be detected at birth in the majority 
of cases (Figure 1.1). Genetic mutations in leukaemic cells were proposed to form the 
prenatal initiating event for B-ALL and then these cells transform to leukaemia upon their 
postnatal exposure to a secondary trigger (secondary hit) (Greaves, 2018). Twin studies 
have clarified the timing of pre and postnatal mutations. Based on twin studies, a 
leukaemic clonal cell most likely arises in-utero from one twin and the cell progeny then 
passes to the other twin by intra-placental anastomoses (Greaves, 2018). These leukaemic 
cells were found to have variable copy number alterations and single nucleotide variants 
postnatally, suggesting that the identical original leukaemic clones acquired different 
genetic mutations independently in the twins after birth.  
Zimmermannova and colleagues (2017) investigated the dynamics of leukaemic cells 
postnatally and prior to their B-ALL development. They collected samples from eight B-
ALL cases who had presented with an aleukaemic atypical anaemia at least 6 weeks before 
ALL was diagnosed. They found the proliferation of “pre-leukaemic” clones pass through 
a “V-shape” course with an initial high proliferation phase followed by a slow phase and a 
final high proliferation phase prior to the diagnosis. They proposed that fluctuations in the 
number of ETV6-RUNX1 leukaemic cells was most likely caused by the effect of the 
circulating Vg9-Jg1.2 T cells, a subset of gdT cells. Interestingly, they found an increase 
proliferation of Vg9-Jg1.2 T cells in their eight B-ALL cases; however, there was an 
“inverse mirroring” in the dynamics of cell proliferation between leukaemic cells and Vg9-
Jg1.2 T cells (i.e., Vg9-Jg1.2 T cells had the opposite proliferation pattern to leukaemic 
cells across the “V-shape” course). In addition, they analysed bone marrow samples from 
167 B-ALL cases and 10 normal individuals and found a significant increase in the size of 
Vg9-Jg1.2 T cells in B-ALL cases compared to normal controls (P-value = 0.0005), 
suggesting their role in cancer immunosurveillance (Zimmermannova et al., 2017).  
Bhojwani and colleagues (2017) suggested that a minor chemoresistant leukaemic clone 
often emerges after the initial treatment and forms the main clone at relapse. The diversity 
of leukaemic clones at diagnosis and relapse reflects the acquisition of genetic mutations at 
different stages and can be divided into three groups: 1) mutations that cause the initiating 
event (e.g. pre-natal ETV6-RUNX1 fusion transcript in the founding leukaemic clone); 2) 
mutations that exist in the founding clone (also referred to “passenger” mutations); and 3) 
mutations that drive the relapse (such as mutations in the RAS signalling pathway). 
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Bashford-Rogers and colleagues (2016) investigated the diversity of leukaemic clones 
from diagnosis to relapse in B-ALL using variations in the B cell receptor as a marker. 
They proposed that sequencing the B cell receptor gene can assist in studying the diversity 
and hierarchy of B cell populations and hence become an appropriate approach to 
understand clonal diversity in ALL. They investigated longitudinal samples (i.e., samples 
at diagnosis, during treatment and at relapse) from 15 B-ALL patients. Interestingly, they 
found > 78% of B cell receptor sequences overlap between diagnosis and relapse samples 
indicating that relapse clones arise from re-emergence of the clones that was present at 
diagnosis. They proposed two scenarios for emergence of clones before relapse: 1) Partial 
chemoresistance after the initial therapy – leukaemic clones at diagnosis were retained and 
similar clones can be detected at relapse; and 2) chemosensitivity after the initial treatment 
– the majority of leukaemic clones at diagnosis were eliminated and few clones can be 
identified at relapse. The majority of relapse clones acquire chemoresistant genetic 
mutations to allow them survive through treatment stages. 
How do B-ALL subclones emerge at diagnosis and relapse? Two models have been 
proposed: the cancer stem cell model (CSC) and the clonal evolution model (Lang et al., 
2015). The cancer stem cell model proposes a unique leukaemic stem cell that proliferates 
and differentiates in an organised hierarchy, similar to that in non-leukaemic stem cell, to 
generate mature leukaemic cells. In contrast, the clonal evolution model suggests the 
acquisition of different genetic mutations throughout the evolution of leukaemic clones 
until successful clones dominate the pool. The ongoing subclonal evolution of the clonal 
evolution model can be: 1) linear clonal evolution – this model was characterised by a 
stepwise acquisition of genetic mutations in each unique subclone; or 2) branched clonal 
evolution - the subclones of this model did not exist in parallel. Lang and colleagues 
(2015) proposed that all of these models play a role for the emergence of different 
leukaemic clones in B-ALL. The diversity of leukaemic clones varies at different stages of 
the disease indicating the presence of selective competition between cancer stem cell 
branches. The switch between each branch represent a “dynamic competition” between the 
subclones at different stages of the disease. In addition, the successful stepwise acquisition 
of chemoresistant genetic mutations can be speculated to be the mechanism of diverse 




1.2 Prenatal origin of B-ALL 
Greaves (2005) proposed that the fetal origin of B-ALL hypothesis was initially described 
when concordant leukaemia was diagnosed in a pair of monozygotic twins, suggesting the 
in-utero development of B-ALL. The pre-natal origin of B-ALL hypothesis has been 
debated in the literature and the following discussion highlights the main aspects of this 
debate. 
1.2.1 In children with ALL, the clone can be usually detected at birth  
Several studies show retrospective evidence for the presence of leukaemic cells (i.e., cells 
containing ALL-associated translocations) on Guthrie cards from children who were later 
diagnosed with childhood B-ALL, suggesting the prenatal origin of the disease. The 
identification of leukaemic cells in the Guthrie cards of B-ALL cases suggests the 
leukaemogenic potential of these cells to transform to B-ALL. In this chapter, “pre-
leukaemic” cells refer to leukaemic cells that were detected in Guthrie cards or cord blood 
samples at birth that harbour ALL-associated genetic mutations. Does the identification of 
these “pre-leukaemic” cells mean B-ALL development? This question will be answered in 
the following sections. 
Wiemels and colleagues (1999) investigated the presence of the ETV6-RUNX1 (previously 
known as “TEL-AML1”) fusion gene at birth in 12 children who were later diagnosed with 
ALL (aged 2-5 years) using long distance inverse PCR on Guthrie card blood spots. The 
ETV6-RUNX1 fusion transcript was detected in six children. In addition, they investigated 
identical twins diagnosed with ETV6-RUNX1 ALL and identified ETV6-RUNX1 positive 
cells in Guthrie cards from both twins. In their follow up report, Wiemels and colleagues 
(1999) found that the twins developed B-ALL at different ages (twin 1 was diagnosed at 
age 5 years and twin 2 was diagnosed at age 14 years). Interestingly, ETV6-RUNX1 clones 
were detected in both the leukaemic and non-leukaemic twins when they were 5 years old. 
The identical twins had the same clone at birth, despite there being nine years delay 
between their B-ALL diagnosis. The transformation of leukaemic clone to B-ALL at 
different ages in the identical twins could reflect later acquisition of mutations in the 
evolving subclones to cause B-ALL. 
Hjalgrim and colleagues (2002) investigated the presence of the ETV6-RUNX1 fusion gene 
at birth in 22 children with t(12;21) translocation B-ALL (aged 2 to 6 years). Using long 
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distance inverse PCR on Guthrie cards, nine DNA samples were successfully tested and 
three of the children had the fusion gene (failed samples were attributed to the low quality 
and quantity of DNA). The variation in the detection rate of the “pre-leukaemic” cells in 
B-ALL children was attributed to the following: (1) variable number of the “pre-
leukaemic” cells at birth; (2) variable number of detectable cells on the Guthrie card (i.e., 
unrepresentative blood sample on the card); (3) DNA quality of the Guthrie card; and/or 
(4) PCR sensitivity. Interestingly, they found that 88% of children diagnosed at 0-1 years, 
67% of children diagnosed at 2-3 years, and 56% of children diagnosed at >4 years had 
detectable “pre-leukaemic” cells. They proposed that the age at B-ALL diagnosis may 
reflect the number of “pre-leukaemic” cells with B-ALL transformation at birth (i.e., 
children with high number of “pre-leukaemic” cells at birth were more likely to develop B-
ALL in their first year of their life). In addition, B-ALL diagnosis at different age groups 
was speculated to be due to: 1) variation in the number of “pre-leukaemic” cells at birth, 
which is about 1:105 to 1:106 cells; 2) variation in leukaemic potential of these cells 
between B-ALL cases which can range from complete to incomplete leukaemic 
transformation; and 3) variation in the rate of acquisition of leukaemogenic genetic 
mutations between B-ALL cases (the postnatal secondary genetic mutations or 
environmental hits) (Hjalgrim et al., 2002).  
Greaves and colleagues (2005) proposed a prenatal origin of ALL hypothesis based on: (1) 
the identification of fusion genes in leukaemia cord blood samples, (2) the presence of 
similar genetic fusions in the Guthrie card, and (3) the presence of the same leukaemia 
clone in monozygotic twins. Taub and colleagues (2004) suggested that three PCR 
amplification strategies can be used to detect “pre-leukaemic” cells in neonatal blood spots 
(Guthrie cards): (1) PCR amplification of the chromosomal translocation; (2) PCR 
amplification of immunoglobulin gene rearrangements, especially heavy chain gene (IGH) 
rearrangements that are present in 90 – 95% of B-ALL cases, and (3) PCR amplification of 
the rearranged T-cell receptor gene (TCR) that is detected in 40 – 60% of B-ALL and T-
ALL cases. However, “pre-leukaemic” cells were not detected in all leukaemia cases, 
which could be due to: (1) undetectable “pre-leukaemic” cells by PCR, (2) the leukaemic 
clone, with its unique IgH/TcR rearrangement, arose postnatally, or (3) poor quality of 
DNA samples (Taub & Ge, 2004).  
Leukaemic clones were not detected in all B-ALL cases, especially in the hyperdiploid 
subtype, suggesting that not all B-ALL cases have pre-natal origin (Taub et al., 2002). 
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Taub and colleagues (2002) investigated the presence of the “pre-leukaemic” cells in 17 B-
ALL children (nine hyperdiploidy, three with acquired trisomy 21, and four with genetic 
translocations) using PCR to detect IGH gene rearrangement. They identified “pre-
leukaemic” cells in 12 children (six with hyperdiploidy), while three B-ALL children with 
hyperdiploidy (≈30%) did not have detectable clones on their Guthrie cards at birth. 
Consequently, they speculated that the presence of multiple leukaemic cells at birth is part 
of normal fetal development and the variable latency periods in B-ALL diagnosis after 
birth between the cases may reflect the natural variation for the full development of these 
fetal cells. In addition, they proposed that “pre-leukaemic” cells may disappear when the 
immune system physiologically switches from T-helper 2 to T-helper 1 system gradually 
after birth in the majority of newborns. Furthermore, the immune system eliminates “pre-
leukaemic” cells during that natural transition; however, some newborns may develop an 
immune response to an infection, as was proposed in Greaves’ infection model, and allow 
some “pre-leukaemic” cells to persist and later transform to B-ALL (Taub et al., 2002). 
Additionally, Maia and colleagues (2004) screened 11 children with hyperdiploid B-ALL 
to detect “pre-leukaemic” cells on Guthrie cards using an IGH gene rearrangement PCR 
assay. They found one sample with a positive PCR assay. They speculated that the 
detection failure was due to the presence of “pre-leukaemic” cells at very low levels (1 in 
10-5 cells); and that Guthrie cards rarely contain more than 105 cells. They identified a low-
level of “pre-leukaemic” cells in CD19+ sorted B cells and confirmed, by FISH assay,  the 
presence of additional chromosomes 15 or 17. Maia and colleagues found that, at birth, 
“pre-leukaemic” cells represent about 0.44% of CD19+ B cells and 6.5% of the CD34+ B 
cell progenitors in hyperdiploid B-ALL cases (Maia et al., 2004). 
1.2.2 Twin studies 
Soon after the study by Taub, Maia and colleagues (2003) showed the presence of “pre-
leukaemic” cells in monozygotic twins, concordant for hyperdiploid B-ALL (>50 
chromosomes: +6, +8, +9, +10, +11, +12, +21, +22). The identical twins shared similar 
TCRD, and IGH rearrangements except for different V regions in some of the analysed 
clones. These similarities between the twins even in immunoglobulin gene rearrangements 
support the in-utero development of B-ALL. However, they speculated that the “pre-
leukaemic” hyperdiploid cells may be derived from a precursor hyperdiploid clone of 
relatively normal B cell progenitors that developed prenatally rather than from a full-
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blown hyperdiploid B-ALL. The hyperdiploid B cell progenitor may be prone to acquire 
further genetic mutations postnatally and hence this progenitor has the potential to 
transform to B-ALL. Furthermore, they argued that if ALL developed in full prenatally, 
the concordance rate for B-ALL between monozygotic twins should be about 100% rather 
than 10%, especially for ETV6-RUNX1 B-ALL (Maia et al., 2003). 
Teuffel and colleagues (2004) investigated the presence of “pre-leukaemic” cells in a 
monozygotic twin pair with concordant ETV6-RUNX1 B-ALL. Bone marrow and neonatal 
blood spot samples were collected and tested for the ETV6-RUNX1 fusion gene then the 
immunoglobulin heavy gene rearrangement was sequenced using long distance PCR. They 
found identical breakpoints of ETV6-RUNX1 fusion gene in the twins in both leukaemia 
and Guthrie card DNA samples indicating the leukaemic cells were derived from a 
common “pre-leukaemic” clone. Surprisingly, further investigation using specific primers 
for VH1-JH4 and VH3-JH4 gene segments in the immunoglobulin gene showed different 
gene rearrangements in the leukaemia samples, suggesting that these leukaemia cells were 
unique to each twin. These results were confirmed by identifying two different clones 
using a FISH assay. In addition, they performed genome wide expression analysis for the 
twins and an additional 31 B-ALL samples. The analysis showed twin pair leukaemia 
samples cluster with other ETV6-RUNX1 B-ALL samples; however, the twins were 
clustered at slightly distant branches and this variation may be related to the postnatal 
evolution of different leukaemic subclones.  
Alpar and colleagues (2015) screened five twins with concordant ETV6-RUNX1 B-ALL 
using IGH and TCR gene rearrangement assays. The sequenced gene rearrangements were 
found to be different in postnatal “pre-leukaemic” cells for each twin pair, suggesting the 
presence of different mechanisms involved in channelling the positive “pre-leukaemic” 
cells (Alpar et al., 2015).  
Based on the above studies, the majority of B-ALL cases, including B-ALL twins, develop 
diverse leukaemic clones postnatally even though they had similar, or sometimes identical, 
“pre-leukaemic” clone at birth. Is it possible to propose that the initiating genetic mutation 
in the “pre-leukaemic” clone at birth, such as on ETV6-RUNX1 fusion transcript, affected 
several and diverse normal fetal B cell progenitors? and is the diversity of the postnatal B-
ALL clones derived from the diverse “pre-leukaemic” clones prenatally? Teuffel and 
colleagues (2004) proposed that B-ALL may not be initiated by a common in-utero gene 
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mutation event that is passed to the proliferating “pre-leukaemic” clone. They proposed the 
presence of an immature common leukaemic precursor cell established as a distinct clone 
prenatally prior to their exposure to an in-utero common triggering factor that caused the 
characteristic genetic mutations such as ETV6-RUNX1 fusion transcript. Consequently, it 
was possible to speculate that gene mutations drive the clones to proliferate and exhibit 
concordant leukaemia following the natural process of disease development. However, the 
timing of the genetic mutation event was not determined in these cases (Teuffel et al., 
2004).  
1.2.3 The detection of “pre-leukaemic” cells in healthy newborns 
Several studies have detected cells with ALL-associated mutations in healthy newborns; 
however, the number and significance of those cells is debated. Mori and colleagues 
(2002) screened 567 cord blood samples from healthy newborns for the presence of ETV6-
RUNX1 (B-ALL) and RUNX1-ETO fusion genes. Using Taqman reverse-transcriptase 
quantitative PCR (RTqPCR) and fluorescence in situ hybridisation (FISH) assays, they 
detected ETV6-RUNX1 in six samples (≈ 1%) and RUNX1-ETO in one sample. The ratio 
of leukaemic cells were found to range between 1:103 to 1:104 in cord blood, which was 
equivalent to the leukaemia detection threshold in diagnosed children (1:104 in B-ALL). 
FISH analysis confirmed the presence of ETV6-RUNX1 and RUNX1-ETO fusion 
transcripts in the analysed samples. Following sorting of the ETV6-RUNX1 fusion 
transcript-positive cord blood samples, the fusion transcript was detected in sorted B 
lymphocytes and CD34+ cells suggesting lineage specificity. Consequently, they proposed 
that these clones might transform to leukaemia after acquiring postnatal genetic mutations 
during childhood development.  
Lausten-Thomsen and colleagues (2011) re-investigated the presence of cells with the 
ETV6-RUNX1 fusion gene in 1417 cord blood samples from healthy newborns. They used 
a reverse-transcriptase quantitative PCR (RTqPCR) approach similar to Mori et al. (2002) 
(as discussed above) with the aim of estimating the number of “pre-leukaemic” cells in 
healthy newborns (i.e., cells with ETV6-RUNX1 fusion gene). They found 14 newborns 
with ETV6-RUNX1 fusion gene with an average level of 1:105 cells, nine cases were 
confirmed for the presence of mRNA transcript by dot-blot analysis. The very low level of 
ETV6-RUNX1 transcripts below 10-5 contradicted the results from Mori et al. who had 
found 10-3 to 10-4 detectable cells (Mori et al., 2002). In addition, their nine positive 
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samples were sorted into CD19+ and CD8+ cells but ETV6-RUNX1 transcripts were not 
detected in the sorted cells. Consequently, Lausten-Thomsen and colleagues argued that 
the difference in the frequency of ETV6-RUNX1 “pre-leukaemic” cells could be due to the 
difference in the studied populations (Danish and British newborns in Lausten-Thomsen et 
al. and Mori et al., respectively). In addition, they used different confirmatory methods 
with different analytical sensitivities (dot-blot analysis and FISH assay in Lausten-
Thomsen et al. and Mori et al., respectively). Lausten-Thomsen and colleagues proposed 
that the low level of ETV6-RUNX1 transcripts in the cord blood samples as well as the 
very small number of positive cases may “reflect very infrequent and low-level 
contamination” or “random RT-PCR positivity of the rarely occurring ETV6-RUNX1 
transcript in a cord blood sample”. These comments from Lausten-Thomsen et al. added 
confusion to the debate and questioned the existence of cells with ETV6-RUNX1 fusion 
gene in healthy neonates. 
Lausten-Thomsen et al. proposed that they have used stringent detection methods, which 
included: (1) using fresh cord blood samples to minimise RNA degradation from multiple 
freezing and thawing cycles; (2) using mRNA to provide higher analytical sensitivity than 
total RNA; (3) using Taqman probes for RTqPCR; and (4) using high cDNA input (seven 
times higher than Mori’s). They speculated that the use of nonquantitative nested PCR can 
be associated with high contamination rate and hence compromise the specificity of clonal 
detection. Since Lausten-Thomsen et al. used stringent methods for their investigation, 
they questioned the reliability of Mori’s findings. They claimed that the high frequency of 
“pre-leukaemic” clones in healthy newborns from Mori’s study was likely attributed to 
laboratory contamination from handling B-ALL samples. Consequently, the detection of 
“pre-leukaemic” cells in healthy newborns, if results were not confounded by 
contamination, may not be frequent as was reported by Mori’s results. 
After Lausten-Thomsen’s paper, Zuna and colleagues (2011) screened 253 cord blood 
samples from healthy newborns using end-point and quantitative reverse transcriptase PCR 
for the presence of ETV6-RUNX1, RUNX1-AF4, and BCR-ABL1 fusion transcripts. They 
found five samples with ETV6-RUNX1 fusion transcript, representing 2% of the studied 
population, and hence they questioned Lausten-Thomsen’s arguments about the frequency 
of “pre-leukaemic” cells. In addition, they tested one spleen and 11 liver tissues from 
aborted fetuses. They found the presence of ETV6-RUNX1 fusion transcripts in the fetal 
spleen sample. They minimized the carryover contamination in their study by following 
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strict techniques: (1) they used a new laboratory facility that had never processed 
leukaemia samples, (2) they used negative and diluted positive controls for their assays for 
specificity and sensitivity evaluations, and (3) they added their positive controls for each 
assay in a separate room after PCR tubes for study samples had been sealed. Furthermore, 
FISH verification of one PCR-positive sample showed an atypical ETV6-RUNX1 fusion 
transcript (truncated exon 5 of ETV6 gene, and 3’ end of RUNX1 gene) suggesting that 
their findings were not attributable to contamination. Finally, they tested 30 children with 
non-malignant fever to check whether ETV6-RUNX1 fusion transcripts could arise from 
cells under stress such as apoptotic cells, and they found negative results (Zuna et al., 
2011). Consequently, their results supported the presence of “pre-leukaemic” cells in 
healthy newborns as suggested by Mori and colleagues. 
Greaves and colleagues (2011) (Mori’s group) responded to Lausten-Thomsen’s comments 
and stated that they used four separate laboratories for their study to minimize 
contamination: (1) a laboratory for RNA extraction, (2) a laboratory for RNA to cDNA 
conversion reaction, (3) a laboratory for PCRs, and (4) a laboratory to prepare and amplify 
leukaemia cell lines and leukaemia samples. In addition, the positive nested PCR assay 
was confirmed using Taqman probe-specific RT-qPCR (in comparison to an intercalating 
dye assay such as SYBR GREEN) and validated by FISH assay, suggesting that their 
results were not confounded by contamination. They confirmed the stability of RNA by 
testing a retrieved RNA from frozen whole blood. Consequently, they questioned Lausten-
Thomsen’s findings and they suggested checking their mRNA handling protocols for 
mRNA stability. 
Schmiegelow and colleagues (2011) (Lausten-Thomsen’s group) responded to the previous 
comments, and to Zuna’s paper. They suggested the ≈ 100-fold difference in the frequency 
of what can be called “pre-leukaemic” cells between the studies was likely to be due to 
technical bias rather than a biological cause. They argued that their PCR assay can identify 
cells from 1:103 to 1:104 on their titrated 10-5 PCR standard curve. They also questioned 
Zuna’s methodology for detecting ETV6-RUNX1 in their PCR protocol suggesting that the 
initial level of these transcripts was low. Due to the low level of positive cells in Lausten-
Thomsen’s study, FISH assay was not performed to confirm the presence of “pre-
leukaemic” cells in their 1417 cord blood study. Schmiegelow and colleagues enriched 
their positive cord blood samples (i.e., samples containing ETV6-RUNX1 fusion gene) for 
CD19+ B cells to enrich for cells with ETV6-RUNX1 fusion transcripts, but with no 
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success. Furthermore, they argued that their ETV6-RUNX1 mRNA was stable as the ABL1 
control gene used for normalisation gave a wide range of cycle threshold (Ct) values 
suggesting good stability. Consequently, Schmiegelow and colleagues questioned Mori’s 
results regarding the number of detected “pre-leukaemic” cells by the FISH assay 
indicating that FISH assay may have low analytic specificity. 
Recently, Schafer and colleagues (2018) developed a DNA-based genomic inverse PCR 
for exploration of ligated breakpoints (GIPFEL) that was claimed to be more specific than 
the RNA-based qPCR method for the detection of the “pre-leukaemic” cells. The GIPFEL 
method was based on the digestion of enriched CD19+ B cells with Sac1 enzyme followed 
by ligation to form circular DNA. The circular DNA was then purified and amplified using 
forward and reverse primers. Primers were designed to anneal to the intron region between 
exons 5 and 6 of ETV6 (upstream of the identified breakpoints cluster) and to the intron 
region between exons 1 and 2 of RUNX1 (downstream of the breakpoints cluster). DNA 
was then amplified by semi-nested qPCR, inspected by gel electrophoresis and positive 
results were confirmed by Sanger sequencing. They argued that GIPFEL can detect one 
ETV6-RUNX1 fusion transcript within 10,000 normal cells with very high specificity (false 
positive < 10-10) suggesting it is a more reliable tool than the long-distance inverse PCR 
technique. Interestingly, they screened 1000 normal cord blood samples and detected 
ETV6-RUNX1 gene fusions in 50 samples suggesting that the prevalence of “pre-
leukaemic” cells is 5% in healthy newborns. The number of ETV6-RUNX1-positive clones 
was very low, representing about 1 in 104 cord blood cells. They argued that the 
prevalence of the “pre-leukaemic” cells could be possibly more than 5% due to the 
complex rearrangements of ETV6-RUNX1 breakpoints that may occur outside the studied 
targets (Schafer et al., 2018). 
Surprisingly, “pre-leukaemic” cells were also detected in the peripheral blood of healthy 
adults. Eguchi-Ishimae and colleagues (2001) found ETV6-RUNX1 transcripts in 13 of 146 
(9%) blood samples from healthy adults. In addition, they tested 67 cord blood samples 
and found one sample positive for the ETV6-RUNX1 transcript. However, the analysis was 
not done on enriched cell populations, and hence the source of the translocation, especially 
in adult samples, may be from an “irrelevant” cell type and not a leukaemia transforming 
event within lymphocytes (Eguchi-Ishimae et al., 2001). 
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1.2.4 Childhood solid tumours 
Supporting the ‘prenatal’ origin of B-ALL hypothesis is the finding that other childhood 
tumours have a fetal origin. Scotting and colleagues (2005) proposed that childhood solid 
tumours resemble embryonic tissues structurally and functionally; for example, 
hepatoblastomas that secrete α-fetoprotein, a fetal liver protein. They suggested that 
childhood solid tumours arise from defects in the physiological regulation of normal 
development causing arrest of tissue maturation. Consequently, the neoplastic features of 
these tumours such as invasiveness, proliferation and plasticity are not due to the direct 
oncogenic transformation of these cells, but rather features of failure in developmental 
progression. In addition, they suggested that the age onset of childhood solid tumours 
reflects the period required for full maturation of the related normal embryonic tissue. 
Furthermore, the nature of childhood solid tumours mimics the characteristic features of 
embryonic tissue microenvironment. An example of this is the broad disorganised 
phenotypic range of teratocarcinoma, which potentially can develop to skin, bone, 
muscles, etc. The variable phenotype of teratocarcinoma reflects the embryonic primitive 
stem cell potential to develop into a wide range of tissues based on their 
microenvironment. Furthermore, the cessation of embryonic tissue development represents 
the end of normal developmental period. They suggested that tumour involution, which 
reflects the cessation of embryonic tissue development, is correlated with age onset of 
these tumours, and is consistent with their embryonic nature (Scotting et al., 2005).  
1.2.5 The significance of “pre-leukaemic” cells to this project 
The debate in the literature about the pre-natal origin of B-ALL and the ability to detect 
“pre-leukaemic” cells (i.e., cells with ALL-associated translocations) from Guthrie cards 
or cord blood in healthy newborns raised many questions about the mechanism of B-ALL 
development. It is still unclear why some B-ALL cases had undetectable leukaemic cells at 
birth. Why is there a latency period for B-ALL development? If “pre-leukaemic” cells 
exist in healthy and leukaemic children, then why does leukaemia develop in some 
children but not in others? What are the secondary hits that transform “pre-leukaemic” 
cells to leukaemia and how early can they be detected? Is it possible to propose that “pre-
leukaemic” cells arise from a normal fetal stem cell that forms the fetal cell of origin for B-
ALL? If “pre-leukaemic” cells were derived from normal fetal cells, can we identify these 
fetal cells? We explored DNA methylation and found a unique and consistent DNA 
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methylation pattern across different B-ALL cases. Does the proposed fetal cell of origin 
carry an epigenotype similar to that reported in B-ALL? If yes, then can we identify the 
fetal cell of origin using ALL-methylation biomarkers. The following sections will try to 
address some of these issues with detailed discussions.  
1.3 B-ALL DNA methylation 
DNA methylation involves the addition of methyl groups to cytosine molecules at CpG 
nucleotides. When located at a gene promoter, DNA methylation can silence the 
expression of that gene. Despite the identical genetic composition of cells in a person, 
methylation differs markedly depending on tissue identity and developmental stage 
(Peltomaki, 2012). Hypermethylation of tumour suppressor genes is a mechanism of 
cancer development (Momparler, 2003). These effects of DNA methylation in cancer, 
often referred to as “epimutations” are recapitulated from cell to cell (Peltomaki, 2012). 
However, it was noted that CpG islands were mostly hypermethylated in cancer with the 
presence of “driver” and “passenger” epimutations (Peltomaki, 2012). Driver epimutations 
promote tumorigenesis, occur at early tumourigenesis and promote methylation-related 
gene splicing (Peltomaki, 2012). Epimutations were described as hypermethylation of an 
allele leading to gene silencing of the affected gene (Peltomaki, 2012). Consequently, 
cancer-related epimutations can serve as potential diagnostic biomarkers for cancers. If 
that is the case, then which methods are best suited to identify methylation biomarkers? 
Genome-wide methylation methods, such as the human Illumina 450k DNA methylation 
array platform, can be used to find a group of candidate cancer-related epimutated genes. 
1.3.1 DNA methylation as a useful tool to explore the prenatal origin of ALL 
Early methylation studies of B-ALL were based on evaluation of known tumour 
suppressor genes, such as calcitonin (now referred to CALCA) (Roman et al., 2001), DBC1 
(now referred to BRINP1) (San Jose-Eneriz et al., 2006), p73, p15, p17 and others (Canalli 
et al., 2005). As an example, Corn and colleagues (1999) investigated the methylation 
status of TP73 in ALL and Burkitt lymphoma samples. TP73 methylation was proposed to 
have a role in ALL development because it is a tumour suppressor gene that encodes for a 
protein with similar structural and functional characteristics to p53. Using methylation-
specific PCR (MSP) and Southern blotting analysis to screen for TP73 methylation in 
cancer cell lines. They reported TP73 methylation and low gene expression (using reverse-
transcriptase PCR) in 60% of breast cancer, 20% of colon cancer and 60% of leukaemia 
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cell lines compared to no methylation in lung cancer and neuroblastoma cell lines. Then, 
they tested TP73 methylation in primary tumour samples of breast cancer, renal cancer, 
colon cancer, ALL (n = 35) and Burkitt lymphoma (n = 10). DNA methylation of TP73 
was not detected in solid tumours. However, 31% of ALL and 30% of Burkitt lymphoma 
cases contained TP73 methylation, with the majority being from T-ALL (numbers of B- 
and T-ALL cases were not reported in the study; however, they found that 62% of T-ALL 
cases had TP73 methylation compared to 17% of B-ALL). Interestingly, none of the acute 
myeloid leukaemia, chronic lymphocytic leukaemia and non-Hodgkin lymphoma samples 
had TP73 methylation. 
Other studies focused on identifying a panel of genes that are usually methylated in cancer 
(referred to as “methylator phenotype”) (Gutierrez et al., 2003). Gutierrez and colleagues 
proposed that cancer cells develop due to methylation of key regulatory genes that 
participate in every cellular process, such as cell cycle genes (RB, CDKN2A and 
CDKN2B), genes involved in DNA repair (BRCA1, MLH1 and MGMT), and genes 
involved in apoptosis pathways (Gutierrez et al., 2003). As a result, the identification of a 
tumour-specific panel of genes to be used as “methylator phenotype” can assist in clinical 
diagnosis and monitoring of ALL cases (Gutierrez et al., 2003). Gutierrez and colleagues 
selected seven genes, which were reported to be methylated in ALL, and used them to 
define a “methylator phenotype”: CDH1, DAPK1, MGMT, TP73, CDKN2A, and 
CDKN2B. Using methylation-specific PCR, methylation of these genes in 129 paediatric 
ALL patients (77% B-ALL and 23% T-ALL) and in 17 healthy controls (five children and 
12 adults) was determined. They found that the majority of ALL samples had CDH1, 
DAPK1, TP73, and CDKN2B methylation (72%, 30%, 26% and 23% of ALL cases, 
respectively); however, MGMT and CDKN2A (p14 and p16) were commonly 





Figure 1.1. Methylation pattern of CDH1 (E-cadherin), DAPK1, TP73, CDKN2A (p16), 
CDKN2B, MGMT and CDKN2A (p14) in 129 paediatric ALL: B-ALL cases with known 
genetic mutations (36 cases of ETV6-RUNX1 (TEL-AML1), BCR-ABL1, TCF3-PBX1 
(E2A-PBX1) and 11q23 mutations) are represented in the left, B-ALL cases with 
undetermined genetic mutations (63 cases) are in the middle panel and T-ALL cases are 
on the right side (seven cases with SIL-SCL fusion transcript and 23 cases had 
undetermined mutations). Green = methylation, yellow = unmethylation and blue = gene 





Genome-wide methylation studies emerged at the time of appearance of early microarray 
methylation chips, such as the 9k CGI microarray chip in 1999 (Taylor et al., 2007). The 
9k CGI microarray chip contained 8,640 MspI fragments, it targeted CpG islands, and it 
interrogated more than 3,400 unique sequences across the human genome (Taylor et al., 
2007). Taylor and colleagues studied 16 ALL DNA samples (six T-ALL and 10 B-ALL), 
four ALL cell lines (NALM6, MN60, SD1 and Jurkat) and four samples from healthy 
donors. They found 262 differentially methylated CpG sites, of which 148 and 131 sites 
were located within 2,500 bases and 500 bases of transcription start sites, respectively. 
They selected 11 genes that had an absolute methylation of more than 31% in ALL (DCC, 
DDX51, DLC1, KCNK2, LRP1B, NKX6-1, NOPE (now referred to as IGDCC4), 
PCDHGA12, RPIB9 (RUNDC3B), ABCB1 and SLC2A14). They validated their results 
using either combined bisulfite restriction analysis (COBRA) or methylation-specific PCR 
(MSP). In validation experiments, each of these genes was methylated in at least 44% of 
ALL cases (Figure 1.2). Interestingly, the majority of genes showed dense DNA 
methylation in both B- and T-ALL samples and in cell lines except for the DDX51 which 
was unmethylated in T-ALL samples and cell lines (Figure 1.2). NKX6-1 was densely 
methylated in all B- and T-ALL samples; however, it was also methylated in the normal 





Figure 1.2. Summary of methylation results for the 11 genes (arranged in columns) in 
ALL and normal control samples (samples arranged in rows). The 11 genes were 
validated in ALL cell lines (1 is Jurkat; 2 is MN60; 3 is NALM6; and 4 is SD1), B-ALL 
cases (B1 to B10), T-ALL cases (T1 to T6) and bone marrow samples from healthy 
controls (BM1 to BM4). N and P refer to negative and positive controls, respectively. 
Grey = methylated, white = unmethylated and hatched block = partial methylation. This 
image was taken from Taylor et al. (2007) with permission. 
 
Since then, several genome-wide methylation studies have investigated the epigenetic 
profile of B-ALL. Lee and colleagues (2015) used Illumina 450k human methylation array 
(hereafter referred to as ‘450k array’) on 227 B-ALL samples as well as on normal 
multipotent progenitors, pre-B-I, pre-B-II, and immature B cells. They found 26,874 (5.7% 
of probes) differentially methylated sites around 4,671 gene promoters. Hierarchical 
clustering analysis separated samples into four groups based on the 500 most variable CpG 
sites (Figure 1.3). Hyperdiploid cases tended to cluster in group I, whereas ETV6-RUNX1 
clustered in group III. Lee and colleagues also found common differentially methylated 
regions between B-ALL cytogenetic subtypes, suggesting that there is a common signature 




Figure 1.3. DNA methylation for different childhood B-ALL subgroups. Each subgroup 
had a distinct methylation profile. This image was taken from Lee et al. (2015) with 
permission. 
 
Using Illumina 450k human methylation arrays, Busche and colleagues (2013) found 
higher DNA methylation in 46 paediatric B-ALL samples compared to controls (median 
methylation of 70% for B-ALL samples and 63% for controls). They proposed that the 
DNA methylation observed in controls reflects the heterogeneous mixture of lymphocytes 
and monocytes compared to the homogeneous leukaemic blasts present in B-ALL cases. In 
addition, they suggested that the DNA profile of controls could be biased by the effect of 
chemotherapy in the remission samples. Consequently, they compared different B-ALL 
subtypes by hierarchical clustering analysis and found different cytogenetic B-ALL 
subgroups clustered randomly, such as 10 cases with hyperdiploidy clustered with four 
cases with no abnormal cytogenetic abnormalities. Furthermore, they analysed remission 
control samples and found a different pattern of clusters compared to their matched B-ALL 
samples at diagnosis. As a result, they suggested that there is a global pattern of B-ALL 
DNA methylation regardless of the cytogenetic abnormality. Furthermore, they identified 
119 densely methylated CpG sites in the ETV6-RUNX1 subtype that had a methylation 
difference of more than 40% compared to other B-ALL subtypes (Busche et al., 2013).  
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Using the HELP assay and MassARRAY EpiTYPER, Figueroa and colleagues (2013) 
investigated DNA methylation in B-ALL of defined cytogenetic subtypes from 167 
children. Hierarchical clustering analysis of DNA methylation profiles showed seven 
groups of B-ALL cases that were determined by cytogenetic or molecular features: 
hyperdiploidy, ETV6-RUNX1, TCF3-PBX1, BCR-ABL1, CRLF2, ERG, KMT2A, and 
miscellaneous karyotype. In addition, they found that the hyperdiploid group contained the 
largest number of differentially methylated regions compared to other B-ALL subtypes 
(635 hypomethylated and 84 hypermethylated CpG sites). In comparison, the CRLF2 
group had the smallest number of differentially methylated regions among B-ALL 
subtypes (32 hypermethylated and 20 hypomethylated CpG sites). Interestingly, 1,808 
differentially methylated regions were identified as distinct in B-ALL compared to normal 
B cells (1,266 hypermethylated and 542 hypomethylated CpG sites) (Figueroa et al., 
2013).  
Borssén and colleagues (2016) investigated the DNA methylation of T-ALL cases. They 
used the Illumina 450k DNA methylation BeadChip to investigate genome-wide DNA 
methylation profile of 65 paediatric cases of T-ALL and used their CpG island methylator 
phenotype (CIMP) panel to classify T-ALL into subgroups. In their previous publication, 
they investigated 43 T-ALL patients using the 27k array methylation BeadChip (hereafter 
referred to as ‘27k array’) and correlated the analysis with the clinical outcome of these 
patients. Interestingly, they identified a panel of 1,293 variable CpG sites and reported that 
the low DNA methylation of these sites was associated with poor prognosis and event free 
survival (Figure 1.4) (Borssén et al., 2013). Using their CIMP panel, 25 of 65 T-ALL 
patients were classified as being CIMP negative, having a methylation profile similar to 
normal CD3+ T cells and CD34+ progenitor cells. Survival analysis showed a significant 
difference in the 3-year cumulative incidence of relapse of 29% for CIMP negative group 
compared to 6% in CIMP positive (P = 0.01). In addition, they found that combining 
minimum residual disease status at day 29 with CIMP results provide a better prognostic 




Figure 1.4. Methylation profile of the CIMP sites classifies T-ALL cases into a CIMP+ 
group with a good overall survival and to a CIMP- group. The heatmap on the left shows 
the distinct methylation pattern of CIMP+ group that can be divided into two subgroups: 
high CIMP+ group (all of CIMP sites were methylated) and intermediate CIMP+ group 
(some of the CIMP sites were methylated). Overall survival plots (Kaplan-Meier 
analysis) on the right show a good prognosis for CIMP+ group (bottom plot) compared 
to all T-ALL cases (top plot). These images were taken from Borssén et al. (2013) under 
the Creative Commons Attribution Licence. 
 
Recently, Borssén and colleagues (2018) investigated the ability of the CpG island 
methylator phenotype (CIMP) to predict clinical outcome in B-ALL cases. They used the 
publicly available 450k array methylation data of 601 B-ALL cases at diagnosis and 137 
cases at relapse from Nordlund et al. (2013). Using their CIMP panel from T-ALL 
analysis, they found 426 CIMP+ and 175 CIMP- cases of B-ALL at diagnosis. However, 
at relapse 95 of 137 cases were classified as CIMP+. Interestingly, the CIMP+ group 
clustered with favourable cytogenetic subtypes, such as ETV6-RUNX1 (88% of CIMP sites 
were methylated) and hyperdiploidy (63% of CIMP sites were methylated). In comparison, 
unfavourable cytogenetic abnormalities, such as TCF3-PBX1 and BCR-ABL1, were 
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clustered in the CIMP- group (83% and 67% of CIMP sites were unmethylated, 
respectively). The overall survival analysis of CIMP groups at diagnosis showed a 
significant difference between groups (Kaplan-Meier analysis P-value = 0.02). Among 
relapsed cases, the CIMP- group had a worse prognosis than CIMP+ group with 5-year 
overall survivals of 33% and 65%, respectively (Figure 1.5).  
 
Figure 1.5. Overall survival plots (Kaplan-Meier analysis) for B-ALL cases at diagnosis 
and relapse show a better prognosis for CIMP+ group. This image was taken from 
Borssén et al. (2018) under the Creative Commons Attribution 4.0 International License. 
 
Navarrete-Menses and Perez-Vera (2017) proposed that some B-ALL subtypes have 
unique methylation patterns. As an example, EPOR was found to have low DNA 
methylation in the promoter region in cases with the ETV6-RUNX1 fusion transcript. It 
was proposed that the ETV6-RUNX1 fusion protein activates EPOR transcription to 
contribute in leukaemia development and cellular proliferation through the JAK2-STAT5 
pathway. In addition, ASNS methylation in ETV6-RUNX1 B-ALL was proposed to 
sensitise cells to L-asparaginase treatment, perhaps explaining the good prognosis of 
patients with ETV6-RUNX1. In contrast, alterations of DNA methylation of ERHV3, 
DMNBP, KCNA3, PAG1 and C11orf52 in patients with ETV6-RUNX1 were associated 
with relapse. Furthermore, a set of genes were found to have increased DNA methylation 





1.3.2 Published B-ALL methylation biomarkers 
Leukaemia cases have a unique DNA methylation profile compared to control samples and 
DNA methylation can be used to classify leukaemia patients and can facilitate prognostic 
outcome. But, can DNA methylation biomarkers be used to diagnose B-ALL? 
Additionally, are there good B-ALL methylation biomarkers in the literature? 
Wang and colleagues (2010) identified three methylation biomarkers for B-ALL: DLC1, 
PCDHGA12 and RPIB9. They used multiple methylation-sensitive restriction enzyme 
PCR (MSRE-PCR) by incubating DNA obtained from leukaemia samples and cell lines 
with Acil, Hpall, HinP1l and BstUl for DNA digestion. Because of the high DNA 
methylation in leukaemia, leukaemia-specific methylated regions were resistant to DNA 
digestion with methylation-sensitive restriction enzymes and could be amplified by PCR, 
unlike the un-amplifiable small fragmented DNA obtained after restriction digest of 
unmethylated DNA from normal samples (Figure 1.6). In addition, they evaluated the 
analytic sensitivity of the MSRE-PCR using serial dilution of DNA from NALM6 (B-ALL 
cell line) and were able to detect DLC1 methylation in as few as five leukaemic cells. 
Furthermore, the relative sensitivity of MSRE-PCR was one leukaemic methylated 






Figure 1.6. Methylation-sensitive restriction PCR protocol. The protocol involved three 
steps: DNA extraction, DNA digestion with methylation sensitive enzymes and PCR 
amplification of the target regions. B-ALL methylated samples were resistant to 
methylation-sensitive DNA digestion and therefore the methylated DLC1, PCDHGA12 
and RPIB9 target regions could be amplified. M = marker; C+ = positive control; C- = 
negative control; P1 and P2 = patients 1 and 2. This image was taken from Wang et al. 
(2010) under the Creative Commons Attribution Noncommercial License.   
 
Using MSRE-PCR for DLC1, PCDHGA12 and RPIB9 on 18 leukaemia and lymphoma 
cell lines, Wang and colleagues found the majority of cell lines produced PCR products for 
DLC1 and PCDHGA12 indicating the methylated status of these two genes. RPIB9 
products were seen in two B-ALL and four B lymphoma cell lines, while very weak bands 
were evident in the other cell lines. To further validate their biomarkers, 31 bone marrow 
samples from B-ALL patients were screened by MSRE-PCR and DLC1 methylation was 
detected in 61% of the patients. In a separate cohort of B-ALL patients (n = 29), 55%, 62% 
and 31% of bone marrow samples were methylated for DLC1, PCDHGA12 and RPIB9, 
respectively. DLC1, PCDHGA12 and RPIB9 methylation was not detected in normal 
control samples (Wang et al., 2010). 
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Another study by Chatterton and colleagues (2014) used MALDI-TOF mass spectrometry 
to evaluate the level of detection of TLX3 and FOXE3 DNA methylation in 95 bone 
marrow samples from ALL patients and 102 healthy controls. They used three MALDI-
TOF-based technologies to measure DNA methylation, EpiTYPER, methylSABER and a 
custom developed multiplex EpiTYPER. They evaluated the limits of detection for low 
DNA methylation using an EpiTYPER fraction (EF) analysis, which was based on the 
mean peak intensity ratios for all analysed CpG-fragments of TLX3 and FOXE3 (13 and 12 
CpG fragments, respectively). They used an EF threshold of 0.2 and found >50% of the 
ALL patients had EF > 0.2 for both genes (85% of ALL patients had EF > 0.5) compared 
to EF < 0.2 in 95% of control samples (specificity = 95% and sensitivity = 93%). They 
evaluated the detection limits of the methods and found methylSABER was capable of 
detecting 10 methylated epialleles of 100,000 copies (i.e., analytic sensitivity of 10-4) 
compared to 1,000 – 5,000 methylated epialleles that could be detected by the EpiTYPER 
and multiplex EpiTYPER techniques (Chatterton, Burke, et al., 2014). 
1.3.3 The use of 450k array datasets to identify methylation biomarkers 
Infinium Human Methylation450K BeadChips have the ability to quantify the DNA 
methylation state of 31% of CpG islands in the human genome with high reproducibility, 
using approximately 450,000 probes (Dedeurwaerder et al., 2011; Ma et al., 2013). 
Dedeurwaerder and colleagues evaluated the reproducibility of the 450k array for colon 
cancer cell lines by using three technical replicates. They found a high correlation of the 
450k array methylation results between the three replicates with a Pearson correlation of 
0.98. In addition, Forest and colleagues (2018) investigated the consistency of 450k array 
DNA methylation of samples and found high agreement between the technical replicates.  
The 450k DNA methylation array technology was based on the quantification of the signal 
intensity of C or T containing fragments of DNA following bisulfite-conversion 
(Nakabayashi, 2017). Once the bisulfite-converted DNA hybridises to the beadchip, a 
single-base extension process occurred from the 3’ terminus using fluorescently labelled 
ddNTPs. After the amplification, the methylated and unmethylated cytosines are detected 
as C and T, respectively (unmethylated cytosines were converted to uracil and amplified as 
thymine). For the Infinium I assay, probes (n = 135,501) were designed with two types of 
beads for each CpG site, methylated and unmethylated. However, for the Infinium II assay, 
probes (n = 350,076) contain one type of bead which can be extended by incorporating 
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ddGTP or ddATP nucleotides for methylated and unmethylated cytosines, respectively. 
Once ddNTPs are incorporated in the assay, the fluorescent molecule detaches from the 
base and can be detected as a signal intensity (Nakabayashi, 2017).  
The interest of the research community in analysing 450k array datasets is reflected in the 
number of available analysis tools. There are more than 500 tools available for 450k array 
data analysis on the OMIC tools website (see section 8.2.2). Morris and Beck (2015) listed 
features of five pipelines (methylumi, minfi, wateRmelon, ChAMP, and RnBeads). These 
five R packages focus on identifying differentially methylated regions based on grouping 
probes in relation to CpG islands and genomic features. Despite the presence of a few 
450k array analysis pipelines that claim to identify differentially methylated regions 
(DMR), the definition of a DMR is not standardised and is widely variable (see section 
8.2.2 for a detailed discussion). 
1.3.4 TES is densely methylated in leukaemia 
Weeks and colleagues (2010) investigated the level of TES methylation in normal blood 
and bone marrow and in leukaemia cases. Bisulfite sequencing at CpG sites within TES 
promoter region showed dense biallelic methylation in B-ALL compared to normal 
peripheral blood. The methylation level for B-ALL samples ranged from 64% to 77% 
compared to 0 to 1.5% in healthy adult blood samples. In addition, they investigated the 
level of TES expression using quantitative PCR and found an inverse correlation between 
methylation and expression. Furthermore, gene expression analysis by microarray 
confirmed the low expression level of TES in various B-ALL subgroups compared to 
normal B-lymphocytes (Figure 1.7) (Weeks et al., 2010). Weeks and colleagues showed 
methylation data of 48 CpG sites within the TES promoter region, and hence TES is 
included as a useful candidate methylation marker for the exploration of ALL-like cells. 
TES is a tumour suppressor gene and its DNA methylation or mutation was proposed to be 
associated with cancer. Tobias and colleagues (2001) used EcoRV/HindIII with or without 
HpaII or MspI restriction enzymes to enrich for methylated CpG islands on breast and 
ovarian cancer cell lines followed by Southern blotting and found that TES DNA 





Figure 1.7. TES is densely methylated and weakly expressed in B-ALL cases. A) 
Bisulfite sequencing of CpG sites within TES promoter region for normal and B-ALL 
cases. B) TES expression analysed by RTqPCR of xenograft leukaemia samples. C) 
Gene expression levels (Affymetrix array) for TES gene in various B-ALL subgroups. 
These images were provided by Rob Weeks (2010). 
 
Using the GoldenGate Methylation Cancer Panel I (Illumina) that can profile 1,505 CpG 
sites from 807 cancer-associated genes (microarray-based methylation analysis), Martin-
Subero and colleagues (2009) identified epigenetically modified genes from 367 
haematological cancer patients. Their analysis found about 58 genes with “de novo” DNA 
methylation in B-ALL and about 202 genes that were hypermethylated in at least one of 
the B cell tumour types (Figure 1.8). Our analysis of their publicly available data found 
more than 200 genes that were epigenetically different between B-ALL cases and normal 
B-lymphocytes (Figure 1.8) (Martin-Subero et al., 2009). For example, TES DNA 






Figure 1.8. DNA methylation for different haematological malignancies and normal 
control samples. The bottom two plots show the methylation level in two genes, TES and 
CTGF. The top figure was taken from Martin-Subero et al. (2009) under the terms of the 
creative commons attribution license. The bottom plots were derived from the 
supplementary data. 
 
1.4 Fetal and adult B lymphocytes 
1.4.1 B-cell development 
An understanding of B lymphocyte development and fetal lineages is relevant with respect 
to the cells of origin of ALL. B cells pass through several stages to develop into mature B 
cells (Figure 1.9). B cell stages are characterised by rearrangement of the immunoglobulin 
gene (Ig) heavy and light chains. It was proposed that rearrangement of the 
immunoglobulin gene heavy chain (IGH) starts at the pro-B stage (Janeway et al., 2001). 
Heavy and light chains are encoded by variable and constant gene regions. V-J segments 
of the light chain genes is composed of 40 V segments in the kappa gene, and 30 in 
lambda; and five J segments in kappa and four in lambda. V-D-J segments of the heavy 
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chain are composed of 65 V segments, 27 D segments, and six J segments. Rearrangement 
of different combinations of V, D and J segments onto the constant regions produces a 
continuous exon, which can then be transcribed and translated to a unique immunoglobulin 
(Janeway et al., 2001).  
 
Figure 1.9. A summary of the developmental stages of human B cells. BCR: B cell 
receptor. 
 
DNA rearrangement is guided by recombination signal sequences, which are conserved 
non-coding DNA sequences consisted of a heptamer (5’-CACAGTG-3’), 12 or 23 
nucleotides called a “spacer”, and a nonamer (5’-ACAAAAACC-3’). Gene segments that 
contain signal sequences on both sides can be rearranged by one of two methods: (1) 
‘looping-out’ (the most common method) involves deleting DNA between gene segments 
if they are in the same orientation, and (2) ‘DNA inversion’ method involves retaining the 
DNA but in an inverted orientation when gene segments are in opposite orientation 
(Janeway et al., 2001). V-D-J recombinase enzyme, which is composed of RAG-1 and 
RAG-2 proteins, along with high mobility group proteins, initiate the gene rearrangement 
(Figure 1.10). The gene rearrangement process passes through the following steps: (1) 
binding of RAG proteins onto the spacer region, (2) binding of RAG proteins to each other 
to bring two gene segments together, (3) activation of RAG enzymes that cleave DNA at 
the end of heptamer sequence forming a hairpin, (4) binding of additional proteins to the 
cut DNA strands (such as Ku70 and Ku80) nicking the hairpin at random sites within the 
recombination signal sequences region, (5) repairing DNA by DNA exonuclease to 
remove nucleotides from the opened hairpin and terminal deoxynucleotidyl transferase 
(TdT) to add nucleotides randomly, and (6) joining of DNA segments by DNA ligase IV 
that produces a continuous double stranded DNA (Janeway et al., 2001).  
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The first immunoglobulin rearrangement, which occurs at the pro-B cell stage, involves 
the heavy chain genes. Cytoplasmic µ immunoglobulin molecules initially appear at the 
pre-BI stage, while large pre-B-II cells are characterised by their expression of the 
immunoglobulin molecule (B cell receptor) on the cell surface. Light and heavy chain gene 
rearrangements occur at the immature B cell stage (Janeway et al., 2001).   
 
Figure 1.10. Summary of the main steps in immunoglobulin gene rearrangement process 
on recombination signal sequences (RSS) region (see text for details). This image was 




1.4.2 Murine fetal “B-1” B lymphocytes 
The literature describes two distinct populations of B-lymphocytes, neonatal B-1 and 
conventional B-2 cells (Alugupalli & Gerstein, 2005). In view of the fetal cell of origin of 
B-ALL, fetal B-1 cells represent a strong candidate cell type, and hence a detailed 
discussion on fetal B-1 cells has a high relevance to the work described in this thesis. 
There is, however, debate about their development and existence in human, and whether 
they originate from the same common lymphoid progenitor. 
Murine B-1 cells are involved with innate immunity against modified self-antigens, as 
shown by their spontaneous production of natural antibodies (IgM and IgA) (Baumgarth, 
2011). They were initially identified in mice and found to populate the pleural and 
peritoneal cavities to enhance T cell independent immunity (Alugupalli & Gerstein, 2005). 
CD5+ B-1a and CD5- B-1b cells are different than conventional follicular B-2 cells 
(Alugupalli & Gerstein, 2005). It has been proposed by some that B-1 and B-2 cells 
develop from separate progenitors (B-1 progenitors: Lin-CD93+CD45Rlow/-CD19+; B-2 
progenitors: Lin-CD45R+CD93+CD19-CD43+) (Montecino-Rodriguez et al., 2014).  
B-1 cells pass through three waves of development in fetal mice (Figure 1.11): 1) in the 
first wave, pre-haematopietic stem cell B-1 progenitors appear at day 10.5 in the yolk sac 
and para-aortic splanchnopleura; 2) in the second wave, B-1 cells and progenitors 
proliferate in the liver, bone marrow and spleen peaking at day 16-17; and 3) in the third 
wave, mature B-1 cells proliferation declines at the second week after birth (Montecino-




Figure 1.11. A diagram illustrating the three waves for murine fetal B-1 lymphocytes 
development. This image was taken from Montecino-Rodriguez et al. (2012) with 
permission.  
 
As yet the DNA methylation profile of murine fetal B-1 cells has not been described, but 
their gene expression profile was described by Yamagata and colleagues (2006). They 
sorted B-1 cells using IgMhiIgDintCD11b+ markers from mice peritoneal lavage and B-2 
cells were sorted from the dissected spleen of the same mice using IgMintIgDhiCD11b- 
markers. They found 1,936 differentially expressed genes and hierarchical clustering of 
these genes is shown in Figure 1.12. 
 
Figure 1.12. Gene expression profile for murine lymphocytes. The heatmap shows a 
distinct expression signature for B-1 cells compared to other lymphocytes. This image 
was taken from Yamagata et al. (2006) with permission. 
 
Montecino-Rodriguez and colleagues (2016) proposed that the progression of B-1 waves 
during cell development was regulated by the transcription factor, PU.1. They used mice 
with a deletion of 14 kb upstream regulatory elements (URE) from the transcription start 
site of Sfpi1. The deletion of URE was associated with downregulation of PU.1, a 
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transcription factor that was proposed to be essential for the regulation of B 
lymphopoiesis. The original studies proposed that the development of all B cells was 
blocked in these mice; however, they found they produce normal numbers of B-1 cells but 
very few B-2 cells. They collected B-1 and B-2 cells from mice at embryonic day E15.5, 
postnatal day 2, and at 9 to 11-weeks, representing cells at fetal, neonatal and adult 
developmental stages, respectively. They used B6 mice for the transcriptomic investigation 
to collect B-1 at E15.5 gestation at yolk sac and para-aortic splanchopleura fetal tissues. 
They found 1,548 differentially expressed genes in B-1 compared to B-2 progenitors (> 2-
fold difference, p-value < 0.01). Interestingly, B-1 cells from fetal, neonatal and adult mice 
did not cluster together in the principal component analysis suggesting that the analysed B-
1 cells were derived from different developmental waves. However, fetal and neonatal B-2 
cells were clustered in one group while adult B-2 cells were found in a separate group 
indicating that B-2 cells have two developmental waves: fetal-neonatal and adult (Figure 
1.13).  
 
Figure 1.13. Results of principal component analysis of transcriptomic data showing B-
1 cells from fetal, neonatal and adult mice were clustered separately, while fetal and 
neonatal B-2 cells cluster away from the adult B-2 cells (left image). These results 
reflect the difference between the developmental waves of B-1 and B-2 progenitors 
suggesting the presence of three and two waves for B-1 and B-2 cells, respectively (right 





Montecino-Rodriguez and colleagues (2016) also found core regulatory genes that regulate 
B cell differentiation were different between B-1 and B-2 cells. As an example, the 
expression of Runx1 and Sfpi1 in B-1 cells was lower than in B-2 cells (Figure 1.14). In 
addition, the expression of Ebf1, Foxo1, PAX5 and Tcf3 transcription factors was higher in 
B-1 cells than B-2 cells indicating that B-1 and B-2 cells had differences in B cell 
transcriptional programs (Figure 1.14). Furthermore, they identified 1,274 and 1,449 genes 
that had altered gene expression at different B-1 and B-2 developmental stages, 
respectively. The majority of differentially expressed genes in fetal and neonatal mice 
samples different from those differentially expressed in adult mice. Fetal and neonatal 
differentially expressed genes were involved in general metabolic and signalling processes.  
 
Figure 1.14. Results for key regulatory genes in B cell development showing distinct 
gene expression patterns between B-1 and B-2 progenitors. This image was taken from 
Montecino-Rodriguez et al. (2016) with permission. 
 
1.4.3 Human fetal “B-1” B lymphocytes 
In 1985, Bofill and colleagues (1985) described a human fetal B cell population that 
showed characteristics similar to murine B-1 cells. They collected washout cell 
suspensions from peritoneal and pleural cavities of 15, 18, and 24 weeks human fetuses. In 
addition, they collected fetal liver, bone marrow, para-aortic lymph nodes, and tonsils from 
other 19 human fetuses of similar gestational ages. Using immunofluorescence, they 
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identified an IgM+CD5+ B cell population in these tissues. IgM+ B cells comprised 13 – 
31% of cells collected from peritoneal and pleural cavities (Bofill et al., 1985). 
Griffin and colleagues (2011b) investigated the presence of the human equivalent of 
murine B-1 B lymphocytes in human cord blood and adult peripheral blood by evaluating 
three main B-1 cell functions: IgM spontaneous secretion, stimulation of T cells, and 
active intracellular signalling. When they enriched for CD20+ B lymphocytes, they 
accidently found a subset of CD27+ cells that spontaneously secreted IgM and represented 
3 to 11% of CD20+ B cells. In addition, they found these CD20+CD27+ B cells expressed 
CD43+, a B-1 cell marker in mice. They measured IgM secretion by CD20+CD27+CD43+ 
cells using ELISPOT test and found it was markedly elevated in B-1 cells compared to 
CD20+CD27-CD43- B cells. They tested the ability of these cells to stimulate T cells and 
found irradiated CD20+CD27+CD43+ cord blood B cells stimulated more CD4+ T cells 
than CD20+CD27-CD43- B cells.  
Furthermore, Griffin and colleagues evaluated the ability of these cord B-1 cells to 
demonstrate tonic intracellular signalling by phosphoflow analysis. They found tyrosine 
phosphorylation fluorescence (phospholipase C gamma 2 and spleen tyrosine kinase) in 
CD20+CD27+CD43+ B lymphocytes after phosphatase inhibition compared to minimum 
phosphorylation in CD20+CD27-CD43- B cells. Similar tests were performed on isolated 
CD20+CD27+CD43+ cells from adult peripheral blood, and they found similar findings. 
They estimated the ratio of CD20+CD27+CD43+ level in relation to the total CD27+ cells 
among different age groups and found their level declined more than four-fold from 0 to 





Figure 1.15. A scatter plot of the percentage of CD20+CD27+CD43+ B lymphocytes at 
different age groups. This image was taken from Griffin et al. (2011b). The Rockefeller 
University Press (RUP) allow the reuse of their published materials for the educational 
purposes without permission. 
 
Immediately after the publication by Griffin et al. (2011b), debate emerged in the literature 
regarding the reliability and reproducibility of the findings. Descatoire and colleagues 
(2011) found that these cells stained positive for CD3 and argued that 
CD20+CD27+CD43+CD3+ cells are doublets of CD27+CD43+ T cells and CD20+IgDhigh 
naïve B cells. Despite gating out CD3- cells, CD3-CD20+CD27+CD43+ cells demonstrated 
expression of IgD and variable expression of CD38, a plasma cell marker (Figure 1.16), 
indicating that the B-1 cells identified by Griffin et al, were either activated B cells on their 
way to become plasma cells or a new unidentified subset of B cells with innate, B-1 like, 
functional features. Consequently, they argued that Griffin’s findings were confounded by 
doublets and by background non-specific staining, which in turn questions the reliability of 




Figure 1.16. Flow cytometry scatter plots showing approximately 5% of the 
CD20+CD27+ B-1 cells expressed CD3 antigen, the pan-T cell marker. The percentage 
was lower with CD19+ pre-enrichment. CD3-CD20+CD27+CD43+ B-1 cells expressed 
IgD and CD38 markers suggesting that they are activated B cells on their way to become 
plasma cells. This figure was taken from Descatoire et al. (2011). The Rockefeller 
University Press (RUP) allow the reuse of their published materials for the educational 
purposes without permission. 
 
 
Perez-Andres and colleagues (2011) also debated Griffin’s findings. They tested whole 
blood samples (cord blood, adult’s and children’s peripheral blood) and childhood tonsils 
using flow cytometry without enrichment. They found 0.1 – 24% of CD19+CD27+CD43+ 
cells highly expressed CD3 in both neonatal and adult samples, suggesting that these cells 
were doublets of T and B cells (cells in red colour and circled in Figures 1.17A, B and C). 
Consequently, the majority of the CD19+CD5+ B cells were incorrectly labelled “B-1 
cells” due to their expression of CD3 marker. In addition, they found 0.1 - 4.6% of CD3-
CD27+CD43+ cells highly expressed the CD38 marker suggesting that the identified “B-1 
cells” were in fact activated B cells on their way to become plasma cells (blue and red bars 
in Figure 1.17D). However, they found a small population (0.3-2.3%) that can be 
considered “true B lymphocytes” from the “CD27+ memory B lymphocytes” that 





Figure 1.17. Flow cytometry scatter plots of whole blood samples and tonsil to 
characterise the phenotype of the proposed B-1 B lymphocytes in human tissues (see text 
for details). Cells in red colour and circled in A, B and C represent B-1 cells. A bar-plot 
in D is showing the relative frequencies of CD3+ (green bars), CD3-CD38high (red bars) 
and CD3-CD38low (blue bars) in relation to the CD27+CD43+ cells at different age 
groups. This image was taken from Perez-Andres et al. (2011). The Rockefeller 
University Press (RUP) allow the reuse of their published materials for the educational 
purposes without permission. 
 
Griffin and colleagues (2011a) responded to the comments concerning the presence of 
CD3+ T cells in the CD20+CD27+CD43+ (Descatoire et al., 2011) and CD19+CD27+CD43+ 
(Perez-Andres et al., 2011) B cells. They proposed that CD19+ enrichment of B cells prior 
to surface marker staining can reduce the observation of CD3+ cells. They found < 1% of 
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CD3+ cells in samples enriched for CD19+ B cells compared to < 3% CD3+ cells in 
unenriched samples. In addition, they conducted single cell confocal microscopy and 
demonstrated the expression of CD19/CD27/CD43 or CD20/CD27/CD43 in single cells 
(Figure 1.18). Furthermore, they recreated the flow cytometry experiments of Descatoire’s 
and Perez-Andres’s to investigate the doublet phenomenon. They found that gating out 
doublets using a FSC-H/FSC-A gate, adequate sample dilution and adequate vortexing 
reduced CD3+ T cells. In addition, they found that samples with concentrated cells 
contained higher numbers of CD3+ T cells and CD3+ T/naïve B cell doublets. To confirm 
their previous experimental work, they showed their flow cytometry gating strategies and 
they validated their findings post-sorting with Hoechst33342 nuclear staining (Figure 
1.19). After fluorescent microscopy examination of more than 1000 CD20+CD27+CD43+ 
cell-sorted B-1 cells, they did not observe any doublets (Griffin et al., 2011a). 
 
 
Figure 1.18. Single cell confocal microscopy analysis demonstrates the expression of 
CD19, CD20, CD27, and CD43 surface markers in B-1 cells. This image was taken from 
Griffin et al., (2011a). The Rockefeller University Press (RUP) allow the reuse of their 
published materials for the educational purposes without permission. 
 
 
Figure 1.19. Flow cytometry gating strategy to purify human B-1 B lymphocytes from 
cord blood. This image was taken from Griffin et al. (2011a). The Rockefeller University 






Bueno and colleagues (2016) investigated the presence of B-1 cells in the developing 
human embryo. They used Griffin’s definition of B-1 cells (CD3-
CD20+CD19+CD27+CD43+), naïve B cells (CD3-CD20+CD19+CD27-CD43-) and 
memory B cells (CD3-CD20+CD19+CD27+CD43-). They enriched for B-1, naïve and 
memory B cells from the following samples: 1) human fetal liver (10 to 11 and 20 to 21 
weeks gestation), 2) human fetal bone marrow (20 to 21 weeks gestation), and 3) cord 
blood. They identified B-1 cells in all of the analysed samples and they were found to have 
spontaneous expression of IgD and IgM. The expression of IgM was found to be higher in 
cord blood (70% of samples) than fetal liver (21% of samples) and fetal bone marrow 
(20% of samples). Interestingly, early fetal liver samples (10-weeks gestation) had the 
highest number of B-1 cells, representing 6.1% (ranged from 5.7% to 6.5%) of total B 
cells. The frequency of B-1 cells declined with age to become 2.1% (1.4% - 2.8%) and 
2.6% (1.9% - 3.3%) at mid-gestation in fetal liver and fetal bone marrow, respectively 
(Figure 1.20). The frequency of B-1 cells was then maintained in fetal liver and bone 
marrow until birth, representing 1.9% (1.8% - 2.7%). In comparison, the frequency of 
naïve B cells increased with age from 53% (38% - 68%) of total B cells in fetal liver at 10 
to 11 weeks gestation to reach a plateau at mid-gestation (21 to 21 weeks), representing 
87% (73% - 100%) in fetal liver, fetal bone marrow and cord blood samples. However, 
memory B cells were found to have the opposite pattern to naïve B cells as they declined 
with age from 22% (7% - 37%) in fetal liver samples at early gestation (10 to 11 weeks) to 





Figure 1.20. Summary results for the frequency of B-1 (e), naïve (f) and memory (g) B 
cells in human fetal liver, fetal bone marrow and cord blood samples. Fetal liver and 
bone marrow samples were collected from embryos at early (10-11 weeks) and mid-
gestation (20-21 weeks). This image was taken from Bueno et al. (2016) with 
permission. 
 
1.4.4 B-1 B lymphocytes and B-ALL 
A recent study investigated the ability of B-1 cells to initiate B-ALL. Montecino-
Rodriguez and colleagues (2014) transduced murine B-1 and B-2 progenitor cells (Lin-
CD93+CD45Rlow/-CD19+ and Lin-CD45R+CD93+CD19-CD43+, respectively) with BCR-
ABL1/GFP or GFP retroviral vectors. Transduced cells were then transplanted into 
immunodeficient mice. Mice receiving BCR-ABL1/GFP B-1 cells developed signs of B-
ALL by day 40 post transplantation compared to 60 - 140 days in controls and up to 2-fold 
more GFP positive cells in the spleen of mice with B-ALL compared to mice BCR-
ABL1/GFP transduced B-2 cells. Since B-1 progenitor cells require IL-7 and TSLP 
receptor to proliferate, the transduced B-1 cells were transplanted into CRLF2-/- (TSLP 
receptor deficient) and IL-7Rα-/- (IL-7 receptor deficient) mice. They proposed that B-ALL 
development could have a slow proliferation or incomplete development when the 
transduced B-1 cells were injected into CRLF2-/- and IL-7Rα-/- mice. They found that few 
B-1 cells could be detected in CRLF2-/- mice and in IL-7Rα-/- mice suggesting the need for 
IL-7 for the proliferation process. Both CRLF2-/- and IL-7Rα-/- B-1 mice developed B-
ALL. In addition, they transplanted BCR-ABL1/GFP B-1 progenitor cells into C57BL/6 
mice (B6) and found they developed leukaemia by day 45 compared to delayed leukaemia 
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development (100-day post transplantation) in the transplanted B-2 transduced mice 
(Montecino-Rodriguez et al., 2014). 
Recently, Gough and colleagues (2017) reported B-ALL leukaemia in NUP98-PHF23 
(NP23) transgenic mice at 14 months of age. Interestingly, they found the majority of mice 
developed either myeloid or T cell leukaemia; however, one mouse developed B-ALL with 
CD19+B220+ B cells in the bone marrow, spleen, lymph nodes and thymus. In addition, 
seven mice (about 9%) developed B-ALL with a confusing CD19+B220- phenotype. This 
is because B220 expression usually proceeds the expression of CD19 antigens. 
Furthermore, two of the seven mice had developed two different leukaemia subtypes (T- 
and B-ALL), showing an underlying complicated biology that did not follow the known 
standard differentiation pathways. They found that the CD19+B220- B-ALL cells had the 
phenotype of pro-B-1 B cells (B220-CD19+AA4.1+CD43+) and they argued that these B-
ALL cells originated from the pro-B-1 lineage. CD43 is a T cell antigen and is known to 
be highly expressed in 80% of ALL cases (Toth et al., 1999). They conducted a gene 
expression microarray analysis and found 946 genes were differentially expressed in B-
ALL NP23 ALL compared to purified normal B cell populations. Then, they validated 
their array data with RNA-seq and found 106 genes commonly expressed in both 
experiments (> 2-fold overexpression in B-ALL mice). Hierarchical clustering of the B-
ALL RNA-sequencing data showed a high similarity to that of fetal liver pro-B-1 B cells. 
Therefore, they proposed that B-ALL patients with increased expression of CRLF2 “may 
have malignancies of pro-B-1 origin”. They speculated that mutations in three pathways 
were critical for the development of precursor B-ALL: “stem-cell self-renewal, B-cell 
differentiation, and cytokine signalling” (Gough et al., 2017). 
Based on Montecino-Rodriguez’s and Gough’s findings, fetal B-1 cells appear to have 
relatively high potential to develop into B-ALL. These findings support this hypothesis 
that B-ALL arise from a fetal cell of origin. However, childhood B-ALL develop years 










Chapter 2: Rationale, Hypotheses and Aims  
2.1 Background and Hypotheses 
Childhood acute lymphoblastic leukaemia (ALL) is a disease that originates before birth 
from the proliferation of neoplastic lymphoid precursor cells in the bone marrow. 
Previously, dense biallelic methylation of the TES promoter was found in over 90% of B-
ALL and 70% of T-ALL cases (Weeks et al., 2010). In addition, hundreds of genes are 
differentially methylated in ALL suggesting a common epigenetic signature in ALL. The 
large number and consistency of epigenetically modified genes raise the possibility that 
methylation-induced gene silencing in ALL may not be an acquired cancer-related 
phenomenon but may reflect the epigenetic profile of the fetal cell of origin for ALL. The 
traditional model for ALL development was based on the acquisition of genetic mutations 
in immature cells and transformation to “pre-leukaemic” cells prenatally, of which a 
subgroup of these may transform later to leukaemia (Figure 2.1, top pathway). The 
proposed model is that ALL arises from a unique fetal cell population that persists after 
birth in a postnatal environment. Transduced fetal cells (BCR-ABL1) were shown to 
develop leukaemia faster than adult-type transduced cells suggesting their high 
susceptibility to leukaemic transformation (Montecino-Rodriguez et al., 2014). The 
development of childhood solid tumours from persistent embryonic cells is also observed 
in Wilms tumours, infantile haemangiomas, and other childhood cancers (Greenberger & 
Bischoff, 2013; Ludgate et al., 2013).  
Some models are proposed:  
1. There is a specific master epigenetic regulator (or possibly group of regulators) that 
is affected in leukaemia, possibly by mutation, causing specific DNA methylation 
in the malignant B cell leukaemia (Figure 2.1, master epigenetic regulator 
pathway). The identification of ALL-like cells with B-ALL epigenotype in healthy 
newborns can disprove this model as the B-ALL master regulator cannot be 
involved in both leukaemic and non-leukaemic states. 
Alternatively, 
2. There is a distinct lineage of normal “fetal” cells, possibly a B cell lineage, gives 
rise to a unique fetal cells with an ALL-like epigenotype. “Pre-leukaemic” cells 
 
 46 
arise from a normal ALL-like fetal stem cell that acquires genetic mutations such 
as ETV6-RUNX1 translocation during early gestation. Then, a common acquired 
environmental factor may acts as a secondary hit to transform the “pre-leukaemic” 
fetal cells in the bone marrow of B-ALL children to leukaemic malignant cells 
(Figure 2.1, “pre-leukaemic” fetal clone pathway).  
3. Alternatively, the normal fetal cell lineage that has an ALL-like epigenotype, could 
persist until childhood. This persistent ALL-like fetal cell lineage in an 
inappropriate niche (i.e., postnatally), can transform to B-ALL due to their 
acquisition to genetic mutations. The transformation to B-ALL may be triggered as 
suggested in (2) above (Figure 2.1, persistent fetal cells pathway). 
 
Figure 2.1. B-ALL models indicating the role of fetal lymphocytes in ALL aetiology 
(see text for details).  
 
2.2 Significance 
The detection of methylation of TES and other ALL-methylated genes in normal neonatal 
lymphocytes would show that cells with an ALL-like epigenotype exist in normal children. 
Additional epigenetic characterization of these cells would determine if they show the 
characteristic DNA methylation pattern seen in ALL and would suggest that they are the 
 
 47 
cell of origin. The identification of these ALL-like fetal cells will provide a contribution to 
our understanding of the development and pathogenesis of ALL.  
2.3 Hypothesis 
• There is a distinct population of normal fetal lymphocytes that carries an epigenetic 
profile similar to that reported in ALL and these are the fetal cells of origin for 
ALL (hereafter referred to as “ALL-like fetal lymphocytes”).  
o This project uses an ALL-methylation biomarker panel to identify these 
ALL-like cells. 
2.4 Aims and Objectives 
To test this hypothesis, three major steps are necessary: 1) develop methods to interrogate 
publicly available 450k array methylation data and identify potential methylation 
biomarkers that are specific to ALL, 2) validate the methylation biomarkers using targeted 
methylation sequencing, and 3) use the methylation biomarker to detect the ALL-like fetal 
cells in normal neonatal blood samples. 
Aim 1: Identify the methylation biomarker panel by exploring publicly available 
datasets 
This aim can be achieved by utilising available tools for 450k array data analysis. Due to 
the limitations of the available tools, a pipeline was needed to analyse the publicly 
available human 450k DNA methylation array datasets. 
• Objective 1a: Identify publicly available 450k and 27k array methylation datasets 
containing methylation values for ALL samples. 
• Objective 1b: Construct a pipeline to facilitate the analysis of 450k array 
methylation datasets.  
• Objective 1c: Analyse the publicly available human 450k DNA methylation array 
datasets and identify a panel of genes that are densely and consistently methylated 





Aim 2: Evaluate the methylation biomarker panel by targeted methylation 
sequencing 
To validate the identified methylation biomarkers, deep targeted DNA methylation 
sequencing experiments will be used to profile the DNA methylation in healthy adults, 
healthy newborns, leukaemia cell lines and ALL xenograft samples. 
• Objective 2a: Optimise protocols for the preparation of targeted methylation 
sequencing experiments, such as DNA extraction, bisulfite-conversion and PCR 
amplifications of the ALL-methylated gene panel. 
• Objective 2b: Collect blood samples for the sequencing experiments from healthy 
adults and newborns and obtain DNA from leukaemia cell lines and ALL xenograft 
samples.   
• Objective 2c: Construct an analysis pipeline to process raw data (FASTQ files) 
from the MiSeq sequencing platform. The pipeline includes reads alignment and 
methylation calling. 
Aim 3: Use the methylation biomarker panel to identify ALL-like fetal cells 
This can be achieved by using targeted methylation sequencing to search for the 
methylation biomarkers in enriched subpopulations of normal neonatal blood samples. 
This has four objectives: 
• Objective 3a: Collect blood samples from premature neonates to study the 
existence of the ALL-like fetal cells at early development.  
• Objective 3b: Enrich for B-lymphocytes from neonatal cord blood cells by cell 
sorting using CD19-coated magnetic beads. The presence of DNA methylation of 
methylation biomarkers in the enriched normal neonatal cells can be investigated.  
• Objective 3c: Enrich for progenitor cells, T cells, B cells and non-B, non-T 
lymphocytes using fluorescence activated cell sorting followed by methylation 
biomarker sequencing.  
• Objective 3d: Investigate the presence of ALL-like fetal cells in early development 





Chapter 3: Method  
3.1 Abstract 
This chapter describes the methods used to identify the ALL-like cells in normal 
newborns. Neonatal and cord blood samples from pre-term and term babies were collected 
from Dunedin Neonatal Intensive Care Unit and Southland Hospital. Peripheral blood 
mononuclear cells (PBMC) were isolated from blood samples using Ficoll separation and 
then either stored in a -80°C freezer or enriched for B cells using CD19+ MicroBeads. 
Stored samples were used for fluorescent-activated cell sorting to enrich for CD34+ 
progenitor cells, CD3+ T cells and CD19+ B cells. DNA was extracted from enriched cell 
populations and bisulfite-converted for targeted DNA methylation sequencing assay. Two-
step PCR was used for the preparation of sequencing libraries to add Illumina adaptors 
(indices) onto the amplified target region. Sequencing libraries were checked by using a 
Bioanalyser and then loaded onto MiSeq (Illumina). 
3.2 Collection of samples 
3.2.1 Neonatal and cord blood samples 
Informed consent was obtained from the families of seven neonates at Dunedin Neonatal 
Intensive Care Unit (NICU) and surplus diagnostic blood samples were collected for the 
project (see section 6.2.1 for more details). Neonatal blood samples had very small 
volumes ranging from 15 to 300 µL. Thirty cord blood samples were collected from 
Southland Hospital, Invercargill by midwives and obstetricians. Cord blood samples were 
collected into ACD-A tubes and then were transferred by laboratory couriers to Dunedin. 
Details about the collected cord blood samples can be found in sections 6.2.2 and 7.2.  
3.2.2 Fetal liver samples 
DNA was extracted from 21 fetal liver samples by Kylie Drake, a previous PhD student in 
the Morison laboratory. These samples were formalin fixed and paraffin-embedded (FFPE) 




3.2.3 Leukaemia cell lines and xenograft samples 
The Morison laboratory have a range of leukaemia cell lines of which 10 were used in this 
project. In addition, 14 leukaemia xenograft samples (B-ALL = 9 and T-ALL = 5) were 
kindly provided by Professor Richard Lock. Details about these samples can be found in 
section 5.2.3.  
3.2.4 Obtaining Ethics Approval 
The Health and Disability Ethics Committee approved the collection of neonatal and cord 
blood samples (Ethics references: CEN/12/06/035 and CEN/12/06/036, respectively. See 
appendix 1 for a copy of the ethics approvals, participant information sheet and participant 
consent form). The collection and use of fetal liver samples was approved by the Otago 
Ethics Committee (Ethics reference: CEN/03/05/033). 
3.3 Isolation and storage of mononuclear cells 
To enrich for the lymphocyte population, peripheral blood mononuclear cells (PBMC) 
were isolated from collected neonatal and cord blood samples using Ficoll separation 
method. The isolated cells were either used for cell enrichment experiments or stored at 
-80°C. 
3.3.1 Protocol for the isolation of PBMCs 
This protocol was modified from the published protocol by Lan et al., (2007). Blood was 
diluted by sterile phosphate-buffered saline (PBS) by 1:1 ratio and then mixed by 
inversion. Three volumes of Ficoll-Paque PLUS (GE Healthcare Bio-Sciences AB, 
Sweden) to four volumes of diluted blood was used to isolate mononuclear cells from 
granulocytes by density gradient (Figure 3.1). The diluted blood was layered slowly on top 
of sterile Ficoll (at 45° angle) using 3 mL plastic transfer pipettes to avoid mixing. Tubes 
were then centrifuged at 800 x g for 20 minutes at 20°C with a slow acceleration and no 
breaks (acceleration = 3, breaks = 0).  
After the centrifugation, the plasma layer was removed and then the mononuclear cell 
layer was collected and transferred to a new 14 mL tube (Figure 3.1). Mononuclear cells 
were then washed twice with 5 mL PBS (centrifuge at 300 x g for 5 minutes at room 
temperature). To remove red blood cells from the isolated mononuclear cells, cells were 
mixed with 5 mL of red blood cell (RBC) lysis buffer and incubated at 37°C for 10 
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minutes. RBC lysis buffer contains 10 mM Tris-HCl and 0.14 M NH4Cl dissolved in water 
(pH of 7.4). Next, cells were washed twice with PBS as described above. Cells were then 
resuspended in 1 mL of RPMI culture media (Gibco) supplemented with 4.5 g/L sterile 
(filtered) D-glucose, 1 mL/L sterile (filtered) sodium pyruvate and 10% sterile fetal calf 
serum (FCS). Cells were then stained with trypan blue and counted using a 
haemocytometer.  
 
Figure 3.1. A diagram demonstrating the isolation of mononuclear cells from blood 
samples using the Ficoll density gradient method. 
 
3.3.2 Isolation of PBMC from samples with small blood volumes (< 1 mL) 
Because the majority of neonatal blood samples had small blood volumes (median volume 
= 100 µL, see section 6.2.1), the above protocol for the isolation of mononuclear cells was 
further optimised. Instead of diluting the blood in a 1:1 ratio with PBS, a ratio of 1:4 was 
done for any sample containing less than 1 mL of blood. Then, in a 2 mL Eppendorf tube, 
up to 500 µL of the diluted blood was layered slowly onto 1 mL of Ficoll-Paque PLUS 
using a plastic disposable transfer pipette. Tubes were then centrifuged in a microfuge 
(Eppendorf 5424, Germany) at 400 x g for 20 minutes at room temperature. Mononuclear 
cells were collected and transferred to a new 1.5 mL tube and washed twice with PBS 
(300 x g for 5 minutes at room temperature) (Figure 3.1). Because of the high PBS to 
blood ratio and the higher Ficoll to diluted blood ratio than the general protocol (see 
section 3.1.1 above), red blood cells were not present in this preparation and hence the 
RBC lysis step was not done. Cells were counted using trypan blue-haemocytometer 
method. 
3.3.3 PBMC storage 
After counting the isolated mononuclear cells, cells were aliquoted into a maximum of 
1 x 107 cells per aliquot, resuspended in 500 µL RPMI culture media and transferred to 
cryovials (Greiner Bio-One, Germany). Then, 500 µL of 2X freezing solution (50% RPMI 
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media, 40% fetal calf serum (FCS) and 10% dimethyl sulfoxide (DMSO)) was added to 
each aliquot. Cryovials were then placed into a -80°C freezer in Mr. Frosty freezing 
containers that were filled with 100% isopropyl alcohol for a slow rate of cooling (-1°C 
per minute). After that, cryovials were stored at -80°C freezer or in liquid nitrogen. 
3.3.4 PBMC thawing 
To thaw the stored cord blood cells, cells were thawed and washed quickly to minimise the 
toxicity of DMSO on stored cells. To do this, cryovials were transferred on ice from the 
-80°C freezer and placed in a 37°C water bath. A warm 1 mL of RPMI culture media was 
slowly added, drop by drop, to the thawed cells over a 30 second period, then the cells 
were mixed with the warm media. The cell suspension was then transferred to 10 mL 
warm media and mixed to dilute the DMSO solution. Cells were then washed twice with 
5 mL warm RPMI culture media by centrifuging at 300 x g for 5 minutes at 4°C and then 
removing the supernatant. To determine the recovery rate of the cryopreserved cells, viable 
cells were counted using trypan blue-haemocytometer method. Cells were incubated at 
room temperature for 30 – 60 minutes after washing to improve the recovery of the cells. 
3.4 Flow cytometry, magnetic cell enrichment and cell sorting 
One of the aims of this project was to enrich for the ALL-like cells using MicroBeads and 
FACS technology. Neonatal blood samples and 10 cord blood samples were used to enrich 
for B cells using CD19+ MicroBeads and magnetic separation columns. The remaining 
19 cord blood samples were sorted using FACSAriaII to enrich for CD34+ progenitor 
cells, CD19+ B cells and CD3+ T cells. 
3.4.1 Enriching for CD19+ B cells using magnetic MicroBeads 
After the isolation of mononuclear cells, cells were suspended in 1 mL of pre-cooled 
MACS buffer to maintain cell viability. MACS buffer contains 0.5% BSA and 2 mM 
EDTA dissolved in PBS. Cells were counted using 1:10 dilution of Trypan Blue using a 
haemocytometer and the number of viable cells was recorded. Then, 4 mL of MACS 
buffer was added to the samples and centrifuged at 300 x g for 7 minutes at 4°C. After the 
removal of supernatant, 80 µL of MACS buffer, 10 µL of CD19+ MicroBeads (Miltenyi 
Biotech) and 10 µL of FcR blocker (Miltenyi Biotech) were added to samples containing 
up to 1 x 107 cells. The cell suspension was then vortexed and incubated at 4°C for 
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18 minutes. Cells were then washed twice with MACS buffer by adding 5 mL MACS 
buffer, centrifuged at 300 x g for 7 minutes at 4°C and then the supernatant was removed. 
Finally, the cells were resuspended in 500 µL MACS buffer for magnetic separation with 
columns. 
For the convenience of sample processing, manual separation columns were used for the 
CD19+ B cell enrichment. Figure 3.2 shows the use of magnet to separate mononuclear 
cells. Each manual separation column is made of a narrow tube containing small 
ferromagnetic particles. The columns are attached to a syringe to assist the flow of cells 
and buffers in a steady stream to the columns. Columns were placed onto the magnet for 
cell separation. The multi-stand holds the magnet in an upright position to assist the 
downward flow of the cells. Each column was rinsed once with 500 µL MACS buffer. 
Then, cell suspension was mixed and applied to the column. The CD19+ cells remain 
bound to the magnetic column while the CD19 negative mononuclear cells pass through. 
The column was then washed three times with 500 µL MACS buffer. After the washing 
steps, the collection tube contained the filtered out CD19 negative mononuclear cells. To 
elute the CD19+ cells, the magnetic column was removed from the magnet and placed on a 
new collection tube. Next, 1 mL of MACS buffer was applied onto the magnetic column 
and flushed out forcefully using the provided plunger (Figure 3.2). Collected CD19+ and 
CD19- cells were then centrifuged at 300 x g for 5 minutes at room temperature and cell 
pellets were used for DNA extraction. 
 
Figure 3.2. A diagram showing the use of manual separation columns for the magnetic 




3.4.2 Flow cytometry 
Flow cytometry experiments were done to titrate the antibodies and to evaluate flow 
cytometry protocols before proceeding to FACS experiments. The antibody panel was 
designed to be used on FACSAriaII (BD Biosciences) and was tested on the Gallios flow 
cytometer (Beckman Coulter). FACSAria II and the Gallios have similar 488 nm blue, 
633 nm red and 405 nm violet lasers; however, the Gallios has 10 filters compared to nine 
filters on the FACSAriaII.  
Antibody Panel Design: The designed panel was compatible with both analysers using the 
same bandwidth filters. They were: 7AAD viability dye (filter 695/40), FITC (filter 
530/30), APC (filter 660/20) and BV421 (filter 450/40). The panel was checked for 
fluorophore overlap and compensation issues. Figure 3.3 shows a fluorophore spectra 
analysis for the designed panel using BioLegend Fluorescence Spectra Analyser tool 
(https://www.biolegend.com/spectraanalyzer). No overlap was detected between the 
fluorophores of the designed panel except for 7AAD and APC. Because 7AAD-negative 
live cells were selected for downstream flow cytometry gating analysis, the overlap was 
not an issue. 
 
Figure 3.3. A fluorescence spectra analysis for the designed 7AAD, FITC, APC and 
BV421 flow cytometry panel. Arrows pointed to the emission peaks of each fluorophore 
for their corresponding detection filters.  
 
Antibodies: Fluorophores for the antibodies were selected based on the expected number 
of cells for each subpopulation. The plan was to gate for CD34+ progenitor cells, CD19+ 
B cells and CD3+ T cells. The median number of T cells in neonatal and cord blood 
samples is 2.6 (1.9 – 4.4) x 109/L and the median number of B cells is 0.8 (0.3 – 1.0) x 
109/L representing about 55% and 17% of total lymphocyte count respectively (de Vries et 
al., 2000). However, CD34+ cells represent only 1.3% (1.1 – 1.5%) of the isolated 
mononuclear cells from cord blood samples (Nimgaonkar et al., 1995). Consequently, a 
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bright fluorophore was selected for the CD34+ progenitor cells compared to slightly 
dimmer fluorophores for B and T cells. The brightness index for BV421 and APC is 5 
while FITC has a brightness index of 2 (the fluorophore brightness index was based on 
BioLegend brightness index website: https://www.biolegend.com/brightness_index). As a 
result, the following antibodies were purchased for flow cytometry and FACS 
experiments: BV421 mouse monoclonal anti-human CD34 (clone: 561, BioLegend), APC 
mouse monoclonal anti-human CD19 (clone: HIB19, BioLegend) and FITC mouse 
monoclonal anti-human CD3 (clone: UCHT1, BD Pharmingen) antibodies. In addition, 
7AAD cell viability dye was included in the panel for the selection of live cells 
(Invitrogen). 
Controls: To set the gating parameters of the analysed data, a set of controls were prepared 
for each flow cytometry experiment. These controls include: 1) cells stained with a single 
fluorophore-labelled antibody, 2) fluorescent-minus-one (FMO) controls, 3) unstained 
cells, and 4) stained controls. The single fluorophore staining was used to set the PMT 
voltages for each antibody in relation to the unstained control, while the FMO controls 
were used to set the compensation matrix. Four FMO controls were prepared for each 
experiment. As an example of this is an FMO for BV421-CD34+ included the 7AAD 
viability dye, APC-CD19 and FITC-CD3 antibodies. FMO controls were used to evaluate 
the spill-over of all fluorophores in each detection channel. Removing one fluorophore 
from the full panel means that it is possible to evaluate spill-over into the unused detected 
channel.  
Fc receptor blocker (FcR blocker) was used to block the nonspecific bindings of antibodies 
and potentially increase the purity of stained cells.  
Flow Cytometry Protocol: After thawing the PBMC and counting viable cells (see section 
3.3.4), the number of cells required for each control were aliquoted into 3 mL Khan tubes. 
Ten control samples were used in every flow cytometry experiment: one tube for unstained 
control; four singularly stained tubes for 7AAD, BV421-CD34, APC-CD19 and FITC-
CD3 antibodies; four FMO controls and one fully stained control. Cells in the 7AAD tube 
were killed by a heat-shock process (50°C for few minutes) to allow the viability dye to 
stain dead cells. This is to ensure a proper 7AAD staining for compensation. The 
10 controls used PBMC aliquoted cells isolated from a healthy adult donor. For the 
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titration of the BV421-CD34 antibody, the control samples were spiked with the CD34+ 
KASUMI cell lines.  
Control and cord blood samples were then centrifuged at 300 x g for 5 minutes at room 
temperature after the addition of 5 mL of RPMI culture media. After the removal of 
supernatant, 2.5 µL of diluted antibody (not including 7AAD viability dye) was added and 
cells were incubated for 30 minutes at room temperature. For FMO and fully stained 
controls, the final volume was adjusted to 50 µL by using FACS buffer. Sterile FACS 
buffer contained 0.1% of bovine serum albumin (BSA), 0.01% sodium azide and 2 mM 
EDTA resuspended in PBS. After antibody incubation, cells were then washed twice with 
2 mL sterile PBS (centrifugation at 300 x g for 5 minutes at room temperature). Then, cells 
were mixed with viability dye that had 2.5 µL 7AAD in 50 µL FACS buffer. The mixed 
cells were incubated for 30 minutes at room temperature and then washed twice with 
FACS buffer. To store samples, cells were resuspended with 150 µL of 
2% paraformaldehyde (PFA) and incubated for 20 minutes at room temperature. Cells 
were then washed twice with FACS buffer and finally resuspended in 300 µL FACS buffer 
to be stored for up to seven days at 4°C. The details of the gating strategies used for the 
flow cytometry experiments are described in Chapter 7 (see section 7.2.2). Flow cytometry 
data analysis was done using Kaluza (Beckman Coulter) and FlowJo (BD) softwares. 
3.4.3 Fluorescence-Activated Cell Sorting (FACS) 
Twenty cord blood samples were stained with 7AAD, BV421-CD34, APC-CD19 and 
FITC-CD3 antibodies (see above for detailed protocol). FACS was done by the Flow 
Cytometry Facility using the FACSAriaII cell sorter (sorting was performed by Michelle 
Wilson, a flow cytometry technician). Four-way purity enrichment was conducted and a 
nozzle speed of 20 psi per second was applied. About 10,000 events of flow cytometry 
data was collected for each sample. Prior to cell sorting, the four collection tubes each 
contained 1 mL of PBS to resuspend the sorted cells. Cord blood samples prepared for 
FACS experiments were not fixed with 2% PFA; instead they were stained with antibodies 
and sorted in the same day. 
3.5 DNA extraction 
This protocol was used for samples containing more than 10,000 cells. DNA was extracted 
using QIAamp DNA Mini and Blood Mini kit (Qiagen, USA) according to the 
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manufacturer’s instructions. Proteinase K (20 µL of 20 mg/mL) was added to 200 µL of 
resuspended cells. Then, cells were vortexed for 15 seconds with 200 µL of the lysis 
Buffer AL and the mixture was incubated at 56°C for at least 10 minutes to inactivate 
proteinase K. Samples were then centrifuged briefly and 200 µL of 100% ethanol was 
added to precipitate the DNA. Samples were then vortexed and centrifuged before 
applying them to the sterile QIAamp Mini spin columns (placed over 2 mL collection 
tubes). The spin columns were centrifuged at 6000 x g for 1 minute at room temperature 
using a microfuge (Eppendorf 5424, Germany).  
After the centrifugation step, columns were transferred to new 2 mL collection tubes. 
Columns were washed by the addition of 500 µL AW1 washing buffer and centrifuged at 
6000 x g for 1 minute at room temperature. Then, columns were washed with 500 µL of 
Buffer AW2 followed by centrifuging columns at 20,000 x g for 3 minutes at room 
temperature. Columns were then transferred to 1.5 mL Eppendorf tubes and 50 µL of the 
elution Buffer AE was added to each column, incubated for five minutes at room 
temperature, and centrifuged at 6000 x g for 1 minute at room temperature to elute the 
DNA. To increase the DNA yield, the eluted DNA was re-applied to the columns and re-
centrifuged at 6000 x g for one minute. DNA concentration was measured using a 
NanoDrop instrument (ThermoFisher Scientific).  
3.6 DNA bisulfite-conversion 
3.6.1 Principle of DNA bisulfite-conversion 
Bisulfite-conversion is based on the ability of bisulfite to convert unmethylated cytosine 
nucleotides to uracil, which subsequently is replaced by thiamine during PCR. In 
comparison, methylated cytosine nucleotides are protected by the methyl group from the 
conversion to uracil. As a result, the use of bisulfite-conversion allows the distinction 
between methylated and unmethylated CpG sites.  
3.6.2 Protocol for bisulfite-conversion 
DNA was bisulfite-converted using the EZ DNA Methylation kit (Zymo Research) 
according to the manufacturer’s instructions. M-Dilution buffer (5 µL) was added to up to 
45 µL of each DNA sample and incubated at 37°C for 15 minutes. Then, 100 µL of the 
prepared CT conversion reagent was added to each 50 µL DNA sample, vortexed, and 
incubated at 50°C for 18 hours (overnight) using a PCR thermal cycler. 
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After the incubation, samples were cooled at 4°C for at least 10 minutes and then 
transferred to Zymo-Spin IC columns. Before the transfer of samples, 400 µL of M-
Binding buffer was added to the columns. Spin columns were then mixed by inversion 
several times and centrifuged at 20,238 x g (full speed of the microfuge) for 30 seconds at 
room temperature. After discarding the filtrate, 100 µL of M-Wash buffer was added to the 
columns and centrifuged again at 20,238 x g for 30 seconds. Next, 200 µL of M-
Desulphonation buffer was added to the columns, incubated for 15 minutes at room 
temperature and then centrifuged at 20,238 x g for 30 seconds. Spin columns were washed 
twice with 200 µL of M-Wash buffer (centrifuge at 20,238 x g for 30 seconds). After 
washing, columns were placed on top of new 1.5 mL Eppendorf tubes and 10 µL of M-
Elution buffer was added directly over the column matrix. Finally, columns were 
centrifuged at 20,238 x g for 30 seconds to elute the bisulfite-converted DNA. To increase 
the DNA yield, the eluted DNA was re-applied again to the columns and re-centrifuged at 
20,238 x g for 30 seconds. The bisulfite-converted DNA was either used immediately for 
PCR experiments or stored at -20°C. 
3.6.3 Optimising the protocol for low DNA input 
The minimum amount of bisulfite DNA input into the conversion reaction was 
investigated to serve as a quality control for the neonatal DNA samples. The collected 
neonatal blood samples were very small (between 15 to 300 µL) and yielded small 
amounts of DNA. NALM6 DNA was titrated using serial dilutions to provide different 
amounts of DNA input for the bisulfite conversion protocol. The following amounts were 
prepared in duplicate: 256 ng, 128 ng, 64 ng, 32 ng, 16 ng, 8 ng, 4 ng, 2 ng, 1 ng, 500 pg 
and 250 pg. The TES PCR was used to evaluate the amplifiability of bisulfite-converted 
DNA. Figure 3.4 shows the PCR products from bisulfite-converted DNA for 250 pg to 






Figure 3.4. An electrophoresis gel of PCR products from bisulfite-converted DNA using 
different amounts of input DNA. As little as 2 ng input DNA yielded PCR products. 
 
3.6.4 DMSO effect on bisulfite-PCR reaction 
This experiment was done to optimise the PCR and enhance the amplifiability using 
DMSO. DMSO was speculated to stabilize DNA molecules, improve primer-annealing 
efficiency and enable the PCR of DNA template with secondary structures (Shen & Hohn, 
1992). A side-by-side comparison experiment was done to evaluate the effect of 
5% DMSO into PCR using the 2 ng, 8 ng and 32 ng bisulfite-converted DNA samples (the 
titrated NALM6 DNA). The use of DMSO did not improve TES PCR performance (Figure 
3.5).  
 
Figure 3.5. Images of gel electrophoresis showing no effect of 5% DMSO on TES 
bisulfite-PCR. PCR products of TES bisulfite-PCR containing 5% DMSO (A) and no 
DMSO (B). (C) Intensities of (A) and (B) gel bands measured using Quantity One 1-D 
software. 
 
3.7 DNA extraction and bisulfite-conversion from 100 cells 
This protocol was optimized to maximize DNA yield from neonatal blood samples and cell 
sorted populations, and to extract DNA from as few as 100 cells. The following 
experiments were conducted for side-by-side to optimise results. 
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3.7.1 DNA extraction methods 
Four methods were selected to compare DNA extraction from 100, 500 and 1000 cultured 
melanoma cell line cells. These methods were: Guo and colleagues’ (2015) method, 
Guanidinium thiocyanate (GITC) method, RLT buffer method and a carrier DNA method.  
Guo’s method was developed for the preparation of a reduced-representation bisulfite 
sequencing (RRBS) library from single cells, and the protocol recommended mixing cells 
with a cell lysis buffer, incubating cells at 50°C for 3 hours and then another incubation at 
75°C for 30 minutes. Guo’s cell lysis buffer is composed of 20 mM Tris-EDTA, 20 mM 
KCl, 0.3% Triton X-100 and 1 mg/mL of protease.  
The second method used GITC lysis buffer which is prepared from 4 M of GITC, 50 mM 
Tris (pH 7.6 to 8.0), 2% sarkosyl, 0.1% antifoam, 20 mM EDTA and 1% of 
2-mercaptoethanol (Chomczynski & Sacchi, 2006).  
The third method used RNA lysis buffer (RLT buffer) that is part of RNeasy Mini for total 
RNA extraction kit (Qiagen). It is assumed that RLT buffer is similar to GITC since it is 
known to contain a high concentration of chaotropic salts. To extract DNA using GITC 
and RLT buffers, cell pellets were mixed with buffers and then used without incubation for 
any downstream application. 
The fourth method used carrier DNA along with lysis buffer. This method was 
recommended by QIAamp DNA mini and Blood Mini DNA extraction kit (Qiagen) for 
samples with expected low-copy DNA. Carrier DNA, a co-precipitant of DNA in alcohol 
solution, increases the binding of DNA to the columns and hence maximizes DNA yield. 
One microgram of carrier DNA was added to 200 µL lysis buffer AL and then cells were 
incubated with proteinase K at 56°C for 10 minutes. Steps of the DNA extraction protocol 
then follow as described above (see section 3.5). 
3.7.2 Evaluation of the extracted DNA by bisulfite-PCR assays 
To evaluate the above four methods, extracted DNA was bisulfite-converted using EZ 
DNA Methylation kit (ZymoResearch, see 3.6.2) and amplified using a touchdown 
multiplexed PCR and FastStart taq polymerase (see section 3.8.3). The multiplexed PCR 
was designed and used to evaluate the quality of bisulfite-converted DNA by testing the 
ability of PCR to amplify three amplicons of different sizes (MLH1 = 182 bp, NFATC1 = 
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277 bp and RMDN2 = 486 bp). Figure 3.6 shows PCR results from the four DNA 
extraction methods. All methods allowed the amplification of the 182 bp amplicon from 
100 cells DNA. However, Guo’s method failed to allow amplification of larger amplicons 
from 500 cells and the carrier DNA method showed weak bands for larger amplicons at 
500 and 1000 cells. The RLT buffer method shows the brightest bands for larger products 
at 500 cells compared to the other three methods. However, differences between replicates 
indicate unidentified source of variability. The RLT buffer method was selected as the 
method for DNA extraction from samples containing less than 10,000 cells. 
 
Figure 3.6. An image of gel electrophoresis showing bands of a multiplex PCR products 
using DNA templates extracted by the four DNA extraction methods. 
 
3.8 Preparation of targeted DNA methylation sequencing libraries 
3.8.1 Principle of two-step PCR 
A two-step PCR approach was developed to amplify a target region using primers 
containing overhanging complementary adaptors to the Illumina flow cell probes. Briefly, 
the first round of PCR amplifies a target region with methylation-independent primers (i.e., 
primers were designed to anneal to regions devoid of CpG dinucleotides). The first-round 
primers include a 5’ tag to which the Illumina adaptor primers anneal during the second 
round (green boxes in Figure 3.7). By using this approach, multiple PCR products of the 
same sample can be pooled after the first round PCR. In addition, PCR products of each 
sample (containing multiple amplicons) receive a unique Illumina adaptor combination 
sequence (also called “Illumina index”) during the second round PCR reaction. 
Furthermore, various libraries, each of which contain samples with unique Illumina 
adaptors can be pooled for sequencing on a single MiSeq run. By pooling numerous 
samples from one or many projects on the same run, the cost of MiSeq sequencing is very 




Figure 3.7. A diagram illustrating the two-step PCR sequencing approach. First round 
PCR reaction used tagged gene-specific primers. The second round PCR reaction uses 
Illumina index primers that are complementary to the first round PCR tags. Second 
round PCR products with Illumina adaptors overhang can anneal to the complementary 
probe sequences on the Illumina MiSeq flowcell. MiSeq FASTQ files were then 
analysed using Galaxy and BiQ Analyser HT (see section 5.3 for more details on data 
analysis). 
 
3.8.2 PCR primers 
Forward and reverse primers were designed for 13 genes. Table 3.1 shows primer 
sequences for the genes used for the methylation sequencing assay (see Chapters 4 and 5 
for more details about these genes). Because of the copyright restriction of Illumina 
sequences, the sequences of the tags and the second round Illumina indices were not listed 







Table 3.1. Sequences of the primers used for the targeted DNA methylation sequencing 
assay. Because of the copyright restriction, the Illumina sequences are not included. 
 Primers Sequence 
1 TES_FP IlluminaSequence -TTAGGGTTATTGAGTTTGTTTAGTAGG 
2 TES_RP IlluminaSequence -CTTTATTTTCCAAATCCATATTAAC  
3 NEFM_FP IlluminaSequence -TTATAAGTAGTTTGGGATTGAAAGG 
4 NEFM_RP IlluminaSequence -TAACTCATCTTAAAAACCTTAAAAC 
5 KCNA4_FP IlluminaSequence -TTTGGAGTTTAGTATAGGAGGGATT 
6 KCNA4_RP IlluminaSequence -CTATAAAAACCACAACCAAAAACTC 
7 C10ORF53_FP IlluminaSequence -GAATTTATTGTGTTTGGTTGTTGTT 
8 C10ORF53_RP IlluminaSequence -AAACCCACCTTACAAACCCTAC 
9 KITLG_FP IlluminaSequence -GATTTAGTATAAATAGTGGTGTGG 
10 KITLG_RP IlluminaSequence -CTACCAAACTTCTAAAACATTTACC 
11 MARCH11_1_FP IlluminaSequence -GGTTTTGGTTGTAGGGAAAGAG 
12 MARCH11_1_RP IlluminaSequence -ACTAAAAAATCCCCCACTTCC 
13 MARCH11_2_FP IlluminaSequence -GGAAGTGGGGGATTTTTTAGT 
14 MARCH11_2_RP IlluminaSequence -CCAAAAACTTCTATTTTAAAACTCTC 
15 RNF180_FP IlluminaSequence -GGATAAGGGAGATTATAGGGATA 
16 RNF180_RP IlluminaSequence -CCAACAACCAAACTCTAAAAACTC 
17 SYBU_FP IlluminaSequence -GGGTTTTGGTAGATTATGTTGTAGG 
18 SYBU_RP IlluminaSequence -TCAATATTCAAAACTCTTCCTCTCC 
19 MACROD2_FP IlluminaSequence -TTTAATAGGGTAGTTGGAGTGAGTA 
20 MACROD2_RP IlluminaSequence -CCTCAAAACCTATCAACTAAATCAC 
21 PAK7_FP IlluminaSequence -AGGGGGTGAGAGGTAGAGTTATAGT 
22 PAK7_RP IlluminaSequence-AATCCTAAACAACATTTCTACAAATCC 
23 ISL1_FP IlluminaSequence-GTTAGTTTTGGAGGAATTAGTTTTT 
24 ISL1_RP IlluminaSequence-ATTCTAACTCTAACCTCCCTCTCCT 
25 GALR1_FP IlluminaSequence-GTTTTTTAGTTGTAGTAGAGAAGTT 
26 GALR1_RP IlluminaSequence-CAAATAAAAAAACCCTTCTCTCC 
 
3.8.3 First round PCR reaction 
The majority of first and second round PCR reactions used KAPA HiFi HotStart Uracil+ 
ReadyMix PCR kit (KAPA BioSystems, USA). Table 3.2 shows the ingredients for a 
10 µL PCR reaction using the KAPA HiFi HotStart Uracil+ ReadyMix. The majority of 
TES bisulfite-amplification reactions were based on Platinum Taq DNA Polymerase High 
Fidelity enzyme (Table 3.3 shows a 25 µL reaction protocol). The 10X High Fidelity PCR 
buffer contains 600 mM of Tris-SO4 (pH 8.9) and 180 mM of (NH4)2SO4. Both KAPA 
HiFi ReadyMix and Platinum Taq DNA Polymerase contain high fidelity enzymes with 
proofreading activity to minimise the PCR amplification errors. PCR preparation was done 
in a separate area of the lab to avoid genomic DNA contamination. For TES PCR and 
sequencing library preparations, a different laboratory, which was never exposed to TES 




Table 3.2. PCR preparation protocol using KAPA HiFi HotStart Uracil+ ReadyMix kit. 
PCR Reagents X1 
2x KAPA HiFi HotStart Uracil+ ReadyMix 5 µL 
Forward Primer (10 µM) 0.5 µL 
Reverse Primer (10 µM) 0.5 µL 
MQ water 3 µL 
Bisulfite-converted DNA 1 µL 
TOTAL 10 µL 
 
Table 3.3. TES PCR reaction protocol using Platinum Taq DNA Polymerase High 
Fidelity enzyme. 
PCR Reagents X1 
10X High Fidelity PCR Buffer 2.5 µL 
50 mM MgSO4 1 µL 
2.5 mM dNTP 2 µL 
Forward Primer (10 µM) 0.5 µL 
Reverse Primer (10 µM) 0.5 µL 
MQ water 17.5 µL 
Platinum Taq DNA polymerase (5 U/µL) 0.1 µL 
Bisulfite-converted DNA 1 µL 
TOTAL 25 µL 
 
 
The Touchdown PCR thermal cycler program (Bio-Rad) was used for MARCH11 
(amplicon 1), MARCH11 (amplicon 2), RNF180, SYBU, MACROD2, PAK7 and ISL1 
(Table 3.4). In addition, NEFM, KCNA4 and KITLG share the same conditions for the PCR 
thermal cycler reaction (Table 3.5). PCR thermal cycler programs for C10orf53 and TES 
(using KAPA HiFi HotStart kit) were similar except for annealing temperatures of 61°C 
and 56°C, respectively. However, there is a different PCR thermal cycler reaction program 
for TES (Table 3.6). PCR preparation protocols and thermal cycler programs were 
optimised on control samples before their use on project samples. 
 
Table 3.4. Thermal cycler program for touchdown PCR reaction. 
Conditions Temperatures Time Cycles 
Initial Denaturation 95°C 4 minutes  
Denaturation 98°C 30 seconds  
20 cycles Annealing 65°C 30 seconds 
Touchdown -0.5C Per cycle 
Extension 72°C 1 minute 
Denaturation 98°C 30 seconds  
40 cycles Annealing 55°C 30 seconds 
Extension 72°C 1 minute 
Final Extension 72°C 5 minutes  






Table 3.5. Thermal cycler program for the PCR reaction for NEFM, KCNA4 and KITLG. 
Conditions Temperatures Time Cycles 
Initial Denaturation 95°C 4 minutes  
Denaturation 98°C 30 seconds  
40 cycles Annealing 57°C 30 seconds 
Extension 72°C 30 seconds 
Final Extension 72°C 7 minutes  
Cooling 4°C Hold  
 
Table 3.6. Thermal cycler program for the TES PCR reaction. 
Conditions Temperatures Time Cycles 
Initial Denaturation 94°C 2 minutes  
Denaturation 94°C 30 seconds  
40 cycles Annealing 58°C 30 seconds 
Extension 68°C 1 minute 
Cooling 4°C Hold  
 
3.8.4 Gel electrophoresis for PCR products 
PCR products were checked by gel electrophoresis in 2% agarose (Bio-Rad) in 0.5 TAE. 
Gel electrophoresis was usually done at 100 V for 30 minutes and the PCR products were 
examined by UV light using a UVIDOC HD6 (Cleaver Scientific, UK). 
3.8.5 Amplicon pooling and purification 
Successfully amplified PCR products were selected for the sequencing library preparation. 
Amplicons of different gene, but from the same sample, were pooled together. Generally, 
for each 10 µL PCR reaction, 3 µL was usually used for the gel electrophoresis and 3 – 
6 µL included in the pool. The pooled amplicons were then cleaned up using the 
Agencourt AMPure XP beads (Beckman Coulter). Agencourt’s solid-phase paramagnetic 
beads selectively bind to PCR amplicons larger than 100 bp. As a result, primer dimers, 
excess primers, salts and any other chemical contaminants can be removed. For a 5 µL 
PCR reaction volume, 9 µL of Agencourt AMPure XP beads (at room temperature) were 
added (1:1.8 ratio) and mixed by pipetting several times and incubated at room 
temperature for 5 minutes. Samples were then placed onto the Agencourt SPRIPlate 96 
Super Magnet Plate for 2 minutes for beads separation. Then, the cleared solution was 
aspirated from the samples without disturbing the magnetically bound beads. Next, the 
beads were washed twice by adding 30 – 200 µL of freshly prepared 70% ethanol to the 
samples, incubating for 30 seconds and discarding the aspirated solution. Samples were 
air-dried on the magnetic plate for 4 minutes at room temperature. The paramagnetic beads 
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were resuspended in 30 – 40 µL of elution buffer (MQ water or TE buffer) and returned to 
the magnetic plate for 1 minute before aspirating the clean PCR products.  
3.8.6 DNA quantification 
The purified and pooled PCR products were quantified using a Qubit dsDNA HS assay kit 
(Invitrogen). This is a fluorescence-based assay in which a dye binds specifically to 
double-stranded DNA molecules. Qubit 2.0 Fluorometer measures the intensity of the dye 
and calculates DNA concentration in relation to a standard curve. A working solution was 
prepared by diluting the Qubit dsDNA HS reagent in Qubit dsDNA HS buffer 
(1:200 ratio). Next, 10 µL of the Qubit dsDNA HS of each standard (Standard 1 and 
Standard 2) and 5 µL of each purified sample were mixed into 190 or 195 µL working 
solution. Tubes were vortexed and then centrifuged briefly. The DNA concentration of the 
standards and of each sample were then measured on the Qubit 2.0 Fluorometer. The QF 
value provides the concentration of the diluted sample in ng/mL. These purified first round 
PCR products were then diluted to 1 ng/µL. 
3.8.7 Second round PCR reaction 
Different Illumina index adapter combinations were used for the second round PCR 
reaction to add unique identifiers for each sample. Our laboratory has 20 forward and 
22 reverse Illumina primers giving 440 different Illumina index combinations. A master 
PCR mix was prepared for each Illumina primer, then 4 µL of forward and 4 µL of reverse 
PCR mixtures were added separately to 2 µL of the diluted first-round PCR products 
(Table 3.7). The PCR reaction mixtures of Illumina primers were prepared using KAPA 
HiFi HotStart ReadyMix kit. Table 3.8 shows the thermal cycler PCR program for second 
round PCR. Agarose gel electrophoresis was used to check the presence of PCR products. 
Figure 3.8 shows a comparison between Platinum Taq DNA Polymerase and KAPA HiFi 
HotStart enzymes. KAPA HiFi HotStart enzyme shows superior results.  
Table 3.7. PCR preparation protocol using KAPA HiFi HotStart Uracil+ ReadyMix kit 
for Illumina forward and reverse primers. 
PCR Reagents X1 
2x KAPA HiFi HotStart Uracil+ ReadyMix 2.5 µL 
Illumina Primer (10 µM) 0.5 µL 
MQ water 1 µL 





Table 3.8. Thermal cycler program for the second round PCR reaction. 
Conditions Temperatures Time Cycles 
Initial Denaturation 95°C 2 minutes  
Denaturation 95°C 20 seconds  
10 cycles Annealing 58°C 20 seconds 
Extension 72°C 20 seconds 
Final Extension 72°C 40 seconds  
Cooling 4°C Hold  
 
 
Figure 3.8. Image of a gel electrophoresis showing PCR products amplified by two 
polymerase enzymes (Platinum Taq DNA Polymerase and KAPA HiFi HotStart Uracil+ 
ReadyMix polymerase). Note the increase in PCR product size after the second round 
PCR reaction due to the addition of Illumina index adapters.  
 
3.8.8 Sample pooling, purification and quantification 
Second round PCR products of different samples were pooled. The volumes used for 
pooling was based on the intensity of the PCR products on the electrophoresed gel. The 
pooled samples were purified using the Agencourt AMPure XP beads and quantified using 
the Qubit dsDNA HS assay kit (see section 3.8.5 for details). The pooled samples were 
then diluted to 1 ng/µL with MQ water prior to assessment using the Bioanalyser. 
3.8.9 Quality check of the pooled PCR products 
Pooled PCR products were assessed using a High Sensitivity DNA protocol on the 
Bioanalyser (Agilent Technologies, Germany) according to the manufacturer’s protocol. 
First, a gel matrix was prepared after equilibrating the kit to room temperature (about 
30 minutes) by adding 15 µL of the blue High Sensitivity DNA dye to the High Sensitivity 
DNA gel matrix (red-top tube). The mixture was then vortexed, centrifuged briefly and 
then transferred to the provided spin filter. The prepared gel matrix was kept away from a 
direct light and centrifuged in a microfuge at 2240 x g for 10 minutes at room temperature. 
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To check sequencing libraries, a new High Sensitivity DNA chip was unpacked and placed 
onto the chip priming station. After adding 9 µL of the gel matrix in the priming well, the 
lid of the priming station was closed and a 1 mL of air pressure was applied to prime the 
High Sensitivity DNA chip for 60 seconds at room temperature. The pressure was released 
for 5 seconds and then the plunger was pulled to the 1 mL position. The lid of the priming 
station was opened and 9 µL of gel matrix was aliquoted into the remaining gel wells. Five 
microlitres of the marker was added to all wells and 1 µL of the High Sensitivity DNA 
ladder (yellow-top tube) and DNA samples were pipetted into the ladder and samples 
wells, respectively. The chip was then vortexed at 2400 rpm for 1 minute at room 
temperature. Once the chip was prepared, it was placed onto the Bioanalyser instrument 
and analysed within 5 minutes. DNA fragments within the chip were electrophoresed to 
measure the size and concentration of peaks in each sample.  
3.8.10 Libraries pooling and MiSeq sequencing 
Based on the Bioanalyser average fragment size for the sequencing library, the molarity 
concentration was calculated using the following equation: 
DNA concentration (nM) = Qubit DNA concentration (ng/µL) ÷ (Bioanalyser average 
fragment size x 0.00065) 
Then, 4 nM of the sequencing library was diluted in 25 µL MQ water. Once the 4 nM 
dilutions were made, DNA sequencing libraries were pooled into one 20 µL tube based on 
the number of amplicons in each sequencing library. Pooled libraries were then mixed and 
DNA concentration was measured before loading them onto the MiSeq instrument 
(Illumina). Nano 250 paired-end MiSeq kits (Illumina) were used for the MiSeq runs. 
MiSeq runs were loaded and conducted by Dr Rob Day (Research Fellow at Cancer 
Genetics Laboratory, Department of Biochemistry, University of Otago). For MiSeq data 
analysis, see Chapter 5 (section 5.3). 
3.9 Discussion 
Methods used for this project required optimisation to handle the low cell number of 
collected blood samples. As demonstrated above, many protocols were optimised to their 
limits. Each processed sample was carefully monitored and variable factors affecting the 
outputs were evaluated. An example of this is the stability of bisulfite-converted DNA 
samples. Despite the use of optimised protocol for DNA extraction and bisulfite 
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conversion, PCR failure was observed for few samples. This could be related to the poor 
quality of DNA input. It was speculated that the multiple thawing and freezing of bisulfite-
converted DNA exposes the single-stranded bisulfite-DNA molecules to further damage 
(Schock & Traeger, 2011). In addition, the multiple freeze and thaw cycles lower the 
sensitivity of bisulfite-converted DNA of the downstream methylation assays due to the 
interference of the eluted particles from the columns (Schock & Traeger, 2011). 
Numerous DNA bisulfite conversion kits are available. Holmes and colleagues (2014) 
performed a side by side comparison for nine kits using DNA samples from a variety of 
sample types including cell lines, FFPE tissues, aspirates, and plasma. To evaluate the 
performance of the kits, five downstream applications were used: 1) qPCR assays to 
evaluate DNA yield, purity and stability; 2) clone sequencing to evaluate bisulfite 
conversion; 3) UV testing to evaluate DNA purity and yield; 4) HLPC to evaluate the 
inappropriate DNA conversion; and 5) gel electrophoresis to evaluate DNA degradation. 
Interestingly, EZ DNA Methylation - Direct kit (ZymoResearch) was included in the 
evaluation, which is a closely similar kit to EZ DNA Methylation kit. They found 65% of 
the detected DNA was of high molecular weight DNA input compared to 43% of FFPE 
DNA input when EZ DNA Methylation–Direct kit was used. Despite the highest 
conversion efficiency of EZ DNA Methylation–Direct kit (99.9%), it also had the highest 
proportion of inappropriate bisulfite conversion of cytosine molecules (2.7%) compared to 
the other eight kits.  
It was speculated that increasing the number or time of denaturation steps in bisulfite-
conversion reaction and/or increasing the duration of treatment can minimise the frequency 
of bisulfite failure (Genereux et al., 2008). Genereux and colleagues (2008) compared low 
molarity, low temperature bisulfite-treatment (5.5 M bisulfite incubated at 55°C) to high 
molarity, high temperature treatment (9 M bisulfite incubated at 70°C) using barcoded 
synthetic single stranded and hairpin-linked oligonucleotides. They found 0.09% to 6.1% 
of inappropriate bisulfite-conversion in both protocols (inappropriate conversion is a 
deamination of methylated cytosines to become thymine that can be misinterpreted as 
unmethylated cytosine). In addition, they found that the inappropriate conversion occurs 
early in bisulfite treatment; however, prolonging the bisulfite treatment time can also 
initiate inappropriate conversion. As a result, the high molarity, high temperature protocol 
showed lower inappropriate and failed conversion rate in comparison to the low molarity, 
low temperature protocol (Genereux et al., 2008). 
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Inaccurate measurement of DNA concentration prior to bisulfite conversion could 
compromise the yield of bisulfite-converted DNA. Interestingly, the NanoDrop 
overestimated the DNA concentration and had very poor precision compared to the Qubit 
(Simbolo et al., 2013). In addition, fragmented DNA samples, such as bisulfite treated 
DNA and DNA extracted from FFPE tissues, had highly overestimated DNA 
concentration on the NanoDrop. The NanoDrop measurement can be further compromised 
when RNA contamination exists in the sample (Simbolo et al., 2013). Furthermore, PCR 





Chapter 4: Identifying the ALL-methylated gene panel  
4.1 Abstract 
This chapter describes the process of designing a panel of genes to be used as leukaemia-
specific methylation biomarkers. Publicly available human 450k DNA methylation array 
datasets were analysed to select differentially methylated genes in leukaemia compared to 
control samples. The limitations of available analysis tools led to the development of a 
unique pipeline for the selection of differentially methylated genes. This chapter outlines 
the following: 1) the use of public data depositories, 2) the use and review of available 
tools and pipelines for data analysis, 3) the development of a unique pipeline that 
overcome the limitations of the available tools, and 4) the use of the developed pipeline to 
identify and design target regions for sequencing a panel of ALL-methylated genes. 
4.2 Criteria for the identification of the ALL-methylated genes 
A set of criteria was proposed to select leukaemia-specific methylated genes. ALL-
methylated genes were selected based on the consistent DNA methylation profiles of the 
genes across leukaemia types (i.e., B and T cell acute lymphoblastic leukaemia) and the 
significant difference in DNA methylation from control samples. Controls were peripheral 
blood, bone marrow or cell sorted samples of healthy children or children in their 
remission phase. The identified genes had at least two CpG sites with statistically 
significant difference in DNA methylation in ALL compared to controls (Bonferroni 
correction on Student’s t-test of P-value < 1 x 10-7 for 450k array datasets and P-value < 2 
x 10-6 for 27k array datasets). In addition, the identified genes should have a distinct 
difference in DNA methylation between ALL and controls (methylation difference of more 
than 0.5).  
4.3 Exploring human 450k DNA methylation array datasets 
As of December 2017, searching the Gene Expression Omnibus (“GEO”) server using 
keywords “acute lymphoblastic leukemia AND methylation” and “homo sapiens” revealed 
282 datasets. After inspecting these datasets to identify those with 450k or 27k methylation 
array data, 11 B and T cell leukaemia datasets were selected for analysis (Table 4.1). 
Similar results were found in ArrayExpress server, as datasets were interconnected 
between GEO and ArrayExpress servers. In contrast, The Cancer Genome Atlas 
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(“TCGA”) which has more than 32,000 cases of cancer including acute myeloid 
leukaemia, does not have methylation data for acute lymphoblastic leukaemia.  
Two of the 11 datasets were excluded (Table 4.1). Loudin’s cohort (2011) investigated the 
methylation of leukaemia in Down syndrome patients, which is not relevant for this 
project. Kim’s cohort (2015) included a mixed lymphoid and myeloid leukaemia case and 
two acute myeloid leukaemia cases, which could not be excluded from the dataset because 
their samples were not described properly. 
Nine cohorts, three of which contained 27k array BeadChip data and six of which had 
450k array BeadChip data were included in the analysis. In addition, four cohorts had gene 
expression data available (Lee; Nordlund; Wong & Bhadri; and Hogan. Table 4.1). 
Nordlund’s was the largest dataset having 944 samples. Two cohorts had no control 
samples: Lee’s cohort investigated the methylation features of B-ALL subgroups and 
Wong & Bhadri’s cohort compared the methylation profile of B-ALL and xenograft 
leukaemia samples. Two cohorts had methylation values for different B-ALL subtypes: 
Lee’s and Gabriel’s. Lee’s cohort (2015) had 73 cases with hyperdiploidy, 52 cases with 
the ETV6-RUNX1 transcript fusion, 73 cases with other genetic mutations, 21 cases with 
unknown cytogenetics, six cases with the TCF3-PBX1 transcript fusion, and two cases 
with mixed lineage leukaemia (MLL). Gabriel’s cohort (2015) had 10 cases with 
hyperdiploidy, 10 cases with the ETV6-RUNX1 transcript fusion, three cases with the 
TCF3-PBX1 transcript fusion and three cases with dic(9;20). 
The nine leukaemia datasets were divided into two groups. Group 1 (investigation 
cohorts), which included those with methylation values for cases and controls, was used to 
search for differentially methylated genes (450k datasets are Nordlund’s, Busche’s, 
Sandoval’s, Gabriel’s and Borssén’s. The 27k dataset is Wong & Ashley’s). Group 2 
(“validation” cohorts) did not have methylation values for control samples and were used 
to investigate the DNA methylation consistency of the identified differentially methylated 
genes across different leukaemia subgroups (the 450k cohort is Lee’s and the 27k cohort is 





Table 4.1. Summary of the human 450k and 27k DNA methylation array datasets. 
Datasets GEO No. Analysis 
Type 
Cases Controls 
Lee (2015) GSE56602 Validation 227 B-ALL None 
Nordlund (2013) GSE49031 Investigation 764 ALL and 32 
Relapse 
86 Remission and 62 
Healthy 
Busche (2013) GSE38235 Investigation 46 B-ALL 46 Remission 
Sandoval (2013) GSE39141 Investigation 29 B-ALL 4 Healthy (CD19+ B 
cells) 
Gabriel (2015) GSE69229 Investigation 26 B-ALL (relapse) 26 Remission 
Borssén (2016) GSE69954 Investigation 65 T-ALL 4 Cord blood (CD3+ 
T cells) 
Wong & Ashley* 
(2012) 
GSE29189 Investigation 17 B-ALL 17 Remission 
Wong & Bhadri* 
(2014) 
GSE57581 Validation 10 B-ALL and 10 
xenograft ALL 
None 
Hogan* (2011) GSE28461 Investigation 35 B-ALL 33 Remission 
Loudin* (2011) GSE20872 Excluded 18 B-ALL (11 has 
Down Syndrome) 
5 Remission 
Kim* (2015) GSE61611 Excluded 4 B-ALL, 1 T-ALL, 2 
AML and 1 mixed 
leukaemia 
4 Healthy 
*27k array datasets. 
 
4.4 Bioinformatics tools and pipelines for 450k array data analysis 
Several analysis tools were available for 450k array data. Different tools and pipelines 
were used to analyse the identified leukaemia datasets listed in Table 4.1. The following 
section outlines some of the main strategies used, such as hierarchical clustering and 
differential methylation position analysis. The aim was to identify a list of differentially 
methylated CpG sites or regions to use as biomarkers for leukaemia. 
4.4.1 Pre-processing and normalisation methods 
The 450k DNA methylation array technology was based on the quantification of the signal 
intensity of C or T containing fragments of DNA following bisulfite-conversion 
(Nakabayashi, 2017). It was highly recommended to remove the values of probes failed the 
hybridisation assay by using a detection P-value of 0.05. In addition, C/T SNPs at the 
interrogated CpG sites can behave as unmethylated CpG site and therefore it was 
recommended to remove probes overlapping common SNPs (Nakabayashi, 2017). 
Interestingly, Chen and colleagues (2013) found 6% of the 450k array probes hybridise to 
sites on the sex chromosomes of the human genome. In addition, Zhang and colleagues 
(2012) used Bowtie alignment tool to map the 450k array probes to the human genome 
(hg19) and found about 140,000 and 1,000 of 450k and 27k array probes mapped to 
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multiple regions, respectively. As a result, Illumina provided an annotation file with details 
for the location of each probe that can be used to complement data analysis. 
The calculated methylation values for each probe in the 450k and 27k arrays are expressed 
as beta values which reflect the proportion of methylated signal to total signal on the 
BeadChip. Prior to data analysis, quality checking of the raw data is an important step to 
reduce technical variation and background noise. A general rule was to perform within-
array and between-array normalisations. Because of the two assay-system that was 
designed in the 450k array chip (Infinium I and II), the derived methylation values from 
each assay were found to be distributed differently (Nakabayashi, 2017). This is mostly 
due to the unreliable performance of the Infinium II probes that show imprecision of 
average beta values between the technical repeats (Dedeurwaerder et al., 2011). As a 
result, within-array normalisation has been mostly used to adjust for type II bias and for 
background correction and dye-biased adjustment (Wilhelm-Benartzi et al., 2013). When 
450k array data were collected from different experiments, different chips or by different 
institutes, then, batch effect adjustment algorithms, such as ComBat, have been generally 
used for the between-array normalisation.  
Several within-array normalisation methods and tools have been developed and made 
available. As an example, the quantile normalisation (QN) method, which is commonly 
used in microarray gene expression data, smoothens the distribution of signal intensities of 
the probes by replacing outliers with the mean intensity value of the same rank from all 
analysed arrays (Cazaly et al., 2016; T. Wang et al., 2015). Another example is peak-based 
correction which estimates the M-values for Infinium I and II probes and then adjusts the 
Infinium II values to match the initial range of Infinium I probes (T. Wang et al., 2015). 
Teschendorff and colleagues (2013) described an interesting normalisation algorithm 
called “the beta-mixture quantile dilation (BMIQ)”. The method was based on three steps: 
1) construct a three-state beta mixture model composed of unmethylated, hemimethylated 
and fully methylated beta values for Infinium I and Infinium II probes, 2) transform the 
probabilities of methylated and unmethylated Infinium II probes to quantiles using the 
inverse of the cumulative Infinium I beta distribution, and 3) perform a dilation 
transformation for the hemimethylated Infinium II probes to “fit the data into the gap” to 
maintain the continuation and monotonicity of the data (Teschendorff et al., 2013). Wang 
and colleagues (2015) compared the performance of eight normalisation methods that were 
available for 450k array pre-processing, and they found peak-based correction and BMIQ 
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methods to have high correlation with the reference whole genome bisulfite sequencing 
data. The Chip Analysis Methylation Pipeline (ChAMP R package) offers four 
normalization methods including the highly recommended BMIQ method for 450k array 
datasets (Morris et al., 2014). To evaluate the performance of normalisation methods, 
density plots and principal component analyses have been generally conducted to check 
the quality and distribution of the pre- and post-normalisation data. In this project, BMIQ 
normalisation method and ComBat adjustment methods were used to pre-process the 450k 
array data. 
4.4.2 Clustering  
Clustering analysis was based on finding the degree of similarity between the analysed 
objects to divide them into “homogeneous groups” (Johnson, 1967). In the case of 450k 
array analysis, it is about finding groups of CpG sites (probes) that can be clustered based 
on the condition of the samples (i.e., leukaemia or control). Clustering analysis was used 
because it is an unsupervised objective classification method that can produce meaningful 
clusters of genes based on the unlabelled patterns (i.e., undefined conditions) of samples 
(Jain et al., 1999). The aim was to identify a list of differentially methylated CpG sites that 
cluster together because of leukaemia (i.e., identifying the leukaemia genes). The analysis 
was done on RStudio using both basic R functions, such as hclust, and plot functions, as 
well as R packages such as ggdendro, ape, and heatmaply. The output results were 
visualized by dendrograms and heatmaps of the differentially methylated CpG sites. As an 
example, the analysis of 1,500 CpG probe dataset from Martin-Subero et al. (2009) 
(released as a supplementary file, not listed in Table 4.1). Figure 4.1 show heatmap and 
dendrogram plots for the leukaemia and control samples from Martin-Subero’s dataset. 
The dendrogram plot, on top of the heatmap, clusters B-ALL cases in the middle branches, 
whereas T-ALL cases and controls are clustered in the left-hand and right-hand branches, 





Figure 4.1. Heatmap plots for the differentially methylated CpG sites in Martin-
Subero’s cohort. B is an enlarged segment from A. B-ALL: B cell acute lymphoblastic 
leukaemia, T-ALL: T cell acute lymphoblastic leukaemia, WPB: whole peripheral blood, 
WBM: whole bone marrow, CD34 pos: CD34+ cells. 
 
4.4.3 Differentially methylated position (DMP) analysis  
This analysis clusters the 450k array datasets based on the largest difference in beta values 
between cases and controls. The analysis is part of minfi R package by using dmpFinder 
function (Aryee et al., 2014). DMP analysis was applied on Busche’s dataset which 
required a user-defined input of the samples (i.e., disease or control). A “categorical” 
option was used to define sample types. Figure 4.2 shows a heatmap of the top 100 
differentially methylated CpG sites that were clustered by this method. DMP analysis 
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applies F-test to investigate the association between methylation level and phenotype. The 
analysis identified 271,157 differentially methylated CpG sites with P-value < 1 x 10-7 
(Bonferroni adjustment for multiple testing). The differentially methylated CpG sites were 
annotated to 19,479 genes. Three genes were selected from this analysis: KITLG, C10orf53 
and FUT9. These genes were selected based on finding multiple differentially methylated 
CpG sites in each of these genes (section 4.5 below outlines the selection process). Primers 
were designed for FUT9, but FUT9 PCR amplification was unsuccessful and hence FUT9 




Figure 4.2. Heatmap of the top 100 differentially methylated CpG sites from Busche’s 






4.4.4 Additional methods 
Other 450k analysis tools and pipelines were used and applied to the leukaemia datasets. 
Non-negative matrix factorization (NMF) method was used to search for leukaemia-
specific methylated “metagenes” using NMF R package (Gaujoux & Seoighe, 2010). The 
NMF method is based on factorizing a large data matrix into two smaller non-negative 
matrices that are potentially easier for computer processing. Brunet and colleagues (2004) 
applied the NMF method on gene expression array data and showed its ability to identify 
“metagenes”, which “provide an interesting decomposition of genes” and “a robust 
clustering of samples”. It was speculated that the identified metagenes are biologically 
important and potentially have a role in the pathogenesis. NMF analysis was performed on 
Martin-Subero’s B-ALL and control subgroup. Figure 4.3 shows the basis matrix heatmap 
clustering DNA methylation values of B-ALL and controls into “metagenes”. The analysis 
clustered B-ALL cases into one group (basis 2) and identified CpG sites that were 
distinctly different from controls group (basis 1). The resulted list of CpG sites from this 
analysis can be called the “meta CpG sites” based on NMF analysis. Consequently, these 
sites apparently associated with B-ALL pathogenesis. 
In addition, City of Hope CpG island analysis pipeline (COHCAP) R package was used. 
This pipeline applies the ANOVA test and calculates the difference in DNA methylation 
between significant sites (delta beta) (Warden et al., 2013). The output is a list of CpG 
sites with significantly different methylation sorted by their relation to the nearest CpG 
island and annotated by the closest gene. The chip analysis methylation pipeline (ChAMP) 
R package was also used to analyse leukaemia 450k array datasets (Morris et al., 2014). 
The package offers normalization and QC checks on the dataset, then applies the 
ProbeLasso analysis method to identify differentially methylated regions (DMR) (Butcher 
& Beck, 2015). The output was a list of differentially methylated CpG sites annotated by 
their distance from or overlap of the closest CpG rich region. DMRcate is another R 
package that was applied to the leukaemia datasets, and the output was similar to ChAMP 





Figure 4.3. Basis component matrix heatmap profiling 271 “meta CpG sites” based on 
differentially methylated CpG sites from Martin-Subero’s dataset (2009). Basis 1 
represents control samples and Basis 2 represents B-ALL cases. 
 
The majority of experimental biologists prefer to identify and investigate biologically 
relevant regions instead of sites as regions are more predictive and provide greater 
statistical power for their detection by validation methods (Robinson et al., 2014). As 
demonstrated above, the majority of the available tools focused on CpG sites analysis and 
there were very few tools that applied region-based analysis (Stockwell et al., 2014). In 
addition, the region-based analysis tools did not have a standardised definition of the 
differentially methylated regions (DMRs) creating more confusion for experimental 
biologists (see Chapter 8 for detailed discussion). In addition, some of the available 
analysis tools offered one type of statistical analysis and had specific forms of data 
































































































































































visualisation tools to construct a customised analysis pipeline. Consequently, relying on 
the above tools to identify the ALL-methylated gene panel, considering that their approach 
was based on identifying differentially methylated CpG sites, required the use of a 
complicated and prolonged pipeline and to customise the results output for the needs of 
this project. From here, a customised pipeline to overcome the limitations of the available 
tools was developed and used to identify a panel of ALL-methylated genes. 
4.5 Array-based CpG-region analysis pipeline (ABC.RAP) R 
package 
The array-based CpG-region analysis pipeline (ABC.RAP) R package was developed to 
identify differentially methylated genes in any 450k array dataset. Majority of the available 
450k array analysis tools define differentially methylated genes based on single 
differentially methylated CpG sites. Consequently, to find ALL-methylated genes, CpG 
sites were required to be evaluated collectively for the selection of biologically-relevant 
target regions. 
The ABC.RAP R package was initially developed (August 2016) as a pipeline composed 
of a list of long R scripts utilising basic R functions and functions from multiple R 
packages. The pipeline included the following steps: 1) calculate beta values from the raw 
signal intensity data and filter probes with detection P-value > 0.05; 2) normalise datasets 
using BMIQ method; 3) adjust for batch effects using ComBat (see section 4.4.1 for more 
details on BMIQ and ComBat); 4) run quality checks; 5) analyse datasets (a statistical test 
and delta beta analysis) to identify differentially methylated genes; 6) plot/tabulate data for 
inspection and evaluation; 7) return back to datasets and extract methylation values for all 
probes of the differentially methylated genes; 8) arrange probes in 5’ to 3’ direction; 9) 
reanalyse data and plot and tabulate the results; 10) compare probe methylation values for 
cases and controls; and 11) select a target region for each gene to check for the consistency 
of its methylation profile across leukaemia datasets. Manipulating the pipeline to 
customise the analysis lead to the development of an independent pipeline based on basic 
R functions that was successfully wrapped as an R package. 
The ABC.RAP R package applies Student’s t-test and delta beta analysis to identify 
differentially methylated genes that have at least two differentially methylated CpG sites 
with a statistically significant difference in DNA methylation between cases and controls. 
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In addition, ABC.RAP was used to profile DNA methylation for any gene of interest, 
providing a powerful feature for comparison between datasets.  
The package required less than 10 minutes to analyse a dataset compromising 92 samples 
on a 2.5 GHz Intel quad-Core i5 processor iMac computer. The package offered an 
efficient one-script workflow that automatically exports an analysis report for each 
differentially methylated gene into the working directory.  
In summary, the workflow was divided into three main stages: processing, analysis and 
results (Figure 4.4). A detailed manual and source codes of ABC.RAP features and 
functions have been published on the comprehensive R archive network (“CRAN”) 
website and the ABC.RAP manual is available in Appendix 2. ABC.RAP was accepted by 
the CRAN on the 20th October 2016 and can be accessed on the following site: 
https://cran.r-project.org/package=ABC.RAP. The package was also peer-reviewed by 
OMIC Tools team and was released onto their website under the category of “DNA 
methylation array analysis” and “Differentially methylated region detection” section 
(Unique identifier: OMICS_18100). The package can be accessed on the following link: 
https://omictools.com/array-based-cpg-region-analysis-pipeline-tool  
 





4.6 The analysis of lymphoblastic leukaemia datasets using 
ABC.RAP package 
ABC.RAP analysis was applied to seven lymphoblastic leukaemia datasets that had 
methylation values for cases and controls (see section 4.1 and Table 4.1). Five of the 450k 
array leukaemia datasets (Busche’s, Sandoval’s, Borssén’s, Gabriel’s and Nordlund’s 
datasets) and two of the 27k array leukaemia datasets (Wong & Ashley’s and Hogan’s 
datasets) were analysed independently to identify differentially methylated genes. The two 
validation datasets (Lee’s and Wong & Bhadri’s) were used to investigate the DNA 
methylation consistency of the identified differentially methylated genes in different 
leukaemia subgroups. A total of 1,261 leukaemia cases and 278 control samples were 
analysed to identify and validate a panel of ALL-specific, differentially methylated genes.  
Stringent cutoffs were used to analyse the “investigation cohorts” by applying a 
Bonferroni adjustment for multiple testing on Student’s t-test (P-value < 1 x 10-7 for 450k 
cohorts and P-value < 2 x 10-6 for 27k cohorts) and then including CpG sites that had 
DNA methylation difference, between cases and controls, of more than 0.5 (delta beta > 
0.5). Table 4.2 shows a summary of the results for the seven analysed cohorts. Gabriel’s 
and Hogan’s datasets failed to show CpG sites with statistically significant difference in 
DNA methylation. Both Nordlund’s and Busche’s datasets had the highest numbers of 
CpG sites with a statistically significant difference in DNA methylation. Interestingly, 
ABC.RAP Student’s t-test and DMP F-test analyses (see section 4.4.3) showed highly 
similar results regarding the number of CpG sites with statistically significant difference in 
DNA methylation (231,060 and 271,157 CpG sites, respectively). Borssén’s and 
Nordlund’s datasets had the highest number of differentially methylated CpG sites (delta 
beta > 0.5) in leukaemia cases compared to controls (Table 4.2). None of the CpG sites in 
Sandoval’s dataset had a difference in DNA methylation of > 0.5 in B-ALL cases 
compared to healthy controls. As a result, four datasets (Nordlund’s, Busche’s, Borssén’s 
and Wong & Ashley’s) contained CpG sites with statistically significant difference in 
DNA methylation and the difference in DNA methylation between ALL and controls was 
more than 0.5.   
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Table 4.2. Summary of ABC.RAP data analysis. Overlap CpG sites means CpG sites 
that are statistically significant and differentially methylated in leukaemia cases 
compared to control samples. Delta beta of > 0.5 means methylation difference of more 
than 0.5 between cases and controls. 
 
Datasets (n) 
Number of CpG sites  
450k: P-value < 1 x 10-7 
27k: P-value < 2 x 10-6 
delta beta > 0.5 Overlap  Genes 
(≥ 2 CpG sites) 
Nordlund (764) 236,937 3,074 3,074 555 
Busche (46) 231,060 453 453 58 
Sandoval (29) 12,145 0 0 0 
Gabriel (26) 0    
Borssén (65) 95,251 5,262 5,232 859 
Wong & Ashley (17) 1,459 557 519 88 
Hogan (35) 0    
 
The aim of ABC.RAP analysis was to identify methylation biomarkers that had at least 
two CpG sites with statistically significant difference in DNA methylation and the 
difference is more than 0.5 between leukaemia cases compared to healthy controls. 
Borssén’s and Nordlund’s cohorts had the highest number of differentially methylated 
genes (859 and 555, respectively). Interestingly, my previous analysis of Busche’s dataset 
using the DMP package (see section 4.4.3), which is based on identification of CpG sites 
with a statistically significant difference in DNA methylation, suggested that there were 
19,479 differentially methylated genes, which seems highly unlikely. In comparison, 
ABC.RAP analysis identified 58 differentially methylated genes with more than 0.5 
difference between B-ALL and controls and it seems likely that these genes are more 
realistic for use as biomarkers.  
Gene lists from each cohort were compared to identify common differentially methylated 
genes in at least three independent leukaemia cohorts. Five common genes were identified 
when all four datasets (Nordlund’s, Busche’s, Borssén’s and Wong & Ashley’s) were 
combined (Table 4.3). To identify additional candidate genes, we then looked for genes in 
common within the three 450k datasets. There were 36 common differentially methylated 






Table 4.3. Differentially methylated genes common to Borssén’s, Nordlund’s, Busche’s 
and Wong’s datasets. 
 
Genes 
Number of differentially methylated CpG sites 
T-ALL (Borssén) ALL (Nordlund) B-ALL (Busche) B-ALL (Wong) 
1 GALR1 15 10 4 4 
2 FOXI2 12 7 4 2 
3 NEFM 11 10 3 2 
4 CIDEA 6 6 2 2 
5 PAK7 3 4 2 2 
 
 
The ABC.RAP pipeline was then used to display the differentially methylated regions of 
the identified ALL-methylated genes by extracting the methylation values of all of their 
probes, arranging them based on their location, and then performing Student’s t-test and 
delta beta analysis of all of the probes. The results of the analysis were exported in a four-
way plot containing information about the difference in beta values between cases and 
controls (i.e., cases minus controls) for each gene probe arranged in 5’ to 3’ direction, the 
mean methylation level for cases (red circles) and controls (blue triangles) and boxplots 
displaying the distribution of methylation for each probe in cases and controls. One of the 
genes that had the highest number of differentially methylated CpG sites and that was 
common between at least three different leukaemia cohorts was MARCH11 (Table 4.4). 
Figures 4.5 and 4.6 show the methylation pattern of MARCH11 in Busche’s (B-ALL) and 
Borssén’s (T-ALL) datasets, respectively. The similarity between the methylation of 
MARCH11 in B-ALL and T-ALL from two independent datasets is remarkable. 
Furthermore, results for each plotted probe were exported in a table containing the mean 
methylation level for cases, mean methylation level for controls, delta beta values and 
















Table 4.4. A list of 36 differentially methylated genes common to Borssén’s, Nordlund’s 
and Busche’s datasets.  
 
Genes 
Number of differentially methylated CpG sites 
T-ALL (Borssén) ALL (Nordlund) B-ALL (Busche) 
1 MARCH11 14 9 8 
2 GALR1 15 10 4 
3 FOXI2 12 7 4 
4 ZIC4 19 5 4 
5 MACROD2 7 4 4 
6 NEFM 11 10 3 
7 VAX1 13 8 3 
8 GPR158 6 7 3 
9 PCDHAC1 7 6 3 
10 MAL2 6 6 3 
11 C14orf23 7 4 3 
12 RNF180 5 4 3 
13 GRIK2 3 3 3 
14 GRM6 3 2 3 
15 FGF14 2 9 2 
16 SYBU (GOLSYN) 3 8 2 
17 VSTM2A 10 6 2 
18 ISL1 9 6 2 
19 CIDEA 6 6 2 
20 POU4F2 6 6 2 
21 FAM190A 5 6 2 
22 KCNV1 4 6 2 
23 DOK6 6 5 2 
24 PHYHIPL 6 5 2 
25 AGBL4 4 5 2 
26 TMEM229A 4 5 2 
27 EBF2 11 4 2 
28 KCNA4 9 4 2 
29 SLC34A2 4 4 2 
30 PAK7 3 4 2 
31 FOXA2 5 3 2 
32 DPP6 4 3 2 
33 STK32A 3 3 2 
34 C6orf41 2 2 2 
35 CCDC67 2 2 2 






Figure 4.5. Four-way plot showing MARCH11 DNA methylation profile in B-ALL 
(Busche et al., 2013). This analysis was done using ABC.RAP R package. Plot_gene 
function produces four plots: the top left shows the difference in beta values between 
cases and controls for each probe, arranged 5’ to 3’; the top right shows the mean 
methylation level for cases (red circles) and controls (blue triangles); and the bottom 
plots show the distribution of DNA methylation in cases (left) and controls (right). 
Boxplots show the median and interquartile range (first and third quartiles) of 
methylation values for each probe. The whiskers represent the minimum and maximum 
values of DNA methylation while the small circles represent the outliers. 
 
 
Figure 4.6. Four-way plot showing MARCH11 DNA methylation profile in T-ALL 
(Borssén et al., 2016). See figure 4.6 for explanation of plots. 
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Table 4.5. Results table for MARCH11 methylation from Busche’s dataset. CGI = CpG 
island. Mean = mean DNA methylation. 




mean Delta beta 
t-test 
P.value 
cg03829734 Body NA 0.656 0.790 -0.134 1.68E-11 
cg11584519 Body N_Shelf 0.591 0.739 -0.148 4.49E-11 
cg03477332 Body N_Shore 0.411 0.415 -0.005 0.843 
cg17507952 Body N_Shore 0.527 0.210 0.317 9.81E-29 
cg06782035 Body Island 0.601 0.065 0.536 1.74E-36 
cg03705912 1stExon Island 0.620 0.165 0.455 5.60E-41 
cg23479922 1stExon Island 0.624 0.051 0.573 2.94E-58 
cg09017434 1stExon Island 0.566 0.058 0.508 1.13E-47 
cg15015920 1stExon Island 0.506 0.067 0.440 9.61E-26 
cg25092681 TSS200 Island 0.473 0.044 0.429 1.14E-21 
cg00339556 TSS200 Island 0.552 0.031 0.522 5.38E-27 
cg01791874 TSS200 Island 0.541 0.042 0.498 6.58E-27 
cg17030173 TSS200 Island 0.579 0.066 0.513 1.23E-27 
cg17712694 TSS200 Island 0.588 0.040 0.547 4.62E-27 
cg16150752 TSS200 Island 0.595 0.031 0.564 1.17E-27 
cg21901718 TSS200 Island 0.523 0.028 0.495 3.26E-23 
cg18325622 TSS1500 Island 0.522 0.061 0.461 1.33E-28 
cg23065934 TSS1500 Island 0.585 0.042 0.544 1.41E-31 
cg11452391 TSS1500 Island 0.459 0.039 0.420 1.49E-26 
cg12456714 TSS1500 Island 0.528 0.072 0.456 3.83E-25 
cg16182986 TSS1500 Island 0.496 0.176 0.321 9.95E-24 
cg21582253 TSS1500 S_Shore 0.620 0.686 -0.066 8.44E-05 
 
4.6.1 Gene ontology analysis of the ALL-methylated genes 
In an attempt to determine if the methylated genes share functional and biological roles, 
gene ontology analysis was done. Gene ontology functional annotation analysis was 
conducted on the 36 common differentially methylated genes identified by ABC.RAP as 
well as TES, KITLG and C10orf53 using Enrichr (Kuleshov et al., 2016). The inclusion of 
TES is based on published data from our group as discussed in section 1.3.4 (Weeks et al., 
2010). The inclusion of KITLG and C10orf53 is based on the differential methylation 
analysis described in section 4.4.3. GO annotation analysis for biological process showed 
that ISL1, POU4F2 and FOXA2 have a positive regulatory role of endodermal cell 
differentiation (adjusted P-value = 0.03). In addition, ISL1 and POU4F2 have positive 
regulation of cell development, cell fate commitment, and cell differentiation (Table 4.6). 
Furthermore, SLC34A2, KCNV1, GRM6, GALR1, KCNA4, GRIK2 and PCDHAC1 were 
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involved in 47 cellular components, such as ab5 integrin-vitronectin complex, G-protein 
coupled receptor complex and others (adjusted P-values < 0.05). However, GO molecular 
function and KEGG pathway analyses were insignificant for any of the ALL-methylated 
genes.   
 
Table 4.6. Enrichr biological process gene ontology analysis shows the role of some of 






positive regulation of endodermal cell 
differentiation 0.00003 0.03 26 ISL1;POU4F2;FOXA2 
positive regulation of sequestering of 
triglyceride  0.0004 0.04 26 CIDEA;VSTM2A 
regulation of synaptic transmission, 
glutamatergic  0.001 0.04 21 GRM6;GRIK2 
G-protein coupled glutamate receptor 
signaling pathway 0.0008 0.04 18 GRM6;GRIK2 
Positive regulation of cell differentiation 
involved in phenotypic switching 0.001 0.04 17 ISL1;POU4F2 
Positive regulation of leukocyte 
differentiation 0.001 0.04 17 ISL1;POU4F2 
Positive regulation of cell fate commitment 0.001 0.04 17 ISL1;POU4F2 
Positive regulation of cell development  0.001 0.04 16 ISL1;POU4F2 
 
Gene Ontology analysis did not provide common pathways or biological roles for all of the 
ALL-methylated genes, but instead it showed associations of few genes (2 – 7 genes) with 
some key regulatory functions during cell development (Table 4.6). In addition, none of 
the pathways listed in Table 4.6 showed an obvious connection to ALL. Assuming that 
ISL1 and POU4F2 were involved in ALL development, they cannot be the only driver 
genes for ALL pathogenesis. Consequently, the gene ontology analysis was not useful to 
determine the role of the ALL-methylated genes in the development of ALL. Furthermore, 
the ALL-methylated genes were selected based on their usage as methylation biomarkers 
and that does not necessarily mean that they have to share common functional or 
biological roles in ALL pathogenesis. 
4.7 The ALL-methylated gene panel 
4.7.1 Criteria for the selection of the ALL-methylated gene panel 
Based on the ALL-methylated genes criteria in section 4.2, ABC.RAP analysis provided a 
list of commonly and highly methylated leukaemia genes. As shown in Figures 4.5, 4.6, 
4.7 and 4.8, MARCH11 is a good example of an ALL-methylated gene that is commonly 
methylated across several leukaemia cohorts, leukaemia subtypes and subgroups. In 
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addition, MARCH11 demonstrated high DNA methylation in leukaemia cases and 
extremely low methylation in control samples for a large cluster of CpG sites located in a 
CpG island within the gene promoter.  
To identify genes, similar to MARCH11, with very low methylation in control samples and 
high methylation in leukaemia cases, DNA methylation levels for 36 genes were 
investigated. Additional filtering criteria was set up to refine the selection process of the 
ALL-methylated gene panel from the 36 genes in Table 4.4. The selection criteria included 
the following: 1) DNA methylation of the differentially methylated CpG sites is consistent 
across different leukaemia subtypes (B and T-ALL); 2) the methylation level of the 
differentially methylated CpG sites should be very low in control samples (< 0.1) and high 
in leukaemia cases (> 0.5); and 3) target regions were within gene promoters defined as 
being within 1,500 bp of the transcription start site (TSS) to select for biomarkers with 
potential biological relevance.  
Busche’s (B-ALL) and Borssén’s (T-ALL) leukaemia cohorts were used for the selection 
process to evaluate the distribution and consistency of DNA methylation for the 36 genes 
listed in Table 4.4 (methylation profile of these genes is available in Appendix 3). In 
addition, the 36 genes were evaluated to identify target regions within gene promoters that 
can be used for sequencing. After inspecting the methylation features of the 36 genes, a 
panel of nine genes was selected to form the ALL-methylated gene panel. Methylation 
PCR of GALR1 was unsuccessful and therefore was removed from the panel.  
Previously, two additional genes (KITLG and C10orf53) from the differentially methylated 
positions analysis (see section 4.4.3) were added to the panel. In addition, the published 
differentially methylated gene, TES, was included (see section 1.3.4). As a result, the ALL-
methylated gene panel was composed of 11 genes: TES, NEFM, KITLG, KCNA4, 
C10orf53, MARCH11, PAK7, RNF180, SYBU (previously known “GOLSYN”), ISL1 and 
MACROD2. 
4.7.2 Validation of the ALL-methylated gene panel 
Four leukaemia validation cohorts were chosen for this analysis: Lee’s (B-ALL subtypes; 
450k array dataset); Gabriel’s (B-ALL subtypes; 450k array dataset); Wong & Bhadri’s 
(primary and xenograft B-ALL; 27k array dataset); and Hogan’s (B-ALL; 27k array 
dataset). Remarkably, the methylation values of the ALL-methylated genes were consistent 
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across different subtypes of B cell leukaemia in both Lee’s and Gabriel’s datasets 
(methylation profiles are available in Appendix 4). The methylation values for leukaemia 
cases with TCF3-PBX1 translocation in Gabriel’s dataset were generally lower than other 
leukaemia subtypes. This could be related to the small number of cases in this subgroup (n 
= 3). In comparison, the methylation values for TCF3-PBX1 translocation in Lee’s cohort 
were consistent with other leukaemia subtypes despite the small number of samples (n=6).  
Differences between the compositions of 27k to 450k array data limited the use of the 27k 
array data for the validation of some of the ALL-methylated gene panel. MARCH11, 
RNF180, SYBU and C10orf53 genes did not have probes on 27k arrays and hence could 
not be validated by Wong & Bhadri’s and Hogan’s datasets. The majority of the ALL-
methylated genes were interrogated by two probes in the 27k array cohorts, with 
MACROD2 being an exception (four probes, see Appendix 4). When the locations of 27k 
probes of the methylated genes were compared to the 450k probes, majority of the profiled 
27k probes were located outside the promoter regions (1500 bp from transcription start 
site). Having the methylation values of two positions for each gene was insufficient to 
evaluate the methylation consistency of the ALL-methylated gene panel. Because of the 
limited information from the 27k array cohorts for the ALL-methylated genes, it was not 
possible to comment on the consistency of DNA methylation in Wong & Bhadri’s and 
Hogan’s datasets (Appendix 4). Based on the above reasons, the evaluation process for the 
ALL-methylated gene panel was based solely on the methylation values from 450k array 
datasets (i.e., Lee’s and Gabriel’s datasets). 
To represent the validation process, MARCH11 is used here as an example. Figures 4.7 and 
4.8 show ABC.RAP output of the DNA methylation in different leukaemia subgroups in 
Lee’s and Gabriel’s datasets, respectively. As mentioned above, there were no probes for 
MARCH11 on the 27k array and hence MARCH11 was not validated by Wong & Bhadri’s 
and Hogan’s datasets. Remarkably, MARCH11 methylation profile (ALL cases ~ 60% and 
controls < 10%) is consistent across different leukaemia cohorts and among leukaemia 
subgroups. The three leukaemia cases with TCF3-PBX1 translocation in Gabriel’s dataset 
showed lower DNA methylation for MARCH11 probes (~ 10 – 40% lower than other 
leukaemia subgroups, Figure 4.8.C). However, methylation of MARCH11 in TCF3-PBX1 
ALL subgroup in Lee’s cohort (n = 6, Figure 4.7.C) was not decreased compared to the 
methylation profile in Gabriel’s cohort. These apparent differences might reflect the low 




Figure 4.7. Boxplots showing the distribution of DNA methylation for MARCH11 CpG 
sites in B-ALL subgroups (Lee’s dataset). A: methylation of 73 hyperdiploidy cases, B: 
methylation of 52 cases with ETV6-RUNX1 translocation, C: methylation of 6 cases with 
TCF3-PBX1 translocation, D: methylation of 2 cases with MLL, E: methylation of 73 
cases with other cytogenetics abnormalities and F: methylation of 21 cases with 
unknown cytogenetic abnormalities. 
 
 
Figure 4.8. Boxplots showing the distribution of DNA methylation for MARCH11 CpG 
sites in B-ALL subgroups (Gabriel’s dataset). A: methylation of 10 hyperdiploidy cases, 
B: methylation of 10 cases with ETV6-RUNX1 translocation, C: methylation of 3 cases 
with TCF3-PBX1 translocation and D: methylation of 3 cases with dic(9;20). Note that 
the ABC.RAP boxplot does not provide an optimal representation of data when the 




The methylation of the ALL-methylated gene panel was examined thoroughly and each 
gene showed consistent DNA methylation across different leukaemia subtypes, similar to 
that of MARCH11. As a result, target regions were selected for experimental validation by 
DNA methylation sequencing. 
4.8 Selecting target regions and designing primers 
For each ALL-methylated gene, a target region was selected based on the location of 
differentially methylated CpG sites within the promoter region. ABC.RAP plot_gene 
function was used to refine the target regions. This function automatically exported a plot 
and result table for any profiled gene. Figure 4.9 shows an example of a differentially 
methylated region adjacent to KCNA4 promoter region based on the probes shown in Table 
4.7 (Busche et al., 2013). The selected region in Figure 4.9 is highlighted in red in Table 
4.8. Methylation plots and tables for the ALL-methylated gene panel are available in 
Appendix 3. 
 
Figure 4.9. Four plots showing the methylation features of KCNA4 in B-ALL and 
control samples. A differentially methylated target region was selected in the promoter 





Table 4.7. A result table from ABC.RAP analysis profiling the DNA methylation 
features of KCNA4 in B-ALL and control samples (Busche’s dataset). The table 
highlights (red colour) the methylation values for the selected target region in Figure 
4.10. 
Site ID Chr Distance 












cg07784428 11 Body N_Shelf 0.714 0.858 -0.144 1.69E-20 
cg02608452 11 5'UTR N_Shelf 0.588 0.754 -0.167 4.06E-10 
cg04063166 11 5'UTR N_Shelf 0.237 0.524 -0.288 3.35E-32 
cg14393466 11 5'UTR N_Shelf 0.647 0.788 -0.141 4.07E-10 
cg03553947 11 5'UTR N_Shore 0.608 0.622 -0.014 0.4 
cg13671841 11 5'UTR N_Shore 0.509 0.597 -0.088 7.05E-06 
cg04719819 11 5'UTR Island 0.428 0.139 0.290 6.56E-20 
cg12164612 11 5'UTR Island 0.550 0.066 0.484 3.02E-27 
cg22639011 11 5'UTR Island 0.627 0.258 0.369 9.77E-44 
cg27319123 11 1stExon N_Shore 0.575 0.165 0.410 2.7E-38 
cg15183083 11 1stExon N_Shore 0.478 0.109 0.369 7.45E-25 
cg10387551 11 TSS200 Island 0.527 0.037 0.490 1.06E-36 
cg17714025 11 TSS200 Island 0.502 0.051 0.450 5.03E-39 
cg15044957 11 TSS200 Island 0.599 0.052 0.546 8.86E-40 
cg08490115 11 TSS200 Island 0.589 0.042 0.547 2.77E-39 
cg15310492 11 TSS200 Island 0.526 0.054 0.472 7.97E-39 
cg05756220 11 TSS200 Island 0.568 0.132 0.436 1.06E-44 
cg22685409 11 TSS1500 Island 0.575 0.147 0.429 1.40E-40 
cg03506489 11 TSS1500 Island 0.590 0.159 0.432 7.24E-45 
cg13161658 11 TSS1500 Island 0.504 0.089 0.415 6.51E-32 
cg12122597 11 TSS1500 Island 0.425 0.178 0.247 3.35E-15 
cg14161359 11 TSS1500 Island 0.460 0.263 0.196 1.79E-12 
cg11735997 11 TSS1500 Island 0.437 0.174 0.264 2.72E-19 
 
Locations of 450k array probes were used to select the DNA sequence for the target 
regions (Figure 4.10). To refine the target region, the UCSC genome browser 
(GRCh37/hg19, http://genome.ucsc.edu) was customised to include genome-wide 
methylation data from leukaemia samples and several normal cell types. To include the 
publicly available genome-wide methylation data, a “DNA Methylation” track from “track 
hub” on the genome browser was selected. “DNA Methylation” track has genome-wide 
DNA methylation sequencing data from 56 datasets containing human samples. The 
customised browser gave more density of information and augmented the limited 450k 
results (Figure 4.10). In this example, the two B-ALL samples from Lee’s cohort (2015) 
show a high methylation level for the selected KCNA4 promoter region compared to 
peripheral blood mononuclear cells (PBMC), CD34+ cells, B cells, T cells, NK cells, 
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neutrophils (Neut) and macrophages (Heyn et al., 2012; Hodges et al., 2011; Li et al., 
2010). These data support the selection of this region for KCNA4. Genome-wide DNA 
methylation data for each of the ALL-methylated gene panel will be described in the 
following chapter (see Chapter 5). 
Methylation-specific primers were then designed for the target sequences of all genes in 
the ALL-methylated gene panel using MethPrimer tool (website: 
http://www.urogene.org/cgi-bin/methprimer/methprimer.cgi) (Li & Dahiya, 2002).  
 
Figure 4.10. Image of the genome browser showing DNA methylation levels of 
leukaemia and normal cell types for KCNA4 promoter target region. Methylation levels 




Analysis of publicly available human 450k array datasets was a useful starting point when 
searching for differentially methylated genes. Interestingly, to identify differentially 
methylated genes, the majority of available 450k analysis tools focus on a single analysis 
method for identifying methylated genes, and either used a statistical test or a methylation 
difference (Wilhelm-Benartzi et al., 2013). The definition of “differentially methylated 
regions (DMR)” across the available analysis tools was widely variable, creating confusion 
for experimental biologists (see chapter 8 for more details) (Robinson et al., 2014). To my 
knowledge, based on the latest review papers of 450k analysis tools, a tool that can 
identify genes based on the criteria in sections 4.2 and 4.7.1 has not been described in the 
literature (Chen et al., 2016; Wilhelm-Benartzi et al., 2013). A user-friendly tool, 
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ABC.RAP, with its ability to find genes based on their highly methylated sites in cases and 
profile the methylation features in a similar way as seen in the UCSC genome browser, 
therefore provides a unique pipeline for biologists. ABC.RAP analysis was conducted on 
leukaemia 450k and 27k array datasets and it revealed lists of genes that were commonly 
methylated across different leukaemia subtypes.  
Sandoval and colleagues (2013) reported 3,414 differentially methylated CpG sites 
(annotated to 412 genes) with a methylation difference of more than 0.3 between B-ALL 
and the enriched CD19+ B cells from healthy controls (FDR < 0.01). In comparison, 
modified ABC.RAP analysis found 823 CpG sites with a methylation difference of more 
than 0.3, of which 74 sites had statistically significance difference in DNA methylation. 
The sites reported by Sandoval’s are located in 412 genes, of which six (containing at least 
two CpG sites) correlated with those detected by the ABC.RAP analysis (GRID1, KCNC3, 
MSC, RPTOR, UGT8 and WDR17). The difference in the number of Sandoval’s reported 
differentially methylated CpG sites are likely due to differences in the applied analysis 
methods. They defined differentially methylated CpG sites by a delta-beta of > 0.3 and an 
FDR < 0.01 using a Wilcoxon rank test using GenomeStudio program. However, delta-
beta of > 0.3 and Bonferroni correction of 1 x 10-7 on Student’s t-test were used to identify 
the differentially methylated CpG sites in our ABC.RAP analysis and revealed 11 genes 
that contained at least two differentially methylated CpG sites.  
Nordlund and colleagues (2013) reported 9,406 CpG sites that were commonly methylated 
in B and T cell leukaemia compared to bone marrow samples from remission controls and 
cell sorted non-leukaemic cells isolated from healthy individuals (methylation difference 
of more than 20% and FDR < 0.01). The identified sites were located near 2,023 genes. 
ABC.RAP analysis identified 3,074 differentially methylated sites (555 differentially 
methylated genes, Table 4.2) in leukaemia cases compared to the controls in Nordlund’s 
dataset (methylation difference of more than 50% and Bonferroni adjustment of Student’s 
t-test of P-value < 1 x10-7). The higher number of differentially methylated CpG sites 
reported by Nordlund’s was due to the relaxed cutoff values (delta-beta of 0.2 and FDR < 
0.01 of Wilcoxon signed-rank test) used for differential methylation analysis.  
Busche et al, Gabriel et al, Borssén et al and Lee et al did not investigate differentially 
methylated genes in leukaemia compared to control samples, but instead their focus was 
mostly on how to classify leukaemia into subgroups (Borssén et al., 2016; Busche et al., 
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2013; Gabriel et al., 2015; Lee et al., 2015). Busche and colleagues (2013) used a single 
CpG site analysis method (WGCNA R package) to “investigate correlation patterns among 
CpG-sites” in leukaemia cases with the ETV6-RUNX1 translocations. They used two 
clustering approaches and found 119 densely methylated CpG sites specific for the cases 
with the ETV6-RUNX1 translocation in comparison to other B-ALL subtypes. We have 
used their datasets for a completely different purpose, finding 58 genes that differ between 
ALL and controls. Consequently, results from ABC.RAP analysis for these cohorts were 
not comparable with the reported results.  
So far, a panel of leukaemia-genes that were shown to be highly methylated in acute 
lymphoblastic leukaemia was selected, but what do we know about these genes? Do they 
share common pathways? Are they involved in other cancers? Have they been reported 
previously to be methylated in leukaemia? (see section 1.1.6 for more details on TES). 
Gene ontology analysis failed to show common pathways or functions between all of the 
ALL-methylated genes and this result questions the usefulness of gene ontology analysis. 
Ashburner and colleagues (2000) proposed that the gene ontology analysis “will find 
favour among biologists so that we can all facilitate, in our writing as well as our thinking, 
the grand unification of biology”. The use of gene ontology analysis was proposed to be 
important as ontologies “embody the abstract knowledge required for data integration and 
analysis” (Soldatova & King, 2005). However, Soldatova and King argued that “almost all 
biological ontologies have been generated in a quick (and arguably dirty) manner and have 
generally ignored ontological logic”. They suggested that gene ontologies were designed 
to provide common vocabularies for human biologists who can interpret the data and get 
around contradictions. However, the reliance on computer programs to conduct machine 
learning and text mining may compromise the analysis as it has no control over 
inconsistent or poorly designed ontologies (Soldatova & King, 2005).  
Gillis and Pavlidis (2013) evaluated the reliability of gene annotations (GO) using the 
following hypotheses: 1) the functional identity of each gene was consistent between 
different GO versions; 2) the degree of GO assignments were distributed equally between 
the genes and were not changed over time; and 3) the degree of GO annotations were 
integrated safely with network data without confounds. They found group of genes lose 
their functional identity across different GO versions (i.e., the selection of a gene X based 
on GO terms in one of GO versions may not reveal the same gene on other versions with a 
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probability of similar identity does not exceed 0.03). In addition, they found that gene 
identity can be changed after five months. Interestingly, Gillis and Pavlidis found that 
there is an increase of annotation bias for human genes. Annotation bias was characterised 
by the prediction of gene identity based on the number of GO terms. The increase in 
annotation bias was proposed to be due to the “proliferation of terms and/or relations in 
GO” and the majority of “popular” genes were associated with the numerical ranking of 
gene IDs on the NCBI, indicating a historical bias towards first entered genes. 
Consequently, Gillis and Pavlidis suggested that “the biases in GO annotation are of 
sufficient magnitude to swamp almost any true result about gene function”. In addition, 
they considered the annotation bias as source of “publication bias” because “GO makes it 
even easier than usual to select genes for study, only because they have already been 
heavily studied”. Furthermore, they found the functional annotations of some genes was 
confounded by the source of the data and hence the annotations were not independent 
across the genes. As a result, Gillis and Pavlidis encouraged “researchers to be cautious in 
the interpretation and use of GO” and the identified issues above “are severe enough to run 
a strong risk of misleading the field if not taken into account”. Based on Gillis and 
Pavlidis’s study, the gene ontology analysis to identify common pathways for the ALL-
methylated genes may be confounded by those genes that were reported in Table 4.6 as 
either being heavily used or heavily annotated genes. 
Whether methylation of genes has functional consequences is not clear. However, three 
examples are discussed here to explain plausible biological relevance. The neurofilament 
medium (NEFM) is a protein coding gene (transcribe to 160 kDa protein) involved in the 
synthesis of the intermediate filaments in the neuronal cytoskeleton (Perrot et al., 2008). 
Neurofilament proteins regulate the axonal calibre for conduction velocity, neuronal 
differentiation, outgrowth, guidance and regeneration (Perrot et al., 2008). Interestingly, 
NEFM expression was detected at early stages of axonal development and its upregulation 
was found in successfully regenerated neurons (Perrot et al., 2008). Mutations and 
abnormal accumulations of NEFM, and other neurofilament genes, were commonly 
associated with neurodegenerative disorders such as amyotrophic lateral sclerosis, 
Alzheimer, Parkinson, Charcot-Marie-Tooth, giant axonal neuropathy, dementia and 
others (Perrot et al., 2008). In addition, DNA methylation of NEFM was found in different 
malignancies such as oesophagus squamous cell carcinoma, renal cell carcinoma, 
hepatocellular carcinoma, Ewing sarcoma and breast cancer (Calmon et al., 2015). Calmon 
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and colleagues investigated the DNA methylation and gene expression of NEFM, NEFL 
and NEFH in 10 primary breast tumours and found dense DNA methylation in NEFM 
promoter region in five cases (50%) and downregulation of gene expression in six cases 
(one case had unmethylated promoter). Then, they investigated the methylation of NEFM, 
NEFL and NEFH in 185 breast cancer samples of different stages and 14 non-cancerous 
normal breast tissues. NEFM methylation was detected in 82% of the breast cancer tissues 
(n = 152) compared to undetected methylation in control samples. Inspecting the clinical 
data of the breast cancer cases, they found NEFM methylation was associated with those at 
late stages (clinical stages 3 and 4) and had adverse prognostic measures (Calmon et al., 
2015). 
KIT ligand (KITLG) protein is a subclass III of tyrosine kinase receptors which activates 
kinase domain upon the binding of KITLG protein to KIT receptors (Galan et al., 2006). 
Once KIT receptors are activated, tyrosine residues become phosphorylated and act as 
“docking sites for transducer molecules that activate different molecular pathways” (Galan 
et al., 2006). As a result, key cellular pathways such as cellular adherence, migration, 
differentiation, proliferation, maturation and survival become activated. These pathways 
were found important in the development and regulation of haematopoiesis, melanogenesis 
and germ cells (Galan et al., 2006). Galan and colleagues investigated KITLG methylation 
in the blood of 153 cases of familial testicular germ cell tumour and 116 healthy male 
controls. They found four CpG sites within the KITLG promoter had significantly lower 
DNA methylation in the cases than the controls (odds ratio of 1.8 to 2.2). There was an 
inverse correlation between KITLG methylation and gene expression; however, the 
correlation was insignificant for the four CpG sites (P-value > 0.1) (Galan et al., 2006). 
Interestingly, Geyh and colleagues (2016) investigated the molecular pathways involved in 
the pathogenesis of haematopoietic insufficiency in acute myeloid leukaemia cells. They 
isolated mesenchymal stromal cells from bone marrow samples of 64 acute myeloid 
leukaemia patients and 128 healthy controls. They found the leukaemia-derived 
mesenchymal stromal cells had a compromised growth and differentiation characterised by 
a downregulation of KITLG expression compared to those derived from controls (Geyh et 
al., 2016). 
There are reports in the literature showing associations between some of the other ALL-
methylation biomarkers and cancer development. As examples, KCNA4 and MARCH11 
methylation was detected in the tissues and serum of gastric cancer and primary non-small 
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cell lung carcinoma patients, respectively (Ooki et al., 2017; Zheng et al., 2011). Another 
example is the high methylation of the RNF180 promoter region in 86% of gastric cancer 
cell lines and downregulation of RNF180 gene expression in nine primary cancer tissues 
compared to the surrounding non-cancerous tissues (Cheung et al., 2012). Furthermore, 
ISL1 was found to be densely methylated in 181 non-muscle invasive bladder cancer 
patients compared to six normal bladder tissues (median methylation of 60% compared to 
about 10% in controls) (Kim et al., 2013). Interestingly, Chatterton and colleagues (2014), 
who are from the same group as Wong & Ashley (2012), conducted another array 
experiment using 450k array platform on 69 paediatric B-ALL patients and 48 control 
samples (methylation data are not publicly available) and listed PAK7 as one of the 
differentially methylated genes in B-ALL. However, they did not further investigate PAK7 
methylation. 
After reviewing the literature, there were no reports documenting the association of any of 
the ALL-methylated genes with acute lymphoblastic leukaemia. This opens an opportunity 
for future research to investigate the role of the ALL-methylation biomarkers in ALL 

















Chapter 5: Evaluating the ALL-methylated genes 
5.1 Abstract 
In the previous chapter, ABC.RAP analysis was applied on the publicly available 
leukaemia cohorts to identify a panel of methylation biomarkers for leukaemia. A panel of 
11 genes was selected for in silico and experimental validation. This chapter shows results 
from the experimental validation of the methylation panel using a targeted methylation 
sequencing approach. Primers were designed to target promoter regions of the ALL-
methylated gene panel. Blood samples from 18 healthy adults, 13 healthy newborns, 10 
leukaemia cell lines and 13 ALL xenograft samples were used for methylation sequencing 
experiments. Sequencing results showed dense methylation in leukaemia xenograft 
samples and cell lines compared to low methylated sequences in the majority of neonatal 
samples. The majority of the ALL-methylated gene panel, except for TES, showed a low 
level of DNA methylation in adult blood samples. The presence of methylated epialleles in 
adult samples was most likely due to the increase of DNA methylation in B and T cells 
with age.   
5.2 Deep targeted sequencing 
The following section shows examples of PCR results representing the preparation process 
of targeted methylation sequencing libraries for the ALL-methylated genes (see section 3.8 
for more details). DNA from CD19+ enriched and CD19- mononuclear cells for 11 healthy 
newborns and from the peripheral blood of 18 healthy adults was extracted and bisulfite-
converted. In addition, DNA was extracted from 10 leukaemia cell lines and 13 ALL 
xenograft samples. 
5.2.1 Adult blood samples 
DNA was extracted from 18 healthy adults and bisulfite-converted using EZ DNA 
Methylation kit (see sections 3.5 and 3.6). The designed primers, which contain Illumina 
tags, were used to amplify target regions of the ALL-methylated gene panel (see section 





Figure 5.1. First round PCR products for the TES promoter region of 18 adult peripheral 
blood samples. TES amplicon size is 439 bp. 
 
GALR1 was originally selected to be one of the ALL-methylated gene panel; however, 
GALR1 PCR experiments were unsuccessful despite multiple optimisation experiments. As 
a result, GALR1 was excluded from the panel as noted in section 4.7.1. PCR reactions for 
NEFM, KCNA4, KITLG and C10orf53 in adult peripheral blood samples were done by 
Sophie Allan (summer student under my supervision). Figure 5.2 shows examples of the 
first round PCR products for three of these genes. 
 
Figure 5.2. First round PCR products for NEFM (A, amplicon size = 357 bp), KCNA4 
(B, amplicon size = 432 bp) and KITLG (C, amplicon size = 406 bp). 
 
5.2.2 Cord blood samples 
Cord blood samples were collected from 11 healthy full-term newborns. CD19+ B cells 
and CD19- cells were isolated from the mononuclear cell layers (see section 3.4.1). After 
cell enrichment, DNA was extracted, bisulfite-converted and used for methylation 
sequencing. Figure 5.3 shows PCR products for two of the genes (SYBU and PAK7). In 





Figure 5.3. First round PCR products showing amplimers for SYBU (A, amplicon size = 
329 bp) and PAK7 (B, amplicon size = 418 bp). Samples labelled with a suffix “-A” are 
CD19+ B cells; “-B” are CD19 negative cells and “-C” is whole cord blood. 
 
5.2.3 Leukaemia cell lines and xenograft samples 
Ten leukaemia cell lines and 13 ALL xenograft samples were selected for evaluation of the 
ALL-methylated gene panel. Tables 5.1 and 5.2 show a summary of the leukaemia cell 
lines and ALL xenograft samples that were used in this project (the description of cell lines 
is from ATCC website). Xenograft ALL DNA samples were kindly provided by Professor 
Richard Lock and have been referred to in previous publications (Liem et al., 2004; Weeks 
et al., 2010). 
Table 5.1. Description of leukaemia cell lines used in this project. 
Cell line Description 
NALM6 B-ALL 
REH Non-T ALL, Non-B ALL 
RAJI Burkitt’s lymphoma: taken from the left maxilla of an 11-year-old African boy 
CCRF-CEM T-ALL: taken from the peripheral blood of 4 year-old Caucasian girl. 
CCRF-SB B-ALL: taken from the peripheral blood of an 11.5 year-old Caucasian boy 
MOLT4 T-ALL in relapse: taken from the peripheral blood of a 19-year-old man 
JURKAT T-ALL: taken from the peripheral blood of a 14-year-old boy 
K562 CML: taken from the bone marrow of a 53 year-old female with pleural effusion. 
RS4 ALL [CALLA (CD10) –, MPO -, Esterase -, TdT +, CD24+, CD9+, HLA DR+]: 
taken from the bone marrow of a 32 year-old Caucasian female. 
SUP-B15 B-ALL: taken from the bone marrow of an 8 year-old Caucasian boy 
(Philadelphia chromosome positive). 
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Figure 5.4 shows the PCR products for two of the genes (MARCH11 and RNF180). The 
cell lines and xenograft samples that failed first round PCR reactions were excluded from 
subsequent sequencing. These PCR reactions were done by Sophie Allan (summer student 
under my supervision). 
 
Figure 5.4. First round PCR products for MARCH11 (A, amplicon size = 467 bp) and 
RNF180 (B, amplicon size = 408 bp). 
 
First round PCR products for the same sample were pooled. For example, PCR products of 
TES, NEFM, KCNA4 and KITLG from X9073 were pooled into an X9073 tube. Small non-
specific products were removed from first round PCR products by using AMPure XP 
beads. The purified PCR products were then quantified using Qubit dsDNA HS kit and 
diluted to 1 ng/µL for the second round PCR reaction in which Illumina adaptors were 
added for MiSeq sequencing. Figure 5.5 shows an example of second round PCR products 
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for the pooled adult blood samples (each sample in this library has four genes: NEFM, 
KCNA4, KITLG and C10orf53).  
After that, samples were then pooled into one tube, purified and checked with a 
bioanalyser prior to sequencing. Figure 5.6 shows an example of a bioanalyser tracing and 
quantification results for leukaemia cell lines and xenograft samples (average fragment 
size is 443 bp). TES PCR preparations and amplification for adult and cord blood samples 
were done in a separate laboratory to avoid contamination by previously amplified TES 
PCR products (see section 3.8 for more details on the method).  
 
Figure 5.5. Second round PCR products of adult blood samples. Each sample contained 
four PCR amplimers. 
 
 
Figure 5.6. Example of Bioanalyser tracing and quantification for the pooled PCR 
products for leukaemia cell lines and xenograft samples. This pool contained seven 
amplicons (NEFM, KITLG, KCNA4, PAK7, MARCH11, RNF180 and ISL1). 
 
Samples were then loaded onto the Miseq for sequencing. The MiSeq Reagent Nano kit v2 
of 500 bp (250 bp paired-end; Illumina) was used to sequence the pooled samples. After 
sequencing, FASTQ files were demultiplexed based on the Illumina adaptor sequences and 




5.3 Analysis of sequencing data  
This project used an epiallelic approach to interpret sequencing data. An epiallele was 
defined as “a distinct pattern of methylation, typically over a short genomic region” and 
“in terms of biological function, CpG methylation should be often considered in an allelic 
fashion over multiple adjacent CpG sites” (Wong et al., 2016b).   
When I started my project, I had limited bioinformatics skills to analyse sequencing data, 
so I searched the literature to find the available pipelines for data analysis. Unfortunately, a 
well-defined pipeline with user-friendly tools for data analysis was not available in the 
literature. As a result, a customised pipeline was constructed based on the use of the 
Galaxy online server to process raw sequencing data followed by the use of BiQ Analyser 
HT program for sequence alignments and methylation calls. The following section 
describes the customised analysis pipeline in more detail.  
5.3.1 Establishing pipelines and evaluating existing tools 
There was no established analysis pipeline in the literature for DNA methylation data 
derived from high depth targeted sequencing. Consequently, the initial stages of data 
analysis included application of available methylation analysis tools to perform a 
customised amplicon-targeted methylation sequencing analysis. Tools such as MethVisual 
(Zackay & Steinhoff, 2010), methylation plotter (Mallona et al., 2014), BSPAT (Hu et al., 
2015), QUMA (Kumaki et al., 2008), BISMA (Rohde et al., 2010), methclone (S. Li et al., 
2014) and CyMATE (Hetzl et al., 2007) were used to quantify the methylated epialleles in 
the sequencing files (Figure 5.7). Unfortunately, these tools were available for online use 





Figure 5.7. Visual outputs from (A) methylation plotter summarising the average 
methylation level for five samples across all CpG sites of the TES amplicon; (B) BSPAT 
results for a neonatal blood sample (X9119) and B-ALL cell line (SUP-B15) showing 
methylation levels for the TES promoter; (C) BISMA heatmap of the methylation status 
of all TES CpG sites (red = methylated, blue = unmethylated) of a neonatal blood sample 
(X9119); and (D) QUMA lollipop presentation of TES CpG sites for a neonatal blood 




A pipeline was customised to analyse MiSeq files. The online Galaxy platform was used to 
process raw files (Galaxy server: https://usegalaxy.org) followed by sequence alignments 
and methylation calls on BiQ Analyser HT program. A cloned copy of the server software 
was installed for faster processing. In addition, it was possible to incorporate more specific 
tools onto the cloned copy, such as bismark, bisulfighter, bsfcall, bsmap, cmeth and others. 
An additional pipeline (bismark and methpat) was used to analyse the patterns of 






5.3.2 Data analysis using Galaxy and BiQ Analyser HT 
1. FASTQ raw files were uploaded onto the Galaxy platform and converted to 
Illumina 1.8+ format using FASTQ Groomer function (Blankenberg et al., 2010). 
FASTQ files contained four lines for each sequence read: 1) the first line contained 
the identification details for the sequence read; 2) the second line contained the raw 
sequence data; 3) the third line contained “+” character; and 4) the fourth line 
contained quality scores for each base in line 2.  
2. Gene specific reads were selected by using Barcode Splitter function. Forward and 
reverse primer sequences were used to select for gene specific sequences in reads 1 
and reads 2, respectively. Reads 1 files contained 250 bp sequence reads produced 
from the 5’ end of the sequenced amplicon and reads 2 files contained 250 bp of 
the reverse sequence reads from the 3’ end.  
3. Quality check analysis was performed on gene specific reads using FastQC 
function, and quality-per-base was evaluated (Figure 5.8A).  
4. Quality filtering was applied using Filter by quality function to select reads with a 
Phred score of > 30. Phred score is a probability scoring system to estimate the 
errors of calling the sequenced nucleotides. The concept originated from a tool 
called “PHRED” that was developed to analyse sequencing files in 1998 (Cock et 
al., 2010). Quality check was then repeated to check the quality of bases after 
filtering (Figure 5.8B). 
5. Reads were then joined after trimming the overlapped regions using FASTQ joiner 
function. If amplicon size was > 250 bp and < 500 bp with Phred score >30 for all 
bases, then reads 1 and 2 were trimmed at half amplicon size to make the size of 
both reads equal the full length of sequenced amplicon. Hard trimming of sequence 
reads was done using Trim sequences function. To join reads, reads 2 were reverse-
complemented using Reverse-Complement function and joined to reads 1. 
6. If the Phred score for reads 1 and 2 was not >30 for all bases, then low quality 
bases were trimmed. If the remaining good quality reads can be joined (i.e, reads 1 
+ reads 2 = amplicon size), then each of the reads 2 was reverse-complemented and 
joined to each of reads 1 (in this case, hard trimming for the bad quality bases). 
However, if reads 1 and 2 cannot be joined, then each reads file was analysed 




Figure 5.8. FASTQC per-base quality report. The plots were from the same sample 
showing the quality of bases before (A) and after filtering (B) by quality.  
 
7. Joined files were then converted from FASTQ to FASTA format using FASTQ to 
FASTA converter function. FASTA files were then downloaded to the current 
directory for BiQ Analyser HT methylation analysis. 
8. FASTA files were imported into BiQ analyser HT program, according to the 
program’s instructions (Lutsik et al., 2011). BiQ Analyser HT is a java-based 
program developed to align and visualise the analysed sequenced methylation data. 
Briefly, reads were aligned against the reference sequence, and DNA methylation 
for each CpG site was scored. The unaligned reads can be filtered out by setting a 
cutoff value for the alignment score, which was generated for each sequence read. 
To determine the alignment score cutoff value, cumulative frequency was 
calculated and plotted to obtain the value on the curve at which the curve increases 
exponentially (Figure 5.9 shows a representative example). In addition, sequences 





Figure 5.9. Cumulative analysis plot for the BiQ analyser HT alignment scores. In this 
example, an alignment score of 2000 was selected as a cutoff value to use for filtering 
unaligned reads. 
 
5.3.3 Interpreting methylation sequencing results 
The standard output of BiQ Analyser HT is a red (methylated) and blue (unmethylated) 
heatmap of the aligned CpG sites as well as a results table for the sequence reads. Figure 
5.10 explains the standard heatmap output. The location of CpG sites (highlighted in bold) 
within the TES promoter sequence and their methylation values were extracted from each 
sequence read and can be represented as lollipops or rectangles. By plotting the 
methylation values of CpG sites next to each other, it is possible to evaluate the 
methylation status of each sequence read. Each sequence read is most likely derived from a 
single cell. All of the sequence reads for each sample are stacked as shown in Figures 5.10 
and 5.11. Different patterns of methylated epialleles can indicate the presence of 
heterogenous cell populations with different epigenotypes (Figure 5.10). In addition, BiQ 
Analyser HT exports a results table, which contains the following details for each read: 
methylation pattern for each CpG site, proportion of DNA methylation, and a calculated 
conversion rate. The conversion rate was calculated by dividing the number of converted 
cytosines in the reads to the total number of non-CpG sites in the reference genome (Lutsik 




Figure 5.10. A flow diagram demonstrating the process of interpreting methylation BiQ 
Analyser HT heatmaps. CpG sites within the TES promoter sequence (highlighted in 
bold) were represented as lollipops or rectangles and the methylation status for each 
CpG site was either red (methylated) or blue (unmethylated). Methylated TES sequence 
reads were most likely derived from ALL-like cells. 
 
The majority of sequence reads contained variable numbers of methylated CpG sites and 
hence the methylation level of reads can range from zero to one. Methylation values of 
sequence reads can be plotted for control and leukaemia samples and a threshold line can 
be estimated based on the observed results. Methylation values for sequence reads can be 
represented by boxplots, which summarise the data into median, 1st and 3rd quartiles. 
However, methylation data generally have a bimodal distribution and were bound between 
zero to one and hence the median can be shifted to each side in the presence of a minor 
difference between methylated and unmethylated values. As a result, boxplots do not 
reflect the methylation pattern that was observed in BiQ Analyser HT heatmaps (Figure 
5.11). In comparison, the use of violin-points plot provided a highly similar reflection to 
the patterns of methylated sequence reads from the heatmaps (methylated, hemimethylated 
and unmethylated), and hence was used to represent the methylation results of control and 
leukaemia samples (Figure 5.11). Unfortunately, the details of the 1000’s of data points 
per sample can be lost when multiple samples were plotted on the same plot as seen in 
ALL7 sample in Figure 5.11. A threshold line of 0.5 was applied as a cutoff to define 
methylated sequence reads for all ALL-methylated gene panel. Methylation results of cord 
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blood samples were found to be less than 0.5 and hence it was used as a cutoff value for 
methylated epialleles. 
 
Figure 5.11. BiQ-Analyser HT amplicon-based methylation values for MARCH11 were 
plotted in violin points plots. A line can be drawn at 0.5 to distinguish unmethylated cord 
blood samples from methylated leukaemia samples. 
 
5.3.4 Site-based methylation analysis 
The selection of ALL-methylated gene panel was based on ABC.RAP analysis of 450k 
array methylation data (see section 4.7). A site-based methylation analysis of the sequence 
reads was conducted to compare the methylation results from our targeted methylation 
sequencing experiments to the publicly available 450k array methylation leukaemia 
datasets. For each gene, the locations of the corresponding 450k array probes was 
annotated on the MiSeq sequencing reads (Figure 5.12). For direct comparison, 
methylation levels for each of the relevant 450k array probe sites were extracted from our 
sequence data. Then, methylation results from our sequenced samples and 450k array 




Figure 5.12. Site-based methylation analysis of the sequence reads was performed to 
compare methylation results to the publicly available 450k array leukaemia datasets. 
Location of array-sites were identified from aligning the amplicon sequence (KCNA4 in 
the above example) to the genome browser. Methylation levels of the corresponding 
CpG sites were extracted from the sequence files and plotted adjacent to the distribution 
of DNA methylation in 450k array datasets.  
 
5.3.5 Data Analysis using bismark and methpat 
This additional pipeline was used to investigate the patterns of methylated epialleles in the 
sequenced samples. The identification of different patterns of methylated epialleles 
indicates the heterogeneity of sequence reads. A high degree of heterogeneity would 
suggest minimal PCR amplification bias.  
The first part of the pipeline used bismark to align sequence reads and to perform 
methylation analysis (Krueger & Andrews, 2011). Bismark is a perl-based program that 
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runs on command line and uses Bowtie program for sequence alignment. To use bismark, 
the following two steps were followed: 1) preparation of the reference genome using 
bismark_genome_preparation function; 2) alignment of the sequence reads using the 
following command line script:  
~$ bismark -n 1 --un --ambiguous <path to genome folder> <sequence file.fastq> 
Options: -n: number of mismatches allowed for the alignment, in this case it is 1; --un: 
export unaligned reads in a separate file called “_unmapped_reads.txt”; and --
ambiguous: export reads that have substantial alignment but not aligned uniquely in a 
separate file called “_ambiguous_reads.txt” (Krueger & Andrews, 2011). 
The outputs from the previous function were aligned “BAM” files, which are binary 
versions of sequence alignment map (SAM) files.  
Then, methylation values for CpG sites in the sequence files were extracted using the 
following function: 
~$ bismark_methylation_extractor -s --bedGraph –counts –buffer_size 10G –
cytosine_report <path to genome folder> <aligned sequence file.bam>   
Options: -s: single-end (not paired-end) read data; --bedGraph --counts: report the 
methylation output in a sorted bedGraph file format; --buffer_size: specify the memory 
usage for sorting the methylation information, in this case it is 10G; and --
cytosine_report: this function relies on the output from bedGraph to produce a report of 
location and methylation status for all cytosine molecules in the aligned file. 
Eight files were exported into the working directory, including “CpG_OT_sampleID.txt”, 
that contained location and methylation results for methylated (+ or Z) and unmethylated (- 
or z) CpG sites. The other seven files were: “CHG_OT_sampleID.txt”, 
“CHH_OT_sampleID.txt”, “sampleID.M-bias.txt”, “sampleID.CpG_report.txt”, 
“sampleID.cov.gz”, “sampleID.bedGraph.gz”, “sampleID_SE_report.txt”. 
The second part of the pipeline was based on the use of the methpat program to perform 
methylation pattern analysis (Wong et al., 2016a). Methpat is a python-based program, 
which runs on command line, and was designed to analyse targeted methylation 
sequencing files. Methpat uses the exported “CpG_OT_sampleID.txt” file and plots 
methylation values for each CpG site to generate a heatmap for the sequence reads. 
Identical methylation patterns were then combined and a histogram plot was provided 
underneath the heatmap to represent the number of combined reads for each pattern. The 
following function was used according to the program’s instructions: 
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~$ methpat --amplicons gene.txt CpG_OT_sampleID.txt > sampleID.tsv 
Options: --amplicons: the reference genome file that was used for the analysis “gene.txt” 
and contains chromosome number, start and end coordinates of the amplicon, name and 
size of the amplicon, and the length of forward and reverse primers. 
The exported methpat result is a heatmap showing a summary of the different patterns of 
methylated epialleles in the sequence file (Figure 5.13). CpG sites are arranged from top to 
bottom and the patterns of methylated epialleles are arranged by their frequency from left 
to right. A histogram was plotted under the heatmap to represent the number of sequence 
reads for each pattern.  
 
 
Figure 5.13. Methpat plot showing 112 different patterns of methylated TES sequence 
reads in PCR products from NALM6 cell line. To assist the interpretation of methpat 
heatmap, the corresponding BiQ Analyser HT methylation heatmap, which was rotated 
90º clockwise, is shown on the right. 
 
5.3.6 Criteria for the identification of methylated epialleles 
Setting the criteria to identify methylated epialleles can be subjective and can vary 
between different users. This project applied the following criteria for the analysis of 
sequence reads: 1) utilise good quality bases with Phred score of more than or equal to 30; 
2) bisulfite conversion of more than 90%; and 3) aligned CpG sites of more than 90%.  
Using less stringent criteria during data analysis may lead to misleading results. For 
example, methylated TES sequences can be identified in some cord blood samples if the 
FASTQC quality per base analysis or the conversion rate analysis were not considered. 
Two sequence reads from X9147 CD3+ cells in Table 5.3 are shown as an example. If 
included, these reads would provide a methylation of 0.18% for this sample (aligned 
sequences = 1,088). These two methylated sequence reads were identified from joining 
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reads 1 and reads 2 files without quality-check or filtering by quality and relying only on 
filtering the unaligned reads after BiQ Analyser HT.  
Table 5.3. BiQ Analyser HT results of two methylated TES sequences in X9147 CD3+ 
cells. 
 ID Methylation Conversion 
A1 M00733:114:000000000-D2EE6:1:1102:4983:9196 92% 92% 
A2 M00733:114:000000000-D2EE6:1:1102:15946:24669 89% 88% 
 
If the conversion rate criterion was not considered in the analysis, then both false-positive 
sequence reads in Table 5.3 could be reported as genuine results. As an example, sequence 
read A1 (Table 5.3) had a conversion rate of > 90% and hence it is more likely to be 
accepted for data interpretation. However, quality-check analysis (FASTQC) shows a 
region with a low-quality score (Phred < 30) in reads 1 and reads 2 located between 35 and 
125 bp (Figure 5.14 A and B, respectively). As described in section 5.3.2, sequence reads 
with poor quality scores get filtered at early stages of the data analysis process and hence 
situations like the example shown here were avoided.  
 
Figure 5.14. FASTQC quality per base plots of a methylated TES sequence read 
identified in X9147 CD3+ sample. The analysis identified a region with low quality 
bases in both forward (A) and reverse (B) sequences. 
 
5.4 Evaluating the ALL-methylated gene panel 
Based on ABC.RAP analysis of 450k array leukaemia datasets, leukaemia cases were 
found to have high methylation for the ALL-methylated genes compared to low 
methylation level in normal blood samples. To validate the 450k array methylation results, 
blood samples from 18 healthy adults and 13 newborns were used for the targeted deep 
sequencing of the ALL-methylated gene panel. In addition, 10 leukaemia cell lines and 13 
leukaemia xenograft samples were used in the sequencing assay. Overall, a total of 1,028 
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samples were sequenced across 12 sequencing runs, generated more than seven million 
raw sequence reads for data analysis (Table 5.4).  
X9194 and X9195 cord blood samples contained variable methylation patterns that were 
inconsistent with other cord blood samples (see section 7.2.7 for detailed discussion about 
X9195. Section 5.5 comments on the methylation results of X9194). In addition, it was 
noted that CCRF-SB, a B-ALL cell line, had low methylation for all of the ALL-
methylated genes unlike the other B-ALL cell lines. 





Adult Blood Cord Blood Fetal Liver ALL xenografts Cell lines TOTAL 
TES 21 113 10 13 8 165 
NEFM 18 88 9 13 8 136 
KITLG 18 87 2 12 8 127 
KCNA4 35 21 0 13 7 76 
C10orf53 33 14 0 13 8 68 
MARCH11_1 15 0 0 13 8 36 
MARCH11_2 17 34 9 11 7 78 
RNF180 15 24 9 7 7 62 
GOLSYN 17 18 0 13 9 57 
PAK7 17 58 7 12 9 103 
MACROD2 22 15 0 13 10 60 
ISL1 17 23 0 12 8 60 
TOTAL 245 495 46 145 97 1,028 
 
 
5.4.1 TES DNA methylation 
The designed target region of TES was located in the promoter CpG island (Figure 5.15). 
The target region was 371 bp long and contained 48 CpG sites encompassing four CpG 
probes from the 450k array (cg19743881, cg20879085, cg16379337 and cg10728469). 
The target region contained three common single nucleotide polymorphisms (i.e, SNPs ≥ 
1% of samples): rs1319886, rs28411392 and rs11549785. The publicly available genome-
wide DNA methylation data from the “DNA Methylation” track on the UCSC genome 
browser showed dense DNA methylation in leukaemia cases (yellow bars) and low 
methylation level in normal cell types (Figure 5.15, see section 4.8 for more information 





Figure 5.15. Image of the genome browser for TES promoter showing methylation data 
for B-ALL cases and normal cell types (yellow bars represent methylation level and 
black bars represent sequence coverage for each CpG site). The target region was 
designed to contain 48 CpG sites (each yellow/black bar represent the methylation result 
for a CpG site), four probes of 450k array and was located in a large CpG island within 
the gene promoter. There were three common SNPs in the target region.  
 
 
Methylated TES sequences were not detected in any of the adult control samples, whereas 
three cord blood samples contained methylated TES sequences (red points in the plot) 
(Figure 5.16). The significance of discovering methylated TES sequences in healthy 
newborns will be discussed in more details in the following chapter (see section 6.3). In 
addition, cord blood sample X9195 (green points on the plot) is discussed in details in 
chapter 7 (see section 7.2.7).  
Interestingly, dense DNA methylation was found in the majority of B-ALL xenograft 
samples and cell lines (NALM6 and SUP-B15) with overall median methylation of 92%; 
however, one sample (ALL17) was unmethylated (Figure 5.16 C and D). CCRF-SB had 
much lower levels of DNA methylation compared to the other B-ALL cell lines with 
methylation of 0.2%. In comparison, the majority of T-ALL xenograft samples and cell 




Figure 5.16. Violin-points plots summarising sequencing results of TES methylation in 
adult blood samples (A), cord blood samples (B), leukaemia xenograft samples (C) and 
leukaemia cell lines (D). Samples were plotted in x-axis and DNA methylation (zero to 
one) was plotted in y-axis. A threshold line at 0.5 was used as a cutoff to define samples 
with methylated sequence reads. Samples plotted in red in A and B represent samples 
with methylated sequence reads. X9195, a cord blood sample, was plotted in green in B 
and was discussed in details in section 7.2.7. B-ALL and T-ALL xenograft samples were 
plotted in red and dark gold colours in C, respectively. B and T leukaemia cell lines were 





Figure 5.17. Heatmap of ALL27 sequencing results, a representative example for T-
ALL samples, showing partially methylated TES sequence reads in T-ALL samples. The 
first 16 CpG sites of TES amplicon were methylated in about 40% of the sequence reads. 
Red = methylated and blue = unmethylated. 
 
 
The majority of T-ALL samples contained a different methylation pattern than the B-ALL 
samples. The first 16 of 48 CpG sites methylated in the majority of T-ALL samples (CpG1 
to CpG16. Figure 5.17 shows a representative example of ALL27). The identified partially 
methylated TES sequences in ALL27 represented about 40% of the aligned sequences. 
Figure 5.18 shows the difference of DNA methylation patterns between B-ALL and T-
ALL samples. Interestingly, the first 20 CpG sites were located before the transcription 
start site of TES (Figure 5.15), suggesting that the majority of T-ALL samples contained 






Figure 5.18. Heatmaps of B- and T-ALL samples showing the difference in DNA 
methylation patterns of TES promoter. The majority of B-ALL samples had fully 
methylated alleles across the TES target region, except for ALL3 and ALL17. In 
comparison, the majority of T-ALL samples (xenograft samples and cell lines) had DNA 
methylation of the TES promoter (i.e., the first 16 CpG sites of TES amplimer). Red = 
methylated and blue = unmethylated. 
 
 
Site-based methylation analysis was done to compare the methylation results of 450k array 
probes (cg19743881, cg20879085, cg16379337 and cg10728469) from the publicly 
available leukaemia datasets to the targeted methylation sequencing results (450k array 
probes correspond to CpG1, CpG2, CpG4 and CpG 48 sites on TES amplicon). Figure 5.19 
shows a high concordance of methylation values between our sequenced samples to 
Busche’s (2013) (B-ALL) and Borssén’s (2016) (T-ALL) datasets (see section 4.3 for 





Figure 5.19. Boxplots of methylation results for TES CpG sites for our cord blood and 
leukaemia samples compared to the corresponding 450k array probes for leukaemia 
datasets. Cord blood samples and B-ALL remission samples were used as controls in 
MiSeq and 450k array plots, respectively. Methylation results of the 450k array probes 
for B-ALL and T-ALL samples were extracted from Busche’s and Borssén’s datasets, 
respectively (see section 4.3). Methylation results for B-ALL and T-ALL xenograft 
samples were represented in the “MiSeq Results”. CpG sites of control samples were 
plotted in blue, CpG sites of B-ALL samples were plotted in red and CpG sites of T-
ALL samples were plotted in green. 
 
 
5.4.2 NEFM DNA methylation 
Primers were designed to amplify a 289 bp region (24 CpG sites) within the gene promoter 
of NEFM and to include four CpG probes from 450k arrays (cg09234518, cg16459364, 
cg07502389 and cg18267374, Figure 5.20). The publicly available genome-wide DNA 
methylation data on the UCSC genome browser of adult normal cells showed low level 
methylation in PBMC and B cell samples, however, the coverage for the methylated sites 
was low (black bars) (Figure 5.20). In comparison, B-ALL cases showed high sequencing 




Figure 5.20. Image of UCSC genome browser showing dense methylation of NEFM 
target region in B-ALL cases compared to low level methylation in adult control 
samples. For more explanation, see Figure 5.15. 
 
Thirteen (76%) of 17 adult peripheral blood samples contained a low level of methylated 
NEFM sequences (samples with red points in Figure 5.21A) with a median methylation of 
0.5%. Methylated NEFM sequences were not detected in cord blood samples except for 
two samples (samples with red points in Figure 5.21B. See section 6.3 for detailed 
discussion on the significance of methylated NEFM sequences in cord blood samples).  
B-ALL xenograft samples were densely methylated with a median methylation of 99% 
(Figure 5.21C). In comparison, T-ALL xenograft samples showed lower methylation level 
than B-ALL samples with a median methylation of 48%. B- and T-ALL cell lines 
(NALM6, SUP-B15, CCRF-CEM and MOLT4) contained higher methylation level than 
T-ALL xenograft samples (methylation of 99%. Figure 5.21C and D).   
Site-based methylation analysis revealed a high concordance between the MiSeq and 450k 
array methylation data for NEFM (Figure 5.22). Despite the higher level of median 
methylation in the MiSeq B-ALL samples, the median level of T-ALL samples was lower 
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Figure 5.21. Violin-points plots showing NEFM DNA methylation results of adult blood 
(A), cord blood (B), leukaemia xenograft samples (C) and leukaemia cell lines (D). The 
majority of adult blood samples contained few methylated sequences compared to dense 
methylation in B- and T-ALL xenograft samples and cell lines. For more explanation, 





Figure 5.22. Boxplots of NEFM methylation for MiSeq and 450k array corresponding 




5.4.3 KITLG DNA methylation 
KITLG target region was 338 bp long, containing 33 CpG sites. The target region 
contained two SNPs (rs17015901 and rs12721560), one of which (rs12721660) was 
located on CpG site number 20 of the target region (reference sequence CCGGC, A = 
0.04%, G = 97.32% and T = 2.64%). Normal cell types from genome-wide methylation 






Figure 5.23. Image of the UCSC genome browser showing high DNA methylation of B-
ALL samples in KITLG target region compared to low methylation in normal cell types. 
For more explanation, see Figure 5.15. 
 
 
Four of 17 adult peripheral blood samples had few methylated KITLG sequences (0.2% to 
5%) (samples plotted in red. Figure 5.24A). In addition, one of 11 cord blood sample 
contained methylated KITLG sequences (sample in red, Figure 5.24B. See section 6.3 for 
detailed discussion on the significance of finding methylated KITLG sequences in healthy 
newborns). Interestingly, CpG sites 15, 16, 19 and 20 were consistently found to show low 
level of methylation in about 5% of the aligned reads in adult and cord blood samples 
(Figure 5.25). The methylation pattern of these CpG sites was detected in both CD19+ B 
cells and CD19 negative cell subpopulations.  
The majority of B-ALL xenograft samples had dense KITLG methylation with the 
exception of two samples (ALL4 and ALL8, Figure 5.24). On the other hand, KITLG was 
generally unmethylated in T-ALL cell lines and xenograft samples except for dense 
methylation in ALL16. KITLG was densely methylated in NALM6 and SUP-B15 (B-ALL) 
cell lines. Interestingly, RAJI, a Burkitt lymphoma cell line, contained only A alleles of the 














































Figure 5.24. Violin-points plots of KITLG showing methylation results of adult blood 
samples (A), cord blood samples (B), leukaemia xenograft samples (C) and leukaemia 





Figure 5.25. Image of sequencing results for an adult blood sample (X9183) showing 
low level of KITLG methylation in CpG15, CpG16, CpG19 and CpG20. Red = 





Figure 5.26. Image of sequencing results showing missing methylation values for 
KITLG CpG20 in RAJI cell line. The missing methylation data was because of the 





KITLG target region was designed to include five probes from 450k array (cg13981545, 
cg25741452, cg10615519, cg12590695 and cg18422443, Figure 5.23). Site-based 
methylation analysis showed a high concordance for control and B-ALL samples between 
methylation results of 450k array datasets and our targeted sequencing samples (Figure 
5.27). However, T-ALL samples had lower DNA methylation for KITLG in the xenograft 
samples than the publicly available Borssén’s dataset. 
 
Figure 5.27. Results of site-based methylation analysis represented by boxplots to 
compare the methylation results of MiSeq and 450k array leukaemia samples for KITLG 
CpG sites. T-ALL xenograft samples (MiSeq results) had lower methylation levels 
compared to publicly available 450k array Borssén’s T-ALL samples. For more 
explanation, see Figure 5.19. 
 
 
5.4.4 KCNA4 DNA methylation 
The target region (364 bp) within the promoter region of KCNA4 contained seven probes 
from the 450k array (cg10387551, cg17714025, cg15044957, cg08490115, cg15310492, 
cg05756220 and cg22685409). The sequenced region contained 34 CpG sites and one 
SNP. The SNP had A and C alleles, and the major allele was C representing CpG site 34 
on the KCNA4 target region (rs142803148: reference sequence ATCGA, A = 1.7% and C 
= 98%). Genome-wide methylation data showed high DNA methylation for KCNA4 





Figure 5.28. Image of the UCSC genome browser showing dense methylation of 
KCNA4 target region in B-ALL cases compared to low methylation level in normal cell 
types. For more explanation, see Figure 5.15. 
 
 
Ten of 16 adult blood samples showed few methylated KCNA4 sequences (median 
methylation = 1.1%, ranged from 0.4% to 11%) compared to undetected methylated 
sequences in cord blood samples (Figure 5.29A and B, respectively). Remarkably, KCNA4 
was densely methylated in almost all B and T leukaemia cell lines and xenograft samples 
(Figure 5.29C and D). As noted previously, CCRF-SB cell line had low methylation 














































Figure 5.29. Violin-points plots showing methylation results of KCNA4 in adult blood 
samples (A), cord blood samples (B), leukaemia xenograft samples (C) and leukaemia 
cell lines (D). Low methylation level was found in adult blood samples, but methylated 
sequences were not detected in cord blood samples. In comparison, dense methylation in 
B and T leukaemia samples and cell lines except for CCRF-SB. For more explanation, 




There was high concordance between the leukaemia xenograft samples and the B-ALL and 
T-ALL samples from the publicly available 450k array leukaemia datasets. B-ALL and T-
ALL samples from our sequencing experiments (MiSeq) had higher methylation levels 
than those from 450k array datasets (Figure 5.30).  
 
Figure 5.30. Boxplots showing methylation results of KCNA4 CpG sites from our 
sequencing experiments and corresponding sites (probes) from the publicly available 
450k array data. For more explanation, see Figure 5.19. 
 
 
5.4.5 C10orf53 DNA methylation 
Primers were designed to amplify 345 bp region (31 CpG sites) from the C10orf53 
promoter. The target region contained three SNPs (rs73303319, rs1153781 and 
rs149069015). The second and third SNPs were located on CpG sites 12 and 30 of the 
target region and the major alleles form the CpG sites (rs1153781: CCGGC, C = 91% and 
G = 8.8%); and rs149069015: CCGGT, A = 1.1%, G = 99% and T = 0.005%). The 
publicly available genome-wide methylation data on the UCSC browser showed high 





Figure 5.31. Image of the UCSC genome browser showing dense methylation of 
C10orf53 promoter region, including the target region, in B-ALL cases compared to low 
methylation level in normal cell types. For more explanation, see Figure 5.15. 
 
 
Methylated C10orf53 sequences were not detected in cord blood samples whereas a low 
number of methylated reads were detected in six of 13 adult blood samples (Figure 5.32B 
and A, respectively). The majority of B-ALL and T-ALL xenograft samples and cell lines 
contained dense DNA methylation. In NALM6, B-ALL cell line, and two T-ALL 
xenograft samples (ALL27 and ALL30), about 50% of reads were methylated (Figure 
5.32C and D). As mentioned previously, CCRF-SB cell line had much lower DNA 
methylation than the other B-ALL cell lines.  
The target region of C10orf53 contained six probes from the 450k array (cg18521914, 
cg22717227, cg06094615, cg14526047, cg15353031 and cg10056132). There was a high 
concordance in methylation results between our sequenced samples (MiSeq) and 
corresponding leukaemia samples from 450k array datasets (Figure 5.33). Interestingly, 
median methylation levels of our sequenced B-ALL and T-ALL samples were higher than 




















































Figure 5.32. Violin-points plots showing methylation results of C10orf53 in adult blood 
samples (A), cord blood samples (B), leukaemia xenograft samples (C) and leukaemia 





Figure 5.33. Boxplots showing the methylation results of C10orf53 CpG sites from 
MiSeq data and data from 450k array leukaemia datasets. Median methylation levels for 
B-ALL and T-ALL MiSeq samples were higher than 450k array samples. For more 
explanation, see Figure 5.19. 
 
 
5.4.6 MARCH11 DNA methylation 
Two adjacent target regions were selected for MARCH11 to sequence a large area of the 
promoter region and to include all of the differentially methylated CpG sites from 
ABC.RAP analysis (Figure 5.34). The size of the two sequenced regions was 773 bp, 
containing a total of 89 CpG sites (fragment 1 was 374 bp and contained 48 CpG sites; 
fragment 2 was 399 bp and contained 41 CpG sites). There was one SNP located at CpG 
site 36 of the first fragment and was an insertion of C to form an additional CpG site 
(rs371550142: sequence C/GGGCGC, 36.3% had the C insertion allele). Based on the 
publicly available genome-wide methylation data on the UCSC genome browser, B-ALL 
cases were found to have high DNA methylation for both MARCH11 fragments compared 




Figure 5.34. Image of the USCS genome browser showing the two designed MARCH11 
fragments labelled with “YourSeq” on the image. B-ALL cases had dense methylation in 
both fragments compared to low methylation level in normal cell types. For more 
explanation, see Figure 5.15. 
 
Sequencing results of the first MARCH11 fragment had poor coverage and the majority of 
sequences in read 2 files had poor quality (average good quality sequence reads = 5, min = 
1 and max = 14) compared to sequences in read 1 files (average good quality sequence 
reads = 115, min = 64 and max = 209). As a result, methylation analysis was based on read 
2 files for the first fragment of MARCH11. 
The majority of adult blood samples (12 to 15 of 16 sequenced samples; Table 5.6) 
showed a low level of methylated MARCH11 sequence reads in both fragments (median 
17%, range 1.1% to 33%; and 0.9%, range 0.1% to 46%, respectively) (samples with red 
points in Figures 5.35A and 5.36A, respectively). However, methylated MARCH11 
sequences (fragment 2) were not detected in cord blood samples (Figure 5.36B; cord blood 
samples were not evaluated by fragment 1).  
B-ALL xenograft samples showed nearly 100% DNA methylation for both fragments 
compared to about 50% methylation in T-ALL samples (Figures 5.35B and 5.36C). 
However, NALM6 and RS4 B-ALL cell lines were not densely methylated (methylation of 



















































and 5.36D). Interestingly, MARCH11 fragments were densely methylated in T-ALL 
(CCRF-CEM and MOLT4), B cell lymphoma (REH) and myeloid leukaemia (K562) cell 
lines (methylation of 100%. Figures 5.35C and 5.36D).  
 
 
Figure 5.35. Violin-points plots summarising methylation results of MARCH11 
(fragment 1) in healthy adult blood samples (A), leukaemia xenograft samples (B) and 
leukaemia cell lines (C). Cord blood samples were not sequenced. For more explanation, 





Figure 5.36. Violin-points plots showing methylation results of MARCH11 (fragment 2) 
in healthy adult blood samples (A), cord blood samples (B), leukaemia xenograft 




Site-based methylation analysis was done on CpG sites of MARCH11 second fragment 
because of the poor coverage in the first fragment sequences. In addition, cord blood 
samples, which were used as control samples for the site-based analysis, were not 
sequenced by the first fragment and hence CpG sites of the first fragment were excluded 
from the analysis. Figure 5.37 shows the methylation results of the MiSeq-450k array 
samples. Two CpG sites in T-ALL xenograft samples (CpG28 and CpG40) had lower 
median methylation levels compared to the corresponding 450k array probes (cg11452391 
and cg16182986). In addition, some cord blood samples contained CpG sites with higher 
methylation (outliers in MiSeq controls) than the 450k array control samples. Interestingly, 
B-ALL xenograft samples had higher methylation of about 100% compared to lower 
methylation values of 450k array samples (Figure 5.37). 
 
Figure 5.37. Boxplots showing the results of site-based methylation analysis of 
MARCH11 second fragment for control and leukaemia samples from MiSeq and publicly 
available 450k array experiments. For more explanation, see Figure 5.19. 
 
 
5.4.7 PAK7 DNA methylation 
A 350 bp-target region was designed for PAK7, containing 22 CpG sites and one SNP 
(rs113658361). Inspecting the publicly available genome-wide methylation data on the 
UCSC genome browser for PAK7 target region showed high DNA methylation in B-ALL 





Figure 5.38. Image of the UCSC genome browser showing PAK7 target region densely 
methylated in B-ALL cases compared to low methylation level in normal adult cell 
types. For more explanation, see Figure 5.15. 
 
 
Sequencing results of adult blood samples showed six of 16 samples contained a few 
methylated PAK7 sequences ranging from 0.1% to 10% of sequences (Figure 5.39A). In 
comparison, methylated PAK7 sequences were not detected in cord blood samples, 
including their CD19+ B cells and CD19 negative cell subpopulations (Figure 5.39B). 
Methylation of X9195 cord blood sample (green points in Figure 5.38B) is discussed in 
details in section 7.2.7. 
All B-ALL xenograft samples were densely methylated with a median methylation of 
98%, except for ALL8, in which 35% of sequences were methylated (Figure 5.39C). In 
comparison, B-ALL cell lines and T-ALL samples, including xenografts and cell lines, had 
low level of DNA methylation (< 10%). ALL16, a T-ALL xenograft sample, and SUP-B15 

















































Figure 5.39. Violin-points plots showing methylation results of adult blood samples (A), 
cord blood samples (B), leukaemia xenograft samples (C) and leukaemia cell lines (D) 




PAK7 target region was designed to include six probes of the 450k array located within the 
promoter region (cg02167438, cg25488669, cg22457984, cg18815779, cg12388309 and 
cg25143824. Figure 5.38). Site-based methylation analysis showed weak concordance 
between our sequenced T-ALL samples and T-ALL samples of Borssén’s 450k array 
dataset. This was because that the majority of our T-ALL xenograft samples contained 
lowly methylated PAK7 sequences (Figure 5.39C) and hence CpG sites had lower median 
methylation levels than the methylation values from 450k array T-ALL samples (Figure 
5.40). Despite the low methylation levels in T-ALL samples from our sequencing data, 
cord blood and B-ALL xenograft samples showed high concordance with 450k array 
results (Figure 5.40).  
 
Figure 5.40. Boxplot comparing methylation results of 450k array leukaemia samples to 
our sequenced xenograft samples for PAK7. For more explanation, see Figure 5.19. 
 
Inspecting sequencing data at CpG14, GpG sequences or unmethylated cytosines at this 
site, were commonly found in samples containing methylated PAK7 sequences. 
Interestingly, the GpG sequence was almost always found in methylated PAK7 sequences 
and was never detected in the unmethylated samples (Figure 5.41). The proportion of GpG 
sequences at CpG14 was low in T-ALL xenograft samples (from 0.8% to 8%) compared to 
higher proportions in B-ALL samples (from 6% to 59%). There are no recorded SNPs at 
CpG14 of the PAK7 target region. In comparison, frequency of the unmethylated CpG14 
in the methylated PAK7 sequences was higher than GpG sequences, especially in T-ALL 
samples. The frequency of unmethylated CpG14 in B-ALL samples ranged from 26% to 
93% while the frequency was > 90% in all of T-ALL samples. It is possible to speculate 
 
 143 
that the GpG allele was most likely derived from a PCR amplification error because of the 
run of six G bases that precedes CpG14 (CpG14 is underlined: 
CGGGGGGCGTGTCTACACTCAGGGTG). 
 
Figure 5.41. Image of sequencing results of PAK7 in a cord blood (A: X9129-CD19+) 
and a B-ALL (B: ALL19) samples. Methylated PAK7 sequences (B) contained either 
GpG allele (white) or unmethylated cytosines (blue) in CpG14 site. 
 
 
5.4.8 RNF180 DNA methylation 
The 340 bp target region for the RNF180 promoter region contained 43 CpG sites. The 
publicly available genome-wide methylation data showed dense DNA methylation in B-





Figure 5.42. Image of the genome browser showing higher DNA methylation in B-ALL 




Sequencing results showed three of 14 adult peripheral blood samples had methylated 
RNF180 sequences (X3236 = 5.5%, X5905 = 4.1% and X5906 = 0.3%. Figure 5.43A). In 
comparison, the sequenced 10 cord blood samples, including CD19+ enriched B cells, did 
not show any methylated RNF180 sequences (Figure 5.43B).  
Three of eight B-ALL xenograft samples were successfully amplified and sequenced and 
they all showed close to 100% methylation (Figure 5.43C). Interestingly, NALM6 and 
RS4 B-ALL cell lines showed very low methylation (0.4% and 7.2%, respectively) 
compared to 100% methylation in SUP-B15 cell line (Figure 5.43D). In comparison, two 
of T-ALL xenograft samples (ALL29 and ALL31) had high methylation of 87% and 
100%, respectively. However, the other two T-ALL samples (ALL27 and ALL30) had low 
methylation level (9% and 39%, respectively. Figure 5.43C). Methylation level in T-ALL 


















































Figure 5.43. Violin-points plot showing methylation results of adult blood samples (A), 
cord blood samples (B), leukaemia xenograft samples (C) and leukaemia cell lines (D) 




The target region of RNF180 contained four probes of 450k array (cg16485558, 
cg14591786, cg06776999 and cg17370163). Site-based methylation analysis for the cord 
blood and leukaemia samples was done to compare results with methylation data from 
450k array datasets. Sequencing data of cord blood and B-ALL samples showed high 
similarity to the 450k array control and B-ALL samples; however, T-ALL xenograft 
samples had lower methylation results than 450k array T-ALL samples (Figure 5.44). 
 
Figure 5.44. Boxplots comparing methylation results of RNF180 sequencing data to 
450k array leukaemia data. For more explanation, see Figure 5.19. 
 
 
5.4.9 SYBU DNA methylation  
A target region for SYBU (also called “GOLSYN”) was selected within the promoter region 
with a size of 261 bp, making it the smallest amplimer for our sequencing experiments. 
The fragment had 12 CpG sites and contained four probes from the 450k array 
(cg05927432, cg13690525, cg27511169 and cg10434152. Figure 5.44). There were two 
common SNPs (rs73314613 and rs78371800). The first SNP was represented by CpG8 on 
the target region (rs73314613: AGCGG; allele frequency: C = 99% and T = 1.3%). The 
target region was densely methylated in B-ALL cases compared to very low methylation in 





Figure 5.45. Image of the UCSC genome browser showing a target region for SYBU 
with a size of 261 bp and 12 CpG sites. The target region contained high DNA 
methylation in B-ALL cases compared to low methylation level in normal cell types. For 
more explanation, see Figure 5.15. 
 
 
Almost all adult blood samples (15 of 16) had methylated SYBU sequences with a median 
methylation of 1.2% (methylation ranged from 0.3% to 28%. Figure 5.46A). Three adult 
blood samples had methylation more than 10% (X3236 = 20%, X5798 = 15% and X5905 
= 28%). In contrast, methylated SYBU sequences were not detected in cord blood samples 
(Figure 5.46B). 
B-ALL xenograft samples and cell lines were densely methylated with methylation levels 
of more than 90% (Figure 5.46C). NALM6 and RS4, B-ALL cell lines, had lower 
methylation level compared to 99% methylation of SUP-B15 (35% and 63%, 
respectively). Two T-ALL xenograft samples (ALL16 and ALL27) had methylation of 
more than 90% while other two samples (ALL30 and ALL31) had methylation of about 
50%, compared to the very low methylation level in ALL29 (3%) (Figure 5.46C). 
Similarly, T-ALL cell lines had methylation ranging from 48% in JURKAT to 91% and 















































Figure 5.46. Violin-points plots showing methylation results for SYBU in the blood 
samples of healthy adults (A), healthy newborns (B), leukaemia xenograft samples (C) 




There was a high concordance between our sequenced leukaemia samples and 450k array 
samples. Methylation results for the four SYBU CpG sites in the target region were 
compared to the corresponding probes from 450k array leukaemia datasets (Figure 5.47). 
Methylation values for the cg2751169 probe in Borssén’s dataset (T-ALL samples) were 
not available. B-ALL xenograft samples had higher median methylation levels compared 
to B-ALL samples from Busche’s dataset.  
 
Figure 5.47. Boxplot showing methylation results of SYBU in cord blood, B-ALL and 
T-ALL xenograft samples for CpG2, CpG6, CpG8 and CpG10. Results were compared 
to methylation values of control and leukaemia samples from publicly available 450k 
array leukaemia datasets. For more explanation, see Figure 5.19. 
 
 
5.4.10 ISL1 DNA methylation 
The ISL1 target region was 354 bp long and located in a CpG island within the gene 
promoter region. The target region contained 28 CpG sites and had no common SNPs. B-
ALL cases showed variable methylation levels across ISL1 selected region, but the 
methylation level was higher than the majority of normal cell types (B cells showed a 





Figure 5.48. Image of the UCSC genome browser showing a target region for ISL1. The 
target region had higher methylation in B-ALL cases compared to normal cell types. For 
more explanation, see Figure 5.15. 
 
Sequencing results showed few methylated ISL1 sequences in 11 of 16 adult peripheral 
blood samples with a median methylation of 0.3% (minimum = 0.1% and max = 3.6%) 
(Figure 5.49A). X3236, X5798 and X5905 adult samples contained the highest 
methylation level (2.7%, 1.3% and 3.6%, respectively). Methylated ISL1 sequences were 
not detected in cord blood samples (Figure 5.49B). 
B-ALL xenograft samples were densely methylated and all samples contained ISL1 
methylation of more than 90%, except for 55% in ALL19 (Figure 5.49C). In comparison, 
three of five T-ALL xenograft samples had high methylation level (methylation ranged 
from 88% to 100%) and two samples contained low methylation (ALL27 was 
unmethylated and ALL30 = 22%) (Figure 5.49C). B-ALL and T-ALL cell lines contained 
low methylation level, except for 100% methylation of SUP-B15 (B-ALL) and CCRF-



















































Figure 5.49. Violin-points plot showing methylation results of ISL1 in adult blood 
samples (A), cord blood samples (B), leukaemia xenograft samples (C) and leukaemia 




The target region of ISL1 contained seven probes from the 450k array (cg14981137, 
cg07270078, cg06424860, cg17412886, cg14834938, cg01587896 and cg17037282). 
Sequencing and 450k array data showed variable results between the analysed CpG sites 
(Figure 5.50). The majority of B-ALL xenograft samples contained higher methylation 
results than the corresponding probes from B-ALL 450k array Busche’s dataset. However, 
the majority of T-ALL xenograft samples contained lower methylation values than those 
from Borssén’s T-ALL 450k array dataset (Figure 5.50). 
 
Figure 5.50. Boxplots comparing the methylation results of ISL1 between MiSeq and 
450k array data. For more explanation, see Figure 5.19. 
 
 
5.4.11 MACROD2 DNA methylation 
The target region for MACROD2 was 492 bp and contained 47 CpG sites. The region was 
located within the promoter region and contained seven probes from the 450k array 
(Figure 5.51). There were two common SNPs (rs2295413 and rs2295414), the first of 
which was expected to create an extra CpG site (CpG site 7) in 19.6% of the sequenced 
samples based on the C allele frequency (reference sequence: CCTGT; allele frequency: 
C= 19.6% and T = 80.4%). Genome-wide methylation data showed dense DNA 





Figure 5.51. Image of the UCSC genome browser showing MACROD2 selected region 
for targeted methylation sequencing experiments. The region had high methylation level 
in B-ALL cases compared to normal cell types. For more explanation, see Figure 5.15. 
 
 
Sequencing results showed seven of 11 adult peripheral blood samples had a low level of 
methylated MACROD2 sequences (median methylation = 0.9%. Figure 5.52A). The 
sequenced cord blood samples failed BiQ Analyser HT alignment and hence no 
methylation data was available.  
All B-ALL xenograft samples showed 100% DNA methylation for MACROD2 (Figure 
5.52B) while B-ALL cell lines had low methylation level. NALM6 and RS4 contained 
0.5% and 0% methylation compared to 100% methylation in SUP-B15 cell line, 
respectively (Figure 5.52C). Similarly, T-ALL xenograft samples and cell lines contained 
100% methylation for MACROD2 except for 54% and 0.3% in ALL27 and JURKAT, 



















































Figure 5.52. Violin-points plots of methylation results for MACROD2 in adult blood 
samples (A), leukaemia xenograft samples (B) and leukaemia cell lines (C). For more 
explanation, see Figure 5.16. 
 
 
Site-based methylation analysis of MACROD2 CpG sites was done to compare 
methylation results of MiSeq samples to leukaemia samples from 450k array datasets. 
Methylation results of adult blood samples were used as controls for the site-based 
methylation analysis. Figure 5.53 shows a remarkable concordance of the methylation 
results between the two methods. Interestingly, B-ALL and T-ALL xenograft samples 




Figure 5.53. Boxplots comparing the methylation results of MiSeq and 450k array 
leukaemia and control samples for MACROD2. For more explanation, see Figure 5.19. 
 
 
5.5 Summary of sequencing results 
A panel of 11 genes was selected based on ABC.RAP analysis of the publicly available 
450k array methylation leukaemia datasets. The panel had consistent methylation pattern 
across different leukaemia samples, including B-ALL, T-ALL and B-ALL subtypes (see 
section 4.7.2). Target regions were selected for each gene of the panel and primers were 
designed to validate the panel using targeted methylation sequencing approach (Table 5.5 
summarises the main features of the target regions). Blood samples from 18 healthy adults 
and 13 healthy newborns were used as control samples. In addition, 13 leukaemia 









Table 5.5. Features of the selected target regions for each of the ALL-methylated gene 
panel. 
Gene Size (bp) CpG sites 450k array probes 
TES 371 48 4 
NEFM 289 24 4 
KCNA4 364 34 7 
C10orf53 344 31 6 
KITLG 338 33 5 
MARCH11_1 374 48 8 
MARCH11_2 399 41 5 
RNF180 340 43 4 
SYBU 261 12 4 
MACROD2 492 47 7 
PAK7 350 22 6 
ISL1 354 28 7 
 
The majority of the genes, except TES, showed low level of DNA methylation in adult 
blood samples with methylation levels of less than 10%. However, methylation levels 
between 10% and 50% were observed in three adult samples (X3236, X5798 and X5905) 
in MARCH11 and SYBU (Figure 5.54 and Table 5.6 summarise the methylation patterns of 
all adult blood samples for all the genes).  
 
Figure 5.54. Methylation results for ALL-methylated genes panel in adult blood samples. 
Methylation heatmaps from BiQ Analyser HT were compressed to small squares or 
rectangles to represent the methylation of the samples across all the genes. Genes were 





Remarkably, methylated sequences for the ALL-methylated gene panel were not detected 
in cord blood samples, except for three samples that contained few methylated TES, NEFM 
and KITLG sequences. The significance of identifying methylated sequences in cord blood 
samples was discussed in details in the following chapter (see section 6.3).  
The first fragment of MARCH11 (“MARCH11 (1)”) was not evaluated by cord blood 
samples because of the insufficient DNA samples. In addition, sequencing results for 
MACROD2 failed the alignment and methylation analysis on BiQ Analyser HT. As a 
result, methylation results for MARCH11 (1) and MACROD2 in cord blood samples were 
not listed in Figure 5.55.  
Two cord blood samples (X9194 and X9195) had interesting methylation patterns (see 
7.2.7 for detailed discussion about X9195). X9194 was an old blood sample (18 days post 
venepuncture) and it was possible that the age of the sample affected the integrity of the 
cells and subsequently affected the methylation status of these genes. As a result, X9194 
was excluded from the evaluation of ALL-methylated gene panel in cord blood samples. 




Figure 5.55. Methylation results for ALL-methylated genes panel in cord blood samples. 
Red = methylated and blue = unmethylated. For more explanation, see Figure 5.54.  
 
In comparison, leukaemia samples, especially B-ALL xenograft samples, showed dense 
methylation for the ALL-methylated gene panel. Table 5.7 summarises the methylation 
results of B-ALL and T-ALL xenograft samples and cell lines. CCRF-SB, a B-ALL cell 
line, consistently showed a low level of DNA methylation across all of the genes. The 
methylation pattern of CCRF-SB was inconsistent with other B-ALL cell lines (Figure 
5.56). KCNA4 and C10orf53 were the only two genes that were densely methylated in B 




Figure 5.56. Methylation results for ALL-methylated genes panel in ALL samples. Red 





Table 5.6. Summary of methylation results for the ALL-methylated gene panel in adult blood samples. Results presented as percentage of DNA 
methylation from the total number of aligned sequence reads. Fields in grey represent results more than 10% 
 Samples TES NEFM KITLG KCNA4 C10orf53 MARCH11(1) MARCH11(2) PAK7 RNF180 SYBU ISL1 MACROD2 
1 X3236 0 3.1 2.1 4.8 0 28 27 8.4 5.5 20 2.7 2.1 
2 X5798 0 0.2 0 1.9 1.1 33 46 8.8 0 15 1.3 3.5 
3 X5905 0 0.8 0 0 0 30 22 9.6 4.1 28 3.6 2.3 
4 X5906 0 0 0 0 0 27 3.2 7.3 0.3 1.2 0.7 1.7 
5 X8619 0 0.5 0.7 1.5 1.3 17 3.8 0 0 2.1 0  
6 X9057 0 0 0 0 2.2 31 0.7 0 0 0.9 0.5 0 
7 X9073 0 2.8 0.3 0 0 20 1.8 0 0 1.0 0.1 0.9 
8 X9097 0 0.2 0 0  13 0.8 0.1 0 0.7 0 0.5 
9 X9177 0 0.1 1.6          
10 X9177_MNC 0 0.8 0.2 10.5 1.7  0.9 0 0 0.5 0.1 0 
11 X9178 0 0.5 1.5 5.1  12 0.1 0 0 1.6 0 0 
12 X9179 0 0.5 0 4.7 4.4 19 0.7 0.1 0 1.3 1.0 1.7 
13 X9183 0 0.5 0 0.5   2.8 0  3.3 0.5  
14 X9184 0 0.2 5.1 0.7 0.7 1.8 0 0 0 0.6 0  
15 X9185 0 0 0 3.9 0 1.1 0.4 0 0 0.3 0.3  
16 X9186 0 2.8 0 2.2 0 0 0.8 0.3  1.1 0.3  
17 X9187 0 0.5 0 0.4 0 0 0.4 0 0 0.7 0 0 







Table 5.7. Summary of methylation results for the ALL-methylated gene panel in leukaemia xenograft samples and cell lines. Results presented as 
percentage of DNA methylation from the total number of aligned sequence reads. Fields in grey represent results less than 50%. 
 Samples TES NEFM KITLG KCNA4 C10orf53 MARCH11(1) MARCH11(2) PAK7 RNF180 SYBU ISL1 MACROD2 
B-ALL xenograft samples 
1 ALL3 23 100  100 53 100 100 98 100 99  100 
2 ALL4 86 100 2.3  99 100    72 100 100 
3 ALL7 97 99 90 100 100 100 76 67  85 94 100 
4 ALL8 99 99 6 100 100 100 100 35  93 100 100 
5 ALL10 89 93 98 100 100 100  98  98 100 100 
6 ALL11 97 100 99 100 99 100 100 99  100 100 100 
7 ALL17 0.2 100 85 99 100 100 100 100 100 98 100 100 
8 ALL19 96 100 94 100 100 100 100 100 100 100 55 100 
 MEDIAN 92 100 90 100 100 100 100 98 100 98 100 100 
T-ALL xenograft samples 
9 ALL16 0 31 100 100 100 100  97  98 100 100 
10 ALL27 0.7 48 0 90 43 6.3 51 0 8.9 92 0 54 
11 ALL29 0.3 46 0 96 100 59 57 0.1 87 3.3 88 100 
12 ALL30 78 49 0 100 51 22 49 0 39 58 22 100 
13 ALL31 34 71 13 98 86 49 90 15 100 47 100 100 
 MEDIAN 0.7 48 0 98 86 49 54 0.1 63 58 88 100 
B-ALL cell lines 
14 NALM6 100 99 99 100 56 30 47 10 0.4 35 5.7 5 
15 RS4      30 29 11 7.2 63 13 0 
16 SUP-B15 94 100 100  100 100 100 48 100 99 100 100 
17 CCRF-SB 0.2 0.1 0 1 5.4 1.6 0 0.1 0 3.4 0 13 
T-ALL cell lines 
18 CCRF-CEM 8.5 100 0 100 100 100  11  98 100 100 
19 MOLT4 12 99 0 100 87 100 100 0 94 91 53 100 
20 JURKAT   12   37 48 8.3 16 48 19 0.3 
Cell lines (Others) 
21 REH 18 0.4   96  100 0.7  100   
22 RAJI 4.1 100 100 100 85   97 100  100  
23 K562 1.4 40 0   100    0.2   
5.6 Age and cell composition effects on the ALL-methylated genes 
Almost all of ALL-methylated genes showed methylated epialleles in adult peripheral 
blood samples except for TES and C10orf53 genes. This raised a few possible 
explanations: 1) the analysed 450k array datasets were from children whereas adult 
samples were used for MiSeq evaluation, so is it possible that methylation of the ALL-
methylated gene panel is affected by age?; 2) alternatively, could the methylated epialleles 
in adult samples reflect the epigenotype of specific cell population in adults?; or 3) is it 
possible that the samples recruited in the 450k cohorts were not representative for our 
study population?. 
5.6.1 Investigating age-effect on the ALL-methylated genes 
Control samples used in ALL 450k cohorts were from children not adults. To explore the 
effect of age on DNA methylation, I used a 450k array dataset containing DNA 
methylation of 19 healthy newborns, 19 healthy middle-aged adults and 19 healthy elderly 
adults (Heyn et al., 2012). MARCH11 was used as an example. The analysis showed a 
significant increase in DNA methylation with age (Student’s t-test P-value for the 
difference between newborns and adults and newborns and elderly was < 0.05 for the 13 
MARCH11 450k array probes used in the sequencing experiments. Table 5.8 and Figure 
5.57). As demonstrated above, methylated epialleles were not detected in cord blood 











Table 5.8. The difference in DNA methylation for MARCH11 between neonatal blood 
and adult and elderly blood samples. Rows highlighted in bold refer to the selected 450k 
array probes in the sequencing experiments. The difference in DNA methylation was 
represented as proportions  
 









cg03829734 2.9 0.009 3.3 0.137 
cg11584519 8.9 1.20E-05 3.5 0.004 
cg03477332 16 2.12E-08 9.9 0.001 
cg17507952 NA 8.62E-05 3.1 0.000 
cg06782035 23 0.004 17 7.50E-08 
cg03705912 11 3.21E-10 11 4.51E-12 
cg23479922 30 8.35E-13 27 5.90E-13 
cg09017434 27 4.33E-13 26 1.84E-13 
cg15015920 1.2 0.003 1.4 0.003 
cg25092681 1.0 0.007 1.6 0.002 
cg00339556 0.7 0.083 1.1 0.016 
cg01791874 1.1 0.006 1.9 0.000 
cg17030173 0.2 0.732 3.8 0.003 
cg17712694 3.7 1.49E-07 6.9 6.01E-05 
cg16150752 3.4 2.17E-06 6.1 0.001 
cg21901718 0.3 0.127 2.7 0.025 
cg18325622 7.8 1.58E-08 9.8 0.003 
cg23065934 4.7 3.33E-06 8.4 0.010 
cg11452391 4.4 3.88E-08 5.1 0.000 
cg12456714 6.3 2.51E-07 5.9 6.27E-07 
cg16182986 3.4 0.030 5.0 0.000 





Figure 5.57. Age-effect on MARCH11 methylation. A: DNA methylation of 19 
newborns, B: DNA methylation of 19 adults, and C: DNA methylation of 19 elderly. 
Box shows promoter region and the red dotted line crosses through the median levels of 
the 450k array probes. Note the increase in DNA methylation with the increase of age 
(see text for details). 
 
The second question was about whether the methylation profile of the ALL-methylated 
genes was affected in 5-year old children. This was explored by investigating Urdinguio’s 
450k array methylation cohort which contained methylation profiles of blood samples 
from 15 newborns and 15 five-year children (Urdinguio et al., 2016). Figure 5.58 shows no 
significant difference in DNA methylation between newborns and 5-year-old children for 




Figure 5.58. Age-effect on MARCH11 methylation. A: DNA methylation of 15 
newborns and B: DNA methylation of 15 pre-school children. 
 
5.6.2 Investigating the cell-composition effect on the ALL-methylated genes 
Methylation analysis of our adult blood samples was based on DNA extracted from whole 
blood whereas DNA from our cord blood samples was extracted from the mononuclear 
cells (i.e., enriched for lymphocytes). Could the increase in DNA methylation in our adult 
blood samples was a reflection of the methylation of granulocytes and macrophage cell 
populations? 
To investigate the effect of different cell subpopulations on the DNA methylation in adult 
blood samples, two cohorts containing 450k array data from sorted cell populations from 
adult and cord blood samples were analysed (de Goede et al., 2015; Reinius et al., 2012). 
Figures 5.59 shows the DNA distribution of MARCH11 in cord blood and adult blood 
samples of CD4+ T cells, CD8+ T cells, CD56+ NK cells, CD19+ B cells, monocytes and 
granulocytes in seven cord blood samples and six healthy adults (aged 24 – 52 years). 
Remarkably, adult immune cells (T cells, NK cells and B cells) showed an increase in 
DNA methylation compared to cord blood samples suggesting that the increase in DNA 
methylation with age is driven by immune cells. In addition, monocytes and granulocytes 
did not show difference in DNA methylation between cord blood and adult blood samples, 
suggesting that the increase in DNA methylation in adult blood samples is unlikely to be 




Figure 5.59. Cell-composition effect of MARCH11 methylation in cord and adult blood 
FACS cell sorted subpopulations: CD4+ T cells (A and B); CD8+ T cells (C and D); 
CD56+ NK cells (E and F); CD19+ B cells (G and H); monocytes (I and J); and 





Target regions were located in CpG islands within gene promoters of the ALL-methylated 
genes. The average amplicon size was 355 bp, containing an average of 33 CpG sites. The 
amplified regions were selected to include the differentially methylated CpG sites from 
ABC.RAP analysis (average number of probes was 6). Sequencing data for the majority of 
samples had good coverage (about 1000 sequences for each gene).  
BiQ analyser HT was used to perform alignment and methylation analysis on MiSeq files. 
BiQ analyser HT is a wild card aligner that uses a pairwise alignment method based on a 
modified Needleman-Wunsch algorithm for scoring (the tool creates queries “reads” and 
scores their alignment based on Needleman-Wunsch algorithm using dynamic 
programming approach) (Bock, 2012; Li & Homer, 2010; Reinert et al., 2015). On the 
other hand, Bismark uses Bowtie for bisulfite DNA alignment (Krueger & Andrews, 2011). 
Bismark is a three-letter aligner that uses Bowtie, which accommodates local and global 
alignment methods. Bowtie uses indexing strategy for approximate string matching (FM 
indexing based on Burrows-Wheeler transform algorithm) (Bock, 2012; Li & Homer, 
2010; Reinert et al., 2015). Because of the difference in alignment and methylation scoring 
methods between BiQ-Analyser HT and Bismark, both tools can be used for data 
processing to provide different perspectives of the data. The Bismark pipeline was used in 
this project to provide methylation pattern analysis for methylated epialleles.  
The majority of ALL-methylated genes showed a low level of methylation in adult blood 
samples (methylation < 10%). TES and C10orf53 were the only two genes that did not 
show methylated sequences in adult blood samples while KCNA4, GOLSYN and 
MARCH11 was methylated in 10, 11 and 12 methylated samples of 18 sequenced samples, 
respectively. The presence of methylated epialleles in adult samples was most likely 
explained by the documented increase in DNA methylation in immune cells with age 
(Gopalan et al., 2017; Horvath, 2013). In comparison, methylated epialleles were not 
detected in any of the cord blood samples for all of the ALL-methylated genes (except for 
three samples in TES, NEFM and KITLG, see chapter 6 for details).  
The majority of the ALL-methylated genes showed dense DNA methylation in B-ALL cell 
lines and xenograft samples and about 50% methylation in T-ALL samples. KITLG was 
the only exception as it had no DNA methylation in T-ALL samples. KCNA4 and 
C10orf53 had dense methylation in both B and T ALL samples. CCRF-SB, a B-ALL cell 
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line, had much lower levels of methylation than other B-ALL cell lines. In addition, 
sequencing results were consistent with the publicly available genome-wide DNA 
methylation data on the UCSC genome browser and the publicly available 450k array 
leukaemia cohorts, suggesting that the selected ALL-methylated genes were good 
methylation biomarkers. 
To my knowledge, the methylation profiles of the ALL-methylated gene panel in acute 
lymphoblastic leukaemia have not been reported in the literature. Remarkably, this work 
was the first to report an ALL-specific methylation panel of genes that can be used to 
evaluate the epigenetic profile of leukaemia cases. In addition, the dense and very low 
methylation profiles of the ALL-methylation gene panel in leukaemia and cord blood 
samples, respectively, suggest the potential utility of these gene to quantify the minimal 
residual disease (MRD) clinically. However, the analytical specificity (1 < 10,000) may be 
an issue because these markers have to have very high specificity for ALL. Since 
methylated TES, NEFM and KITLG sequence reads can be detected in some cord blood 
samples (see section 5.5), the use of these three genes for MRD can be challenging. This is 
because the presence of methylated epialleles in any of the three genes might indicate a 
methylation signal from the normal ALL-like fetal cell lineage, rather than from leukaemic 





Chapter 6: Discovery of fetal ALL-like cells in neonatal 
blood 
6.1 Abstract 
In previous chapters, 450k array data analysis of leukaemia datasets was used to select 11 
genes that discriminated between ALL and cord blood. The identification of methylated 
reads in cord blood samples suggested the presence of an ALL-like normal cell lineage in 
healthy newborns. This chapter sheds light onto the discovery of ALL-like cells that exist 
in healthy babies based on finding methylated TES, NEFM and KITLG epialleles. 
Remarkably, methylated TES sequence reads were detected in B cells of a preterm neonate 
(methylation of 3.4%) and in the mononuclear cells of three full term newborns 
(methylation of 1.3%, 0.2% and 1.5%). Methylated NEFM and KITLG sequence reads 
were also detected in mononuclear cells in two of the full term newborns (methylations of 
< 5%). Based on these findings, the prevalence of ALL-like cells in our study is 27% (four 
of 15 healthy newborns) and the frequency of these cells ranged from 2:1000 to 3:100 
cells. The interesting discovery raises more questions about the fetal origin of these ALL-
like cells and whether they can be detected in early fetal development. 
6.2 Collection and deep-targeted methylation sequencing of neonatal 
and cord blood samples 
Blood samples used in this project were collected from premature and mature newborns. 
The reason for using neonatal blood samples is because they are the only readily accessible 
source of human fetal blood cells. Premature babies provide a window in which we can 
search for the ALL-like fetal cells. However, premature babies are in an abnormal clinical 
state, and they may not always represent normal development.  
6.2.1 Neonatal blood samples 
Neonatal blood samples are routinely collected by the Neonatal Intensive Care Unit 
(NICU), Dunedin Hospital for diagnostic testing. Surplus blood from premature newborns 
was collected from consenting families and used in this study.  
Six neonates were recruited into the study and a total of 24 EDTA-anticoagulated 
paediatric blood samples were collected (15 – 300 µL) (Table 6.1). One to seven of 
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samples were collected from each neonate (Table 6.1). Mononuclear cell layer (MNC) 
isolation was optimized to deal with very small blood volumes (see section 3.3.2). CD19+ 
B cells were enriched from MNC by incubation with CD19+MicroBeads (Miltenyi). The 
number of CD19+ B cells varied from 5,000 to 153,000 cells and did not correlate with the 
volume of blood samples (Figure 6.1). DNA was extracted using QIAamp Blood Mini 
DNA Extraction kit (Qiagen). The median DNA yield from these B cells was 155 ng. 
There was about 6-fold difference in the median of total DNA yield between CD19+ and 
CD19 negative cells (Table 6.1).  
Table 6.1. A table showing the characteristics of the six premature neonates and their 
associated samples. Samples are arranged by postnatal age for each neonate. 
Sample ID Specimens 
Postnatal age 
(days) 
Volume (µL) CD19+ cells DNA (ng) CD19- cells DNA (ng) 
Neonate 1: 24 week-gestation 
X9099* 101 300 Not counted 290 Not counted 660 
X9110 129 100 4 x 104 80 5.25 x 105 70 
X9116 136 100 2 x 104 60 1.65 x 105 705 
X9121 141 100 1 x 104 155 3.58 x 105 1,670 
X9120* 143 100 7.5 x 103 160 4.9 x 105 2125 
Neonate 2: 27 week-gestation 
X9101 7 50 Not counted 15 Not counted 225 
X9104 14 100 Not counted 60 Not counted 465 
X9105 21 15 none 155 3.5 x 104 240 
X9112 27 200 2.75 x 104 255 1.28 x 106 3,020 
X9114* 28 100 2 x 104 165 8.1 x 105 1980 
X9119* 35 300 1.5 x 105 930 2.8 x 106 6580 
Neonate 3: 29 week-gestation (twin 1) 
X9102 19 70 Not counted 85 Not counted 100 
X9106* 26 100 1 x 104  180 3.5 x 105 1025 
X9113 33 100 2.75 x 104 165 2.63 x 105 1,190 
X9118* 39 100 2 x 104 190 5.5 x 105 1455 
Neonate 4: 29 week-gestation (twin 2) 
X9103 19 70 Not counted 40 Not counted 435 
X9107 24 40 2.5 x 104 145 3.33 x 105 915 
X9108* 27 80 2.8 x 104 210 1.2 x 106 1365 
X9109 28 100 3.25 x 104 150 6.95 x 105 515 
X9117* 31 150 2.5 x 104 245 9.2 x 105 3000 
X9115 34 100 2.5 x 104 70 5.08 x 105 1,245 
X9122* 39 100 5 x 103 175 8.4 x 105 2045 
Neonate 5: 33 week-gestation 
X9111 1 300 7.5 x 104 12 8.55 x 105 24 
Neonate 6: 34 week-gestation 
X9100 4 70 Not counted 10 Not counted 675 
Median 
 100 25,000 155 538,000 970 





Nine of 24 neonatal samples containing the enriched B cells and CD19-negative cells (n = 
18) successfully amplified by TES PCR (Figure 6.3). Blood samples from neonates 5 and 6 
failed TES PCR amplification. Figure 6.2 shows a correlation plot between the total DNA 
yield and number of cells from the successfully amplified samples. 
 
Figure 6.1. A correlation plot between the number of the enriched CD19+B cells and the 
volume of neonatal blood samples. 
 
Assuming that 1 mL of cord blood contains approximately five million white blood cells 
(WBC), of which 60% are lymphocytes (i.e. three million cells) and B cells represent 
approximately 13% of total lymphocytes, the expected number of CD19+ B cells from 1 
mL of cord blood is 390,000 (Comans-Bitter et al., 1997). Consequently, 100 µL of 
neonatal blood is expected to have 39,000 B cells, which is about 1.6-fold higher than the 
median cell count of the enriched CD19+ B cells from neonatal blood samples. DNA yield 
from CD19+ B cells was quantified by the Nanodrop and ranged 40 to 930 ng. Nanodrop 
was found to overestimate DNA concentration suggesting that the lowest measured results 
are not accurate (Simbolo et al., 2013). 
Because of the low DNA yield from the enriched CD19+ B cells, the extracted DNA was 
concentrated using a SpeedVac. A total of about 50 ng of DNA input was used for 
bisulfite-conversion. Successful amplification of TES PCR was obtained for nine CD19+ B 





Figure 6.2. A correlation plot between total DNA yield and number of cells from 




Figure 6.3. Image of gel electrophoresis showing the first round TES PCR products for 
neonatal blood samples (amplicon size = 439 bp). Suffix-A = CD19+ B cells and suffix-
B = CD19- cells. 
 
 
PCR products from first round TES PCR were purified with AMPure XP beads and then 
quantified using a Qubit dsDNA HS assay kit. In the second round PCR, Illumina index 
adapters were attached to the first round PCR products using KAPA HiFi polymerase 
enzyme. PCR products were then electrophoresed on 2% agarose gel (Figure 6.4). Samples 
were pooled, re-purified with AMPure XP beads and the quality was checked by a 
Bioanalyser tracing prior to Miseq sequencing. Because of the insufficient genomic and 





Figure 6.4. Image of gel electrophoresis showing second round PCR products for TES 
(amplicon size = 461 bp). Suffix-A = CD19+ B cells and suffix-B = CD19- cells. 
 
6.2.2 Cord blood samples 
Midwives and obstetricians at Southland Hospital, Invercargill recruited women who 
consented to give cord blood samples. These samples were collected in acid citrate 
dextrose (ACD-A) tubes to maintain cell viability for several days. Thirty cord blood 
samples were collected. From these, mononuclear cells were isolated and stored at -80°C. 
The first 11 samples were used for B cell enrichment using CD19+ MicroBeads followed 
by targeted DNA methylation sequencing (Table 6.2 shows a summary of number of 
enriched B cells and DNA yield). The remaining cord blood samples were stored for 
fluorescence-activated cell sorting (see Chapter 7 for more details). The median number of 
enriched CD19+ B cells from cord blood samples was one million cells, which was about 
40-fold higher than the enriched B cells from neonatal blood samples. In addition, the 
median total DNA yield from the enriched CD19+ B cells was 1265 ng, which is 8-fold 
higher than that for the neonatal samples (Tables 6.2 and 6.1). 
Table 6.2. Summary of the initial 11 cord blood samples used for CD19+ B cell 
enrichment. 
Sample ID Volume (mL) CD19+ B cells DNA (ng) CD19- cells DNA (ng) 
X9124 7.5 9.2 x 105 545 3.6 x 107 12575 
X9125 10 6 x 105 275 5 x 107 13675 
X9127 8.0 3.4 x 106 4080 3.7 x 107 7190 
X9128 7.0 1.7 x 106 2035 1.1 x 108 35765 
X9129 3.5 1.7 x 106 1265 3.8 x 108 7100 
X9130 7.0 1.1 x 106 1115 2.9 x 108 13295 
X9131 10 2.2 x 106 2985 8.6 x 107 12530 
X9132 15 9.3 x 105 1310 5.6 x 107 18510 
X9133 2.5 5 x 104 255 2.6 x 107 1565 
X9134 6.0  8.9 x 105 1495 2.9 x 107 7785 
C1101 1.0 Not counted 705 Not counted 2565 
Median 7 1.0 x 106 1265 5.3 x 107 12530 
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Extracted DNA from the enriched CD19+ B cells and CD19-negative cells was used for 
bisulfite-PCR reactions, an example of which is shown in Figure 6.5. 
 
Figure 6.5. Image of gel electrophoresis showing first round PCR products for TES from 
bisulfite-converted DNA for the CD19+ enriched B cells (suffix-A) and CD19- cells 
(suffix-B) cord blood samples.  
 
6.3 The identification of ALL-like cell population in healthy 
newborns 
6.3.1 The discovery of methylated TES epialleles in healthy newborns 
This project uses an epiallelic approach to interpret sequencing data because of its utility 
for detecting the presence of ALL-like cells (see section 5.3 for more details). As 
demonstrated in section 5.4.1, methylation TES reads, or “epialleles”, were not detected in 
adult blood samples suggesting the high specificity of TES DNA methylation to leukaemia. 
Figure 6.6 represents TES sequencing results of the neonatal blood samples. Remarkably, 
the ALL-like methylation profile, i.e., methylated TES epialleles, were detected in one of 
the premature babies (3.4% of the CD19+ B cells of a four-week old, 28 week-gestation 
baby, sample ID: X9108-A. Figure 6.7). Methylated TES epialleles were not detected in 
the CD19-negative subpopulation of the X9108 sample. Two technical replicates were 
sequenced from the first round bisulfite-PCR products and confirmed the presence of 
methylated TES epialleles (27%, Figure 6.8 A and B). See section 5.3.3 for details on how 









Figure 6.6. Violin points plot showing TES methylation in neonatal blood samples. Each 






Figure 6.7. Heatmap of sequencing reads showing methylated TES epialleles in CD19+ 
B cells from X9108, a preterm neonate (sequences = 291, methylated epialleles = 10). 
Methylated reads were enlarged to illustrate the presence of different patterns of the 







Figure 6.8. Heatmap of sequencing reads showing methylated TES epialleles in two 
technical replicates (A and B) of X9108 CD19+ B cells (A: sequences = 1,968, 
methylated epialleles = 530; and B: sequences = 1,667, methylated epialleles = 446). 
Methylated reads of each technical replicate are enlarged. Red = methylated CpG sites, 
blue = unmethylated CpG sites. 
 
 
In addition, three of 11 sequenced cord blood samples showed methylated reads in the 
CD19 negative cells (C1101 = 1.3%, X9127 = 0.2%, and X9129 = 1.5%, Figures 6.9, 6.10 
and 6.11, respectively). Methylated reads in Figures 6.9, 6.10 and 6.11 were enlarged to 
illustrate the presence of different patterns of the methylated TES epialleles. The CD19 
negative cells included all cell components of the mononuclear cell layer except for B 
cells, i.e., monocytes, T and Natural Killer cells (see section 3.4.1 for more details on the 
enrichment protocol). Due to the insufficient amount of genomic and bisulfite-converted 
DNA of C1101, X9127 and X9129 samples, technical replicates were prepared from the 
first-round bisulfite-PCR products. The technical replicates for these samples confirmed 
the presence of methylated reads (TES methylation of 6%, 11%, and 6% in the technical 
replicates of C1101, X9127 and X9129, respectively). Figures 6.12, 6.13 and 6.14 show 








Figure 6.9. Heatmap of sequencing reads showing methylated TES epialleles in C1101 
CD19 negative sample (sequences = 934, methylated epialleles = 14). Red = methylated, 











Figure 6.10. Heatmap of sequencing reads showing one methylated TES epiallele in 
X9127 CD19 negative sample (sequences = 600, methylated epialleles = 1). Red = 








Figure 6.11. Heatmap of sequencing reads showing methylated TES epialleles in X9129 
CD19 negative sample (sequences = 625, methylated epialleles = 8). Red = methylated, 










Figure 6.12. Heatmap of sequencing reads showing methylated TES epialleles in two 
technical replicates of C1101 CD19 negative sample (A: sequences = 4,112, methylated 
epialleles = 229; and B: sequences = 3,505, methylated epialleles = 212). Red = 








Figure 6.13. Heatmap of sequencing reads showing methylated TES epialleles in two 
technical replicates of X9127 CD19 negative sample (A: sequences = 1,906, methylated 
epialleles = 230; and B: sequences = 1,714, methylated epialleles = 219). Red = 




Figure 6.14. Heatmap of sequencing reads showing methylated TES epialleles in two 
technical replicates of X9129 CD19 negative sample (A: sequences = 2,313, methylated 
epialleles = 156; and B: sequences = 1,937, methylated epialleles = 19). Red = 
methylated, blue = unmethylated. 
 
To investigate whether the methylated sequence reads were the result of PCR 
amplification bias, methylation pattern analysis was used to analyse methylated TES 
epialleles in the methylated samples. Methylation pattern analysis using methpat provides 
the number of each pattern in the reads (see section 5.3.5 for more details). Figure 6.15 
shows the different patterns of methylated TES reads in the CD19+ B cells of the 
premature baby from Figure 6.7 (X9108). The output of methpat is a heatmap of CpG sites 
arranged vertically from top to bottom and the methylation patterns of the sequenced reads 
arranged in columns instead of rows. Each methylated TES epiallele (yellow lines) had a 






Figure 6.15. Heatmap from methpat showing different methylation pattern of 
methylated TES epialleles. There are 38 different methylation patterns (epialleles) 
among the 291 sequenced reads, of which six patterns are methylated reads (yellow 
vertical lines). Note, there are five methylated reads represented by one type of 
methylation pattern, which is pattern number 3. 
 
The technical replicates had higher methylation level than the first sequenced samples. 
Technical replicates were prepared from bisulfite-PCR products stored at 4ºC for about 
two years. It was recommended to store bisulfite-PCR products for up to a week at 4ºC or 
for several weeks at -20ºC (Tost & Gut, 2007). In addition, the large difference in DNA 
methylation between the replicates or between the replicates and the first sequenced 
samples could be due to the very small DNA input for PCR (Tost & Gut, 2007). 
Unfortunately, there was nothing in the literature to provide an explanation for the increase 
of DNA methylation from bisulfite-PCR products after prolonged storage. I propose that 
the prolonged storage of bisulfite-PCR products caused a gradual damage to the PCR 
product and that product containing more cytosines (derived from methylated CpGs) was 
protected from that damage. To test this hypothesis in the future, genomic DNA could be 
ligated to unique barcodes prior to bisulfite-conversion and PCR amplification, then PCR 
products could be aliquoted and sequenced at different time points. Using the unique 
barcodes, the methylated and unmethylated reads can be traced for comparison.  
Interestingly, the methylation pattern in C1101 (Figure 6.9), especially for the 
unmethylated CpG sites 31 and 32 within the methylated epialleles, matches the 
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methylation pattern in the technical replicates which have the same unmethylated CpG 
sites in the methylated reads (Figure 6.12). This suggests that the methylation pattern of 
TES methylated epialleles was preserved despite the increase in DNA methylation level. 
6.3.2 NEFM and KITLG are also methylated in TES positive samples 
Cord blood samples that showed the presence of methylated TES sequences (CB1101-
CD19 negative, X9127-CD19 negative and X9129-CD19 negative cells) were investigated 
by sequencing other ALL-methylated genes. Two of the cord blood samples containing 
methylated TES epialleles also contained methylated NEFM epialleles: X9127 CD19 
negative cells (4% methylation) and X9129 CD19 negative cells (2% methylation) 
(Figures 6.16 and 6.17, respectively). Technical replicates of the first round PCR products 
confirmed the presence of the methylated reads in these samples (methylation of X9127 
technical replicates = 16% and 13%; methylation of X9129 technical replicates = 7.5%, 
Figures 6.18 and 6.19, respectively). 
 
 
Figure 6.16. Heatmap of sequencing reads showing methylated NEFM epialleles in 
X9127-CD19 negative cells (sequences = 145, methylated epialleles = 6). Methylated 



















Figure 6.17. Heatmap of sequencing reads showing methylated NEFM epialleles in 
X9127-CD19 negative cells (sequences = 172, methylated epialleles = 4). Red = 






Figure 6.18. Heatmaps of sequencing results showing the technical replicates of NEFM 
of X9127 CD19 negative cord blood sample (A: sequences = 94, methylated epialleles = 






Figure 6.19. Heatmaps of sequencing results showing the technical replicates of NEFM 
of X9129 CD19 negative cord blood sample (A: sequences = 200, methylated epialleles 
= 15; and B: sequences = 186, methylated epialleles = 14). Red = methylated, blue = 
unmethylated. 
 
Methylated epialleles were detected at the KITLG in one of the TES positive samples 
(X9127 CD19 negative cells; 0.7% methylation) (Figures 6.20). Technical replicates of the 
first round bisulfite-PCR products confirmed the presence of methylated reads 
(methylation of the technical replicates were 0.06% and 0.25%, Figure 6.21). 
 
 
Figure 6.20. Heatmap of sequencing results showing a methylated KITLG read in 
X9127-CD19 negative cord blood sample (sequences = 145, methylated epialleles = 1). 





Figure 6.21. Technical replicates of X9127-CD19 negative cord blood sample 
confirmed the presence of methylated KITLG epiallele (A: sequences = 1,725, 
methylated epialleles = 1; and B: sequences = 1,596, methylated epialleles = 4). Red = 
methylated, blue = unmethylated. 
 
 
Table 6.3 shows a summary of the sequencing results for cord blood samples containing 
methylated epialleles for TES, NEFM and KITLG. The independent observation of 
methylated epialleles in three of the ALL-methylated genes in the same samples supports 
the presence of an ALL-like cell population in the peripheral blood of some healthy 
newborns. 
Table 6.3. Summary of the sequencing results for X9108, C1101, X9127 and X9129 
blood samples.  
Samples Percentage of methylated epialleles 
TES NEFM KITLG 
X9108 CD19+ cells 
Sample 1 3.4 ND† ND† 
Sample 2* 26.9 ND† ND† 
Sample 3* 26.7 ND† ND† 
C1101 CD19 negative 
Sample 1 1.3 0 0 
Sample 2* 6.1 ND† ND† 
Sample 3* 5.7 ND† ND† 
X9127 CD19 negative 
Sample 1 0.2 4 0.7 
Sample 2* 10.5 15.9 0.1 
Sample 3* 11.7 12.5 0.3 
X9129 CD19 negative 
Sample 1 1.5 2 0 
Sample 2* 6.5 7.5 ND† 
Sample 3* 1.3 7.5 ND† 
*Technical replicates prepared from bisulfite-PCR products. 
†ND = not done. 
 
 185 
6.4 Investigating the presence of the ALL-like cells at early fetal 
development 
Twenty-one fetal liver samples were collected in 2006 for the study of leukaemia-related 
genetic changes (Drake, 2006). From there, eleven formalin-fixed paraffin-embedded 
(FFPE) samples that contained liver tissue were selected (Table 6.4). These samples were 
from fetuses at 7 to 11 weeks’ gestation. 
Table 6.4. Summary notes on the fetal liver samples.  













The extracted DNA was bisulfite converted and used to amplify TES, NEFM, KITLG, 
PAK7 and MARCH11 (Figure 6.22 shows first round PCR products for NEFM and 
KITLG). The amplified PCR amplicons were pooled and sequenced on the MiSeq. 
 
Figure 6.22. Image of gel electrophoresis showing first round PCR products of fetal 
liver samples for NEFM (amplicon size = 357 bp) and KITLG (amplicon size = 406). 
 
Each FFPE sample contains different type of fetal tissues, and fetal liver represents a small 
proportion of the sections (about 10% in some of the sections).  Figure 6.23 shows an 
example of a low power magnification of FFPE sections stained with Haematoxylin and 
Eosin (H&E). F50H had small patches of fetal liver tissues scattered around the section 




Figure 6.23. H&E staining of FFPE fetal tissue sections showing the differences in the 
amount of fetal liver tissues between the samples. Fetal liver tissues, circled and 
arrowed, are scattered around the tissue section in F50H sample compared to pure liver 
sections in F63C sample. 
 
In addition to the variation in the amount of liver on each section, there are also a variable 
number of haematopoietic cells in each fetal liver tissue. Haematoxylin and Eosin stained 
slides from F76A and F93B in Figure 6.24 show patches of haematopoietic cells 
characterised by their pink cytoplasm and dark purple nuclei (yellow arrows). 
Haematopoietic cells were surrounded by hepatic cells that were characterised by purple 
cytoplasm and dark purple nuclei (yellow arrows in F76A). The size of the haematopoietic 
islands (circled with yellow arrow in F93B) varies with gestational age. 
 
Figure 6.24. Haematoxylin and Eosin stain for F76A and F93B samples show fetal 
haematopoietic cells form islands of cells of different sizes (circled in F93B).  
 
Sequencing of TES and other ALL-methylated genes did not show methylated epialleles in 
fetal liver samples (Figures 6.25 and 6.26). This may be because fetal samples contained 
small amounts of fetal liver (about 10%). In addition, the proportion on non-erythroid 
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haematopoietic cells will be small. As a result, the methylated signal, if present, may be 
diluted out in the sequenced heterogenous tissues and cells.  
Alternatively, it is possible that the fetal non-erythroid haematopoietic cells with an ALL-
like epigenotype do not exist. Therefore, the hypothesis that an ALL-like fetal stem cell 
exist at early development is wrong. 
 
 
Figure 6.25. Violin points plots for the sequencing results of fetal liver samples. 
Sequencing results for TES (A), NEFM (B), KITLG (C), PAK7 (D), MARCH11 (E), and 







Figure 6.26. Heatmaps of sequencing results showing the methylation pattern of 
different ALL-methylated genes in fetal liver samples: A: F91B (TES, sequences = 918), 
B: F65B (NEFM, sequences = 1,327), C: F53B (KITLG, sequences = 581), D: F96A 
(PAK7, sequences = 627) and E: F84B (MARCH11, sequences = 335). Red = 
methylated, blue = unmethylated. 
 
6.5 Maternal blood effect on DNA methylation 
The discovery of ALL-methylated reads in the blood of healthy newborns could raise 
questions about the presence of contaminating maternal blood cells in the cord blood 
samples. This is because of the majority of the ALL-methylated genes are affected by age, 
and methylated epialleles were detected in adult blood samples. However, methylated TES 
epialleles were not detected in the blood of healthy adults (see section 5.4.1). To 
investigate whether the methylated epialleles were derived from maternal blood cells, a 
publicly available 450k array dataset (Hogan’s dataset) containing 19 blood samples from 
newborns and 19 samples from their corresponding mothers was investigated (Hughes et 
al., 2014). ABC.RAP R package was used to investigate the statistical differences in 
methylation levels of TES, NEFM and KITLG between maternal and cord blood samples. 
Figure 6.27 shows the distribution of methylation in cord and maternal blood samples for 
TES, NEFM and KITLG. The analysis did not show any significant difference in DNA 
methylation for the analysed TES and KITLG probes between maternal and cord blood 
samples; however, NEFM probes show significant differences (Student’s t-test: P-values 
for TES-targeted probes = 0.39, 0.77, 0.89 and 0.73; P-values for KITLG-targeted probes = 
0.096, 0.096, 0.095, 0.126 and 0.36; P-values for NEFM-targeted probes = 2.3 x 10-5, 3.1 x 
10-11, 0.04 and 0.003).  
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Assuming that our cord blood samples contained cells from maternal blood, these cells 
will have insignificant effect on DNA methylation for at least TES and KITLG. In addition, 
methylated TES epialleles were not detected in adult blood samples. As a result, it is very 
unlikely that TES, NEFM and KITLG methylated epialleles that were detected in our cord 
blood samples were derived from maternal blood cells. 
 
Figure 6.27. DNA methylation in healthy cord blood (A, C and E) and maternal blood 
(B, D and F) samples for TES, NEFM and KITLG, respectively (n = 19 for each sample 
type). Target regions in the sequencing assay were shown in boxes. 
 
6.6 Discussion 
The remarkable discovery of ALL-like methylated epialleles in healthy newborns suggests 
the presence of a normal cell lineage with an ALL-like methylome. As demonstrated 
previously (see chapter 5), TES, NEFM and KITLG were densely methylated in B-ALL 
samples. Based on the results presented in this chapter, methylated epialleles of the ALL-
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genes were identified in about 27% of healthy newborns (four of 15 samples). It is widely 
accepted that B-ALL originates prenatally and the majority of B-ALL cases have 
detectable “pre-leukaemic” clones at birth. In addition, “pre-leukaemic” clones were 
detected occasionally in the cord blood samples of healthy newborns (see section 1.2 for 
more details). Do our methylated TES, NEFM and KITLG epialleles indicate the presence 
of “pre-leukaemic” clones in healthy newborns? The reported prevalence of “pre-
leukaemic” clones in healthy babies was reported to be about 1%, compared to the 
prevalence of 27% of our samples (4 out of 15 healthy newborns). There was low 
methylation level of the ALL-methylated genes in cord blood samples, which ranged from 
0.2% to 4% of mononuclear cells. The number of “pre-leukaemic” cells in healthy 
newborns was debated and ranged from less than 10-5 to 10-3 cells in cord blood samples 
(Lausten-Thomsen et al., 2011; Mori et al., 2002). Considering that the “pre-leukaemic” 
cells have a frequency of 1:1000 as the highest possible frequency in cord blood samples, 
the estimated number of ALL-like cells in our cord blood samples is higher than the 
estimated number of “pre-leukaemic” cells (number of ALL-like cells in our cord blood 
samples ranged from 2:1000 to 3:100 cells). As a result, the methylated TES, NEFM and 
KITLG epialleles were not derived from “pre-leukaemic” cells (see chapter 8 for detailed 
discussion about the potential identity of the ALL-like cells). 
This discovery raises questions about the origin of the ALL-like cells and whether they are 
derived from embryonic tissues. Sequencing fetal liver sections did not show evidence of a 
fetal origin of these cells, nor could it refute it. This could be because of the very small 
number of non-erythroid haemopoietic cells in our fetal liver slides. As a result, it is 
possible that the methylation signals of ALL-like cells were not detected because of the 
limitation of the samples. Assuming that the ALL-like cells are from the fetal 
haematopoietic stem cells, how many haematopoietic stem cells are in fetal liver? 
Fetal liver tissue is composed of heterogenous cells including liver epithelium, 
macrophages, fibroblasts, hepatocytes, myeofibroblasts and others (Payushina, 2012). 
Consequently, fetal haematopoietic cells represent a small pool of the various cell types 
within the fetal liver tissue. It was estimated that haematopoietic stem cells in murine fetal 
liver tissue at embryonic day E12.5 (approximately week 6 gestation in human) represent 1 
in 10,000, compared to common lymphoid progenitors (1 in 1000 cells) and myeloid 
progenitors (1 in 100 cells) (Kajikhina et al., 2015). The differentiation kinetics of 
haematopoietic stem cells in fetal liver is driven by various factors, such as Sox17, Lin28b, 
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Hmga2, Ezh2, Pten, Bmi1 and Cebpa (Babovic & Eaves, 2014). In addition, there are four 
haematopoietic stem subtypes (a, b, g and d) that have been classified based on their 
ability to differentiate to myeloid or lymphoid cells (Babovic & Eaves, 2014). Even though 
haematopoietic stem cells can be classified into different subtypes, their cellular output is 
not always predictable. The variation in stem cell behaviour is proposed to be due to the 
presence of a mixture of cells with different potentials for proliferation or the influence of 
different stochastic fates combined with extrinsic environmental factors (Schroeder, 2010). 
Consequently, the failure to identify methylated reads in the sequencing results of fetal 
liver samples could be due to the absence or low number of the ALL-like fetal cell lineage 






















Chapter 7: Enriching for ALL-like cells 
7.1 Abstract 
In the previous chapter, it was shown that about 30% of the neonatal study population 
showed a small proportion of methylated sequence reads for the ALL-methylated genes. 
This suggests the presence of an ALL-like normal cell lineage in healthy newborns. To 
explore the identity of the ALL-like cells, fluorescence-activated cell sorting was done to 
search for the ALL-like methylated epialleles in CD34+ progenitor cells, CD3+ T cells, 
and CD19+ B cells. Deep targeted methylation sequencing was used to detect methylated 
TES, NEFM and KITLG epialleles in the sorted subpopulations. Interestingly, 44% of 
sorted cord blood samples showed methylated TES sequences in CD3+ T cells and/or in 
CD3-CD19- lymphocytes, and these results were supported by similar findings for NEFM. 
However, methylated NEFM sequences were also found in CD19+ B cells and CD34+ 
progenitor cells. Despite the interesting methylation results, a high-level enrichment of the 
ALL-like cells was not achieved. To refine the enrichment process, a search for an ALL-
specific differentially-hypomethylated genes was considered. 
7.2 Fluorescence-activated cell sorting for cord blood samples 
Mononuclear cells isolated from 20 cord blood samples were stored for cell sorting 
experiments (Table 7.1). Of 19 samples, seven samples had one stored vial whereas 12 
samples had multiple vials with a median of 4 vials per sample. The median number of 
isolated mononuclear cells was 7.3 million cells with an estimated 40,000 to 10 million 
cells per stored vial (Table 7.1). There is a high correlation between the blood volume and 
the number of mononuclear cells isolated from each sample (R2 = 0.81, Figure 7.1). One 
sample (X9194) was missing for about 18 days during the collection-transfer process, and 
hence blood cells were not viable for any flow cytometry experiments. As a result, DNA 




Figure 7.1. Correlation analysis between the number of mononuclear cells and blood 
volume (R2 = 0.81).   
 
Table 7.1. A list of the stored cord blood samples for cell sorting experiments. Note, 
X9194 was an old sample and hence was excluded from the sorting experiments. 
 Sample ID Volume (mL) MNC (cells) Vials Cells/vial 
1 X9135 11 5.2 x 107 5 1 x 107 
2 X9136 6 1.2 x 107 2 5 x 106 
3 X9137 10 5.7 x 107 6 1 x 107 
4 X9138 4 5.2 x 106 1 5.2 x 106 
5 X9139 11 3.8 x 107 4 1 x 107 
6 X9141 3 4.0 x 104 1 4 x 104 
7 X9144 3.5 4.2 x 105 1 4.2 x 105 
8 X9145 1.5 5.0 x 104 1 5 x 104 
9 X9147 3 2.6 x 106 1 2.6 x 106 
10 X9148 4 3.6 x 106 1 3.6 x 106 
11 X9149 3 2.2 x 105 1 2.2 x 105 
12 X9150 7.5 1.9 x 107 2 1 x 107 
13 X9155 8.5 7.3 x 106 7 1 x 106 
14 X9156 10 3.7 x 107 4 1 x 107 
15 X9165 4.5 1.4 x 107 2 7 x 106 
16 X9167 2.5 2.9 x 106 2 1.4 x 106 
17 X9175 3.5 2.5 x 106 3 8.3 x 105 
18 X9194 8 Old sample 
19 X9195 10 4.2 x 107 10 4.2 x 106 
20 X9197 40 1.0 x 108 14 6.3 x 106 
Median 4.5 mL 7.3 x 106 2 4.2 x 106 
 
The discovery of leukaemia-specific methylated sequence reads in the blood of newborns 
is remarkable, suggesting the presence of an ALL-like normal cell lineage. Since three 
babies had methylated TES, NEFM and KITLG sequence reads in the CD19 negative 
population (see section 6.3), further investigation was needed to characterise the 
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phenotypic features of the ALL-like cells. Consequently, a broader cell sorting strategy 
was used to identify the phenotype of these cells by enriching for B, T and progenitor 
cells. 
7.2.1 Antibody titration 
The following antibodies were used for the flow cytometry experiments: APC-CD19, 
FITC-CD3 and BV421-CD34. Titration experiments were performed to calculate the 
optimum concentration of the antibodies. Two parameters were used to determine optimal 
antibody titrations: signal to noise ratio and stain index (Figure 7.2). Titration experiments 
aimed at selecting antibodies with the lowest background noise (high signal to noise ratio) 
and highest signal (high stain index). The optimum concentration for an antibody was 
based on selecting a point that had the highest signal (the point where the signal reached a 
plateau) and had a low background noise. As a result, the optimum concentrations for the 
antibodies were 2.5 µg/mL for FITC-CD3, 25 µg/mL for APC-CD19 and 50 µg/mL for 
BV421-CD34 antibodies (Figure 7.2). 
 
 
Figure 7.2. Signal to noise ratio (left) and stain index (right) plots for the titration of 





7.2.2 Flow cytometry gating strategy and enrichment for B, T and progenitor 
cells 
Cord blood samples were prepared in four batches of different samples for the cell sorting 
experiments. The gating strategy was based on excluding doublet cells, then selecting 
lymphocytes. Three gating strategies were used to exclude doublets: FSC-height vs FSC-
Area, SSC-height vs SSC-Area and FSC-height vs FSC-width (Figure 7.3). Then, 
lymphocytes and 7AAD-negative live cells were selected. The gating scheme for cell 
sorting was based on first sorting CD34+ cells from live lymphocytes, and then CD3+, 
CD19+ and CD3-CD19- cells were sorted from the CD34 negative cells. A representative 
example (X9195) is shown in Figure 7.3. CD3-CD19- cells are referred to as “non-B, non-
T lymphocytes” in this thesis. Based on the gating strategy, it is expected that the majority 
of CD3-CD19- cells are lymphocytes, and most likely are NK cells (Figure 7.3). Since no 
specific lymphocyte marker was used to gate on lymphocyte population, it is possible that 
some non-lymphoid cells, such as monocytes, can be sorted into the CD3-CD19- subset.  
Nineteen cord blood samples were sorted (Table 7.1) by the Flow Cytometry Facility using 
a FACSAria II cell sorter. Table 7.2 shows a summary of the numbers of each type of the 
enriched cell populations. Three samples (X9167, X9145 and X9149) failed FACS due to 
insufficient events (stored vials contained approximately 1.4 x 106, 5 x 104 and 2.2 x 105 
cells, respectively). The number of cells in these vials were below the median of stored 
cells per vial (4.2 x 106 cells, Table 7.1). Two vials for X9167 were used for FACS but 
failed to give more than 100 cells per cell population. The failed samples possibly had high 
number of dead cells while their live cells were either washed out during the preparation or 
gated out during FACS. Consequently, 16 of 19 samples were sorted and their 
subpopulations were evaluated by targeted DNA methylated sequencing. In addition, a 






Figure 7.3. Cell sorting strategy used to enrich for BV421-CD34+ (P6 population), 
APC-CD19+ (P8 population), FITC-CD3+ (P9 population) and CD3-CD19- double 
negative population (P10 population). The top three plots show the gating strategy to 
select single lymphocytes, the middle two plots show gating on 7AAD-negative cells 











Table 7.2. Summary of the enriched cell populations of the cord blood samples. Note, 
X9145, X9149 and X9167 failed FACS due to insufficient events.  
Sample ID CD34+ progenitor cells CD19+ B cells CD3+ T cells CD3-CD19- cells 
X9135 2,296 52,508 289,001 43,328 
X9136 12,703 118,210 405,749 198,372 
X9137 10,784 77,048 70,312 30,559 
X9138 3,841 5,422 28,201 3,370 
X9139 1,879 53,988 15,171 50,558 
X9141 119 142 492 215 
X9144 589 2,263 4,423 1,976 
X9145 insufficient events 
X9147 900 2,403 51,120 4,851 
X9148 1,430 2,682 39,469 8,422 
X9149 insufficient events 
X9150 17,998 14,931 93,994 86,806 
X9155 2,845 8,945 39,962 80,177 
X9156 21,836 109,406 92,480 219,157 
X9165 1,495 1,399 44,255 5,404 
X9167 insufficient events 
X9175 341 1,036 1,225 3,772 
X9195 7,161 11,066 52,015 32,409 
X9197 10,833 9,558 19,417 123,113 
Median 2,571 9,252 42,109 31,484 
 
7.2.3 Preparation of sorted samples for targeted sequencing 
Due to the small number of cells in each cell sorted population, DNA extraction and PCR 
amplification protocols were optimised. To maximise the bisulfite-DNA yield, all of the 
extracted DNA was bisulfite-converted (see section 3.7). PCR reactions for NEFM and 
KITLG successfully amplified the majority of samples (Figures 7.4 and 7.5). In 
comparison, TES PCR reactions were difficult and fewer samples were amplified and used 
for sequencing (Figure 7.6). As a result, 64% of FACS subpopulations were amplified by 
TES PCR (six samples of CD34+ cells, eight of CD19+ cells, 14 of CD3+ cells and 13 of 





Figure 7.4. KITLG first round PCR products electrophoresed in 2% agarose showing 




Figure 7.5. The majority of sorted samples were successfully amplified by the NEFM 




Figure 7.6. Variable success of TES PCR for the sorted samples. Despite the very weak 





7.2.4 TES methylated reads were detected in T cells and double negative cells 
As mentioned above, three samples (X9145, X9149 and X9167) had unsuccessful sorting, 
but the methylation results from their mononuclear cells were included. In addition, 
methylation results of X9195 sorted subpopulations were excluded from the analysis (see 
section 7.2.7 for more details). Furthermore, blood cells of X9194 were not sorted because 
of the age of the sample, and hence the sample was excluded to avoid the prolonged 
storage effect on DNA methylation. Consequently, 18 cord blood samples were used for 
the analysis, of which 15 samples were sorted into B cells, T cells, progenitor cells and 
non-B, non-T lymphocytes. 
Eight (44%) of the 18 sequenced sorted cord blood samples had methylated TES 
sequences. Four samples showed methylated TES sequences in mononuclear cells and their 
methylation range from 0.15% to 13% (X9141 = 13%, X9147 = 0.15%, X9149 = 0.18% 
and X9167 = 0.20%. Figures 7.7, 7.8, 7.9 and 7.10, respectively).  
 
 
Figure 7.7. Image of methylation sequencing result of X9141 mononuclear cells 
showing 13% of TES sequences were methylated (sequences = 437, methylated 
sequences = 55). The image on the right side is an enlarged section of the methylated 













Figure 7.8. Image of methylation sequencing result for the mononuclear cells of X9147 











Figure 7.9. Image of methylation sequencing results of X9149 mononuclear cells 
showing 0.18% of methylated TES sequences (sequences = 562, methylated sequences = 










Figure 7.10. Image of methylation sequencing results for the mononuclear cells of 
X9167 showing 0.20% of methylated TES sequences (sequences = 506, methylated 
sequences = 1). Red = methylated and Blue = unmethylated. 
 
The majority of methylated TES sequences were either in CD3+ T cells or CD3-CD19- 
lymphocytes. Only one sample (X9138) showed methylated TES sequences in two 
subpopulations: CD3+ and CD3-CD19- lymphocytes (methylation levels: CD3+ cells = 
0.08% and CD3-CD19- cells = 0.31%. Figures 7.11 and 7.12, respectively).  
 
 
Figure 7.11. Few methylated TES sequences were detected in CD3+ T cells of X9138 
samples representing 0.08% of TES sequences (sequences = 1,254, methylated 








Figure 7.12. Methylated TES sequences (0.31%) were identified in CD3-CD19- 
lymphocytes of X9138 samples (sequences = 967, methylated sequences = 3). Red = 
methylated and Blue = unmethylated. 
 
One sample (X9144) had methylated TES sequences in CD3+ T cells (methylation = 
0.20%, Figure 7.13). In addition, two samples (X9147 and X9197) had methylated TES 
sequences in CD3-CD19- lymphocytes (methylation of X9147 CD3-CD19- = 0.24% and 
X9197 CD3-CD19- = 0.05%, Figures 7.14 and 7.15, respectively).   
 
 
Figure 7.13. Methylated TES sequences were detected in CD3+ T cells of X9144 









Figure 7.14. Image of methylated TES sequences in the CD3-CD19- lymphocytes of 
X9147 representing 0.24% of TES aligned sequences (sequences = 820, methylated 






Figure 7.15. Image of methylated sequencings from CD3-CD19- lymphocytes in 
X9197. Methylated TES sequences represent 0.05% of the aligned sequences (sequences 







Methylated TES sequencing results of all sorted samples are summarised in violin-point 
plots (Figure 7.16). In addition, TES methylation results are summarised in Table 7.3.  
Table 7.3. The percentage of TES methylation in the 18 sorted samples. Note, fields in 
grey show samples that failed TES PCR amplification. 
Samples MNC cells CD34+ cells CD19+ cells CD3+ cells CD3-CD19- cells 
X9135   0 0 0 
X9136  0 0 0 0 
X9137 0 0 0 0 0 
X9138 0 0  0.08 0.31 
X9139 0  0 0 0 
X9141 13     
X9144 0 0 0 0.20  
X9145 0     
X9147 0.15   0 0.24 
X9148 0   0 0 
X9149 0.18     
X9150  0 0 0 0 
X9155 0  0  0 
X9156 0 0 0 0 0 
X9165    0 0 
X9167 0.20     
X9175 0   0  
X9197 0   0 0.05 
 
There was a markedly high methylation level in X9195 CD3+ and CD3-CD19- 
subpopulations, and further investigation was carried out to evaluate their methylated TES 
sequences. Full details about the methylated sequences of X9195 for TES and other ALL-





Figure 7.16. Proportions of TES DNA methylation sequencing results of sorted samples 
plotted on violin-points plots. For each plot, the methylation results of two samples, 
including their sorted subpopulations, are grouped. Samples with methylated TES 





7.2.5 NEFM sequencing results support TES findings 
As mentioned above (see section 7.2.4), 15 of 18 cord blood samples were sorted; 
however, methylation results from mononuclear cells of the 18 samples were included. 
Ten of the 18 sorted samples had methylated NEFM sequences representing 56% of the 
study population compared to 44% of methylated TES sequences. Methylated NEFM 
sequences were detected in all sorted subpopulations of X9138, X9147, X9148 and X9197. 
In addition, methylated NEFM sequences were detected in the CD19+ B cells and CD3-
CD19- lymphocytes of X9141 and in the CD19+ B cells, CD3+ T cells and CD3-CD19- 
lymphocytes of X9144 (Figure 7.17 shows violin-points plots of methylated NEFM 
sequences). The methylation level of NEFM in sorted samples ranged between 0.11% to 
13%; that is, similar to 0.05% to 13% for TES sequences (Table 7.4). Interestingly, the 
highest methylated TES and NEFM sequences (13%) were detected in the mononuclear 
cells and CD19+ B cells of X9141, respectively.  
All of the samples containing methylated TES sequences also had methylated NEFM 
sequences: 1) CD3+ T cells and CD3-CD19- lymphocytes of X9138; 2) X9141 
mononuclear cells; 3) CD3+ T cells of X9144; 4) mononuclear cells and CD3-CD19- 
lymphocytes of X9147; 5) mononuclear cells of X9149; 6) mononuclear cells of X9167; 
and 7) mononuclear cells of X9197. The majority of these samples had low methylation 
level for both TES and NEFM ranged between 0.01% to 1%. Figure 7.18 shows a 
correlation plot of methylation levels for samples contained methylated TES and NEFM 
sequences. Interestingly, methylated NEFM sequences were detected in X9145 
(mononuclear cells) and X9148 (all sorted cells, including mononuclear cells); however, 
methylated TES methylated sequences were not found in these two samples. Figures 7.19, 
7.20, 7.21, 7.22 and 7.23 show methylated NEFM sequences in mononuclear cells, CD34+ 




Figure 7.17. Violin-point plots summarising DNA methylation results of NEFM 
sequences. For each plot, methylation results of every two samples, including their 
sorted subpopulations, are grouped. Samples plotted in red represent those containing 






Figure 7.18. A correlation plot of DNA methylation levels (percentage) for samples 
contained methylated TES and NEFM sequences (axes were in log scale). Nine samples, 
including their sorted subpopulations, had unmethylated TES and NEFM sequences (the 
point at 0.01 on both axes). X9141 mononuclear cells had high TES (13%) but low 




Table 7.4. The percentage of methylated NEFM sequences in the 18 FACS sorted 
samples. Note, fields in grey are samples for which no result was obtained. 
Samples MNC cells CD34+ cells CD19+ cells CD3+ cells CD3-CD19- cells 
X9135 0  0 0 0 
X9136  0 0 0 0 
X9137 0 0 0 0 0 
X9138 0 1.5 0.56 0.75 0.63 
X9139 0  0 0  
X9141 0.8  13  0.68 
X9144 0.85  3.7 0.11 1.4 
X9145 1.0     
X9147 0.26 0.74 0.44 0.31 1.0 
X9148 0.27 1.7 0.62 0.31 0.83 
X9149 0.24     
X9150  0  0  
X9155 0  0 0 0 
X9156 0 0  0 0 
X9165   0  0 
X9167 3.5     
X9175     0 







Figure 7.19. Image of methylated NEFM sequencing results of the mononuclear cells in 
X9148 (sequences = 753, methylated sequences = 2). The image on the right side is an 






Figure 7.20. Image of methylated NEFM sequencing results of the CD34+ progenitor 
cells in X9148 (sequences = 642, methylated sequences = 11). Red = methylated and 





Figure 7.21. Image of methylated NEFM sequencing results of the CD19+ B cells in 






Figure 7.22. Image of methylated NEFM sequencing results of the CD3+ T cells in 






Figure 7.23. Image of methylated NEFM sequencing results of the CD3-CD19- 
lymphocytes in X9148 (sequences = 1,322, methylated sequences = 11). Red = 
methylated and Blue = unmethylated. 
 
Interestingly, no methylated reads were detected for KITLG in the 19 FACS samples, 
except for the low methylation level in the mononuclear cells of X9145 (Figure 7.24). 
Despite the undetected methylated TES sequences in the mononuclear cells of X9145, 
three methylated NEFM sequences (represents 1% of the sequences) were identified in the 
same sample supporting KITLG results. Figure 7.25 shows violin-points plots summarising 
the KITLG methylation results of the sorted samples. 
 
Figure 7.24. Low level DNA methylation of KITLG in the mononuclear cells of X9145 






Figure 7.25. Violin-point plots summarising DNA methylation results of KITLG 
sequences. For each plot, methylation results for every two samples, including their 
sorted subpopulations, are grouped. Mononuclear cells of X9145 are plotted in red to 
highlight the presence of methylated KITLG sequences. X9195 is plotted in dark green 




Sorted samples containing methylated TES and NEFM sequences were investigated for the 
presence of methylated PAK7 sequences. Figure 7.26 shows violin-points plots 
summarising the methylation results of the 10 sequenced samples. Methylated PAK7 
sequences were detected in the CD3-CD19- lymphocytes of X9138 (methylation = 0.72%, 
Figure 7.27). Interestingly, low level methylation for TES (0.32%), NEFM (0.63%) and 
PAK7 (0.72%) was detected in the CD3-CD19- lymphocytes of X9138.  
 
 
Figure 7.26. Violin-points plots of the sorted samples showing methylated PAK7 
sequences. For each plot, methylation results for every two samples are grouped. CD3-
CD19- lymphocytes of X9138 had methylated PAK7 sequences (red points). 





Figure 7.27. Low level DNA methylation of PAK7 (sequences = 2,091, methylated 
reads = 15) was detected in X9138 CD3-CD19- lymphocytes. Red = methylated and 
Blue = unmethylated. 
 
7.2.6 Summary of methylation results 
Twenty cord blood samples were used for sorting experiments. Two samples (X9194 and 
X9195) were excluded. Sixteen were successfully sorted into CD34+ progenitor cells, 
CD19+ B cells, CD3+ T cells and CD3-CD19- lymphocytes. In addition, mononuclear 
cells of the 18 samples were included in the sequencing experiments. Seven samples had 
methylated TES and NEFM sequences in the same sorted subpopulations suggesting a high 
correlation between these two genes. Table 7.5 provides a summary for the methylation 
results for TES and NEFM. Methylation levels for both genes was mostly lower than 5% 
across all the samples. Nine samples did not show methylated sequences for TES and 
NEFM and the methylation pattern for these samples was represented by X9156 in Table 
7.5. The mononuclear cells of X9145 also had methylated KITLG sequences. In addition, 
the CD3-CD19- lymphocytes of X9138 had methylated PAK7 sequences. 
In Chapter 6, one of four premature babies had methylated TES sequences and three of 11 
cord blood samples had methylated TES, NEFM and KITLG sequences. In this chapter, 
seven of 18 cord blood samples had methylated TES and NEFM sequences, one sample 
(X9145) had methylated NEFM and KITLG sequences and one sample (X9148) had 
methylated NEFM sequences. As a result, 13 blood samples from 33 healthy newborns had 
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ALL-like methylated sequences at a low methylation level, representing a prevalence of 
39% in our study population. 
Table 7.5. Summary of methylation sequencing results for TES and NEFM in the sorted 
samples. Methylation of X9156* was included as an example to represent X9135, 
X9136, X9137, X9139, X9150, X9155, X9165 and X9175. Red and blue nucleated cells 
represent the presence of methylated and unmethylated sequences in the samples, 
respectively. Samples containing both methylated TES and NEFM sequences are 
highlighted by red squares.  
 
7.2.7 Exploring sample X9195 
The mononuclear cells of X9195 had an interesting methylation pattern across all of the 
ALL-methylated gene panel (see chapter 5). Interestingly, CD3+ and CD3-CD19- showed 
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a markedly elevated TES DNA methylation (32% and 56%, respectively. Figures 7.29). 
TES PCR failed to amplify bisulfite-DNA of CD34+ and CD19+ cells, and hence the 
methylation level of these two subpopulations was undetermined.  
 
Figure 7.29. Image of methylated TES sequences showing a markedly elevated 
methylation level in CD3+ T cells (A; sequences = 1,270, methylated sequences = 402) 
and CD3-CD19- lymphocytes (B; sequences = 761, methylated sequences = 423) of 
X9195. Red = methylated and Blue = unmethylated. 
 
To investigate whether methylated TES sequences arise from PCR amplification bias, 
methylation pattern analysis was done using ‘methpat’ tool (see section 5.3.4). Figure 
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7.30A shows 112 patterns, of which 82 are methylated in CD3+ cells compared to 70 
methylated of total 95 patterns in CD3-CD19- lymphocytes (Figure 7.30B). The 
methylation pattern analysis suggests that at least 6.5% and 9.2% of the methylated reads 
were not derived from PCR amplification bias (82 and 70 unique methylation patterns of 
1,270 and 761 aligned reads in CD3+ and CD3-CD19- cells, respectively). 
 
 
Figure 7.30. Methylation pattern analysis of X9195 CD3+ cells (A) and CD3-CD19- 
lymphocytes (B). The rows show CpG sites from 1 to 48 of the TES amplicon and 




Methylated reads were analysed further by hierarchical clustering using Levenshtein 
distance method implemented in “stringdist” R package (Figures 7.31 and 7.32). 
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Levenshtein distance method is a character-based similarity metrics method based on the 
number of edits to transform one string of characters into another (Elmagarmid et al., 
2007). The edits can be insertions, deletions or replacements of characters and each edit 
operation has a weight of one. Edits can then be used to conduct string matching clusters. 
Figures 7.31 and 7.32 show the results of clustering analysis of methylated TES sequences 
in CD3+ cells and CD3-CD19- lymphocytes of X9195, respectively.  
There were two steps for the methylation clustering analysis: 1) identify identical 
sequences and represent them by one sequence; and then 2) identify the unique methylated 
sequences of sequences in step one. The clustering analysis identified 292 uniquely 
methylated TES patterns among 405 methylated sequences in CD3+ T cells. In 
comparison, the clustering methylation analysis revealed 296 unique methylated TES 
patterns of 425 sequences of CD3-CD19- lymphocytes. In both samples, there were minor 
differences between the sequences represented by similar clustering distance values 
(median height = 3, first quartile = 2 and third quartile = 5). However, the means are 
different for both samples (mean height = 4.045 and 3.834 for CD3+ and CD3-CD19- 
cells, respectively). The small difference between the branches suggests the presence of 
variable sequences. Nearly all the sequences were unique indicating minimal PCR 
amplification bias or contamination. Despite the similarity of sequences between the two 
samples, there were no noticeable distinct clusters of sequences that could suggest the 
presence of a common contaminant. In addition, it is very unlikely to have contaminating 
bisulfite-TES DNA in these two samples only, and no contamination in other sorted 




Figure 7.31. A dendrogram plot of Levenshtein distance clustering of the 292 unique 
methylated TES sequences in X9195 CD3+ cells. Each branch represents a unique 




Figure 7.32. A dendrogram plot shows the 296 unique methylated TES sequences that 
were clustered using Levenstein distance clustering method of X9195 CD3-CD19- cells. 




Unfortunately, genomic and bisulfite-DNA of CD3+ T cells and CD3-CD19- lymphocytes 
were insufficient for the preparation of technical replicates. As a result, technical replicates 
of X9195 sorted cells were prepared from first round TES bisulfite-PCR products. 
Methylation levels for the technical replicates of CD3+ T cells were 37% and 32% (Figure 
7.33). In addition, methylation levels of 53% and 57% were detected in the technical 
replicates of CD3-CD19- lymphocytes (Figure 7.34). Technical replicates of CD3+ and 
CD3-CD19- cells had similar TES DNA methylation level to their corresponding initially 
sequenced samples (32% and 56%, respectively). 
 
 
Figure 7.33. Images of the methylated TES sequences in the two technical replicates of 
CD3+ T cells of X9195. A: sequences = 200, methylated sequences = 73; and B: 
sequences = 210, methylated sequences = 67. 
 
 
Figure 7.34. Images of the methylated TES sequences in the two technical replicates of 
CD3-CD19- lymphocytes of X9195. A: sequences = 194, methylated sequences = 103; 




To confirm the results, one of the eight stored vials containing X9195 mononuclear cells 
was thawed to re-evaluate the consistency of the TES methylation. Two technical 
replicates were prepared from the extracted genomic DNA of the mononuclear cells. 
Interestingly, methylated TES sequences were not detected in any of the technical 
replicates (Figure 7.35). 
 
Figure 7.35. Images of the methylated TES sequences in the two technical replicates of 




In comparison, methylated NEFM sequences were detected in all sorted cells of X9195 
(CD34+ = 3.4%, CD19+ = 2.8%, CD3+ = 0.32% and CD3-CD19- lymphocytes = 0.06%, 
Figures 7.36, 7.37, 7.38 and 7.39, respectively). Technical replicates for these samples 
were not investigated for NEFM methylation. Methylated KITLG and PAK7 sequences 
were not detected in the sorted cells of X9195. 
Based on the above results, X9195 was excluded from the analysis for the following 
reasons: 1) variations in the DNA methylation of X9195 mononuclear cells among all of 
the ALL-methylated gene panel (see chapter 5); 2) the presence of markedly elevated TES 
DNA methylation in CD3+ and CD3-CD19- cells and the high methylation level was 
inconsistent with other cord blood samples; and 3) methylated TES sequences were 
undetected in a different vial of mononuclear cells indicating the inconsistency of results.  
 
 
Figure 7.36. Image of methylated NEFM sequencing results of CD34+ cells from 
X9195 (sequences = 269, methylated sequences = 9). The image on the right side is an 







Figure 7.37. Image of methylated NEFM sequences in CD19+ cells of X9195 








Figure 7.38. Image of methylated NEFM sequences showing few methylated sequences 
in CD3+ cells of X9195 (sequences = 1,868, methylated sequences = 6). Red = 





Figure 7.39. Image of methylated NEFM sequencing results showing one methylated 
NEFM sequence in the CD3-CD19- lymphocytes of X9195 (sequences = 1,691, 
methylated sequences = 1). Red = methylated and Blue = unmethylated. 
 
7.3 ALL-specific differentially hypomethylated genes 
Cell sorting is ideally performed on expressed antigens, which can be either on the surface 
of the sorted cells or intracellular. To enhance the enrichment of the ALL-like cells in 
healthy newborns, it would be useful to have a positive marker for cell sorting. The aim of 
this analysis is to identify a group of genes that are highly methylated in normal blood 
cells and hypomethylated (low DNA methylation) in ALL cells. This was achieved by 
searching for ALL-specific hypomethylated genes from 450k array methylation analysis. 
Chapter 4 demonstrated the 450k array ABC.RAP analysis for nine leukaemia datasets and 
revealed 36 common differentially methylated genes (section 4.4.2). All of the ALL-
methylated genes were highly methylated in leukaemia cases compared to normal blood 
cells. Consequently, datasets were investigated separately to search for hypomethylated 
genes in leukaemia. Busche’s dataset revealed 14 genes that were differentially 
hypomethylated in B-ALL (Table 7.6) (Busche et al., 2013). Three genes had 
hypomethylated CpG sites in the promoter region (i.e., TSS1500 or TS200): APOM, LTA 
and ZGLP1. Since the differential methylation of these three genes was not present in the 
other ALL datasets, they were not included in the previously described ALL-methylated 
gene panel. Figure 7.40 show plots of the mean methylation values for the array probes 
arranged from 5’ to 3’ for the three hypomethylated genes.  
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Table 7.6. A list of differentially hypomethylated genes in B-ALL cases from ABC.RAP 
analysis of Busche’s dataset (2013). 
Gene CpG sites Location 
ACSF3 2 Body* 
APOM 4 TSS1500* 
ARHGEF10 2 Body 
CBFA2T3 3 Body 
LTA 3 TSS1500, TSS200* and Body 
MAD1L1 7 Body 
NPHP4 2 Body 
NR1D1 2 Body 
SFRS8 2 Body 
SORBS1 2 Body 
TBCD 4 Body 
TMCO3 3 Body 
TRAPPC9 2 Body 
ZGLP1 3 TSS1500, TSS200 and Body 
*Body refers to gene body, TSS1500 and TSS200 refer to within 1500 bp and 200 bp 
upstream of transcription start site, respectively. 
 
 
Figure 7.40. ABC.RAP mean methylation plots for APOM (A), LTA (B) and ZGLP1 (C) 
for 46 B-ALL cases and 46 remission controls from Busche’s dataset. Red circles = B-




Unfortunately, methylation patterns of APOM and ZGLP1 were different in T-ALL 
(Borssén et al., 2016). Figure 7.41 shows that APOM and ZGLP1 had high DNA 
methylation in T-ALL cases and in controls indicating the specificity of APOM and 
ZGLP1 hypomethylation to B-ALL. 
 
Figure 7.41. ABC.RAP mean methylation plots for APOM (A), LTA (B) and ZGLP1 (C) 
for 65 T-ALL cases and 4 controls from Borssén’s dataset. Red circles = T-ALL cases 
and blue triangles = controls. 
 
Methylation of LTA in the control samples in T-ALL dataset was different than the pattern 
in the controls in B-ALL dataset (blue triangles in 7.41B and 7.40B, respectively). To 
establish the methylation level for LTA in normal cord blood samples, LTA was further 
evaluated in different cell subpopulations. Figure 7.42 shows ABC.RAP plots of the 
distribution of LTA methylation in granulocytes, CD4+ T cells, CD8+ T cells, CD19+ B 
cells, CD56+ NK cells and CD14+ monocytes of seven healthy newborns (450k array data 
of deGoede’s dataset (2015)). As shown, the methylation of LTA in cord blood 
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subpopulations is highly variable and overlaps to that reported in B-ALL and T-ALL 
cases. 
 
Figure 7.42. ABC.RAP plots of LTA methylation in the blood cell subpopulations of 
seven healthy newborns (deGoede’s dataset): (A) Granulocytes, (B) CD4+ T cells, (C) 
CD8+ T cells, (D) CD19+ B cells, (E) CD56+ NK cells and (F) CD14+ monocytes.  
 
Analysis of GoldenGate 1500 array leukaemia dataset showed a list of genes that are 
hypomethylated in B-ALL compared to controls, such as CTGF, CSF1R, IAPP, GNG7, 
IL1B, NPR2 and TNFRSF1A  (Martin-Subero et al., 2009). Previously, I have evaluated 
CTGF protein expression by western blotting, immunohistochemistry, 
immunofluorescence and flow cytometry (Alsaleh, 2014). Using reverse transcriptase 
PCR, CTGF mRNA was expressed in REH, RS4 and human skin fibroblasts cell lines, and 
hence these cell lines were used as positive controls for the protein expression 
experiments. Four commercial anti-CTGF antibodies were used in western blotting 
experiments; however, none of the antibodies showed specific bands for CTGF in the 
positive cell lines. A commissioned antibody that was specifically raised against a 
synthetic short CTGF peptide was used and was successful. Unfortunately, the 
commissioned antibody failed to work in flow cytometry, immunohistochemistry and 
immunofluorescence experiments. The evaluation of CTGF expression in B-ALL cell lines 
was inconclusive due to the lack of antibody specificity and to the weak expression of 
CTGF protein intracellularly (Alsaleh, 2014). 
7.4 Discussion 
The remarkable findings of methylated TES and NEFM sequences in about 40% of healthy 
babies strongly suggests the presence of a normal ALL-like fetal cell lineage. Cell sorting 
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experiments revealed the presence of methylated TES sequences in CD3+ and CD3-CD19- 
lymphocytes suggesting that the ALL-like cells were from a common fetal stem cell that 
has the potential to differentiate into fetal T and possibly NK cell lineages (the identity of 
the ALL-like fetal cells is discussed in details in chapter 8, see section 8.3).  
Methylation results of the mononuclear cells of X9195 showed an inconsistent pattern of 
methylation across all of the ALL-methylated gene panel compared to other cord blood 
samples. There was a markedly elevated TES methylation in CD3+ and CD3-CD19- cells 
compared to the inconsistently low methylation level for NEFM. In addition, technical 
replicates from mononuclear cells of a different vial failed to show the methylated TES 
sequences. Based on these results, X9195 was excluded from the analysis until further 
investigation. Robasky and colleagues (2014) suggested that using low amounts of 
genomic DNA can affect the quality of sequence reads by increasing the amplification 
errors and compromising the sequence coverage. They also suggested that using 
fragmented DNA in library preparation for next generation sequencing may lead to PCR 
amplification bias and to the incorporation of sequence errors in the amplified amplicon. 
One approach to enhance the sensitivity and accuracy of sequence reads is to use high 
sequencing coverage; however, this approach cannot minimise errors arise from 
experimental preparations (Robasky et al., 2014). As a result, I can speculate that there is 
most likely an unidentified problem in the first vial of X9195 that was used for sequencing 
the ALL-methylated gene panel and for the cell sorting experiments. The problem most 
likely occurred in the affected vial after aliquoting the mononuclear cells into vials for 
cryopreservation as the second vial had different methylation results for TES.  
The methylation results of X9195 were contradictory as methylated TES sequences were 
detected in one vial and undetected in another vial, so which of these is the accurate 
reflection of X9195 methylation status? This is a difficult question and may not be 
answered at this stage without more independent experiments on the other stored vials. 
There was no clear suggestion in the literature on how to handle results like X9195. 
Gracely (2008) suggested that researchers sometimes select results for publications 
without readers knowledge about the overall results of the study. In addition, majority of 
studies with minor or nonsignificant results never get published showing a high 
publication record for studies with statistically significant results. As a result, Gracely 
suggested that experimental results should be replicated, which can work as “an effective 
antidote to selectivity and publication bias”. Parton (2008) suggested that “the purpose of 
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publication is to promulgate the methods and results to the scientific community, allowing 
other researchers to independently replicate the results, which adds to the validity of the 
findings”. These suggestions indicate the importance of repeating X9195 experiments to 
avoid the selectivity bias of results. 
To enhance the enrichment of the ALL-like cells in cord blood, it would be useful to have 
a positive selectable marker for cell sorting. Genes that are highly methylated in normal 
blood cells and hypomethylated in ALL cells might therefore provide useful biomarkers. 
Analysing 450k array methylation datasets, three genes were found to be specifically 
hypomethylated in B-ALL (APOM, LTA and ZGLP1); however, their methylation was 
inconsistent in T-ALL dataset. In addition, analysis of GoldenGate leukaemia dataset 
revealed a group of hypomethylated genes in B-ALL, including CTGF. Previously, CTGF 
protein expression experiments were conducted to evaluate its expression level in B-ALL 
cell lines; however, the experiments were unsuccessful due to the lack of antibody 
specificity (Alsaleh, 2014).  There are a few differentially expressed genes reported in the 
literature that could be potential candidates for the enrichment of ALL-like fetal cells, such 





Chapter 8: Discussion of results and future directions  
8.1 Summary of results 
In previous chapters, a panel of ALL-methylation biomarkers was selected based on 
ABC.RAP analysis of the publicly available human 450k array methylation datasets. The 
panel was shown by targeted DNA methylation sequencing to be densely methylated in 
leukaemia and to have very low methylation in normal peripheral blood. Consequently, the 
panel was used to search for an ALL-like fetal cell population in the blood of healthy 
newborns.  
Methylated TES epialleles were detected in B cells of a premature neonatal blood. In 
addition, methylated TES and NEFM epialleles were detected in T cells; non-B, non-T 
lymphocytes and mononuclear cells in cord blood samples from mature newborns. 
Furthermore, B cells of cord blood samples contained methylated NEFM epialleles. Figure 
8.1 shows a summary of the sequencing results: methylated epialleles are represented by 
cells.  
The number of methylated epialleles was low in the sequenced samples (methylation level 
ranged from 0.1% to 13.1%). The prevalence of samples containing methylated TES and 
NEFM epialleles was 39% in our study population consistent with the presence of a 
normal ALL-like fetal cell lineage that can be detected in a substantial population of 
healthy newborns. The discovery of TES and NEFM methylation in neonatal blood cells 
raised questions about the identity of the cells and their role in B-ALL. Do methylated TES 
and NEFM epialleles reflect the epigenotype of a pre-leukaemic clone? If not, do they 
indicate the presence of different fetal cell lineages derived from a common fetal stem 
cell? If different fetal cell lineages have an ALL-like epigenome, then what is their role in 




Figure 8.1. A diagram showing a summary of the sequencing results. Red nucleated 
cells represent cells containing methylated epialleles. 
 
8.2 Selection of the ALL-methylated genes 
In this section, three aspects will be discussed: 1) viewpoints on sharing research data to 
the scientific community; 2) methods used in the 450k array analysis tools to identify 
differentially methylated regions; and 3) validation processes to evaluate discovered 
biomarkers. 
8.2.1 Sharing research data 
Analysis of publicly available 450k methylation array data was used to select a panel of 
leukaemia biomarkers. These biomarkers were then used to search for the existence of the 
fetal ALL-like cells in healthy newborns. The use of publicly available data for other 
projects has sparked an interesting discussion in the literature. Who owns the research 
data? There is a trend in the scientific community toward the use and sharing of publicly 
available data, but does it mean that these scientists are stealing the data? or are they 
“research parasites” who feed on other research projects? Is the use of publicly available 
research data the new norm for future “parasitic” projects? 
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Majority of the viewpoints favoured the deposition of raw data and urged scientists not to 
“let useful data go to waste” (Denk, 2017). The concept of data sharing was officially 
discussed during the Human Genome Project convention, specifically in a Bermuda 
convention in 1996. The five nations at Bermuda convention agreed to release DNA 
sequencing data daily to monitor the sequencing accuracy and allocate genome assembly 
between the laboratories (Cook-Deegan & McGuire, 2017). The convention released a list 
of principles, “Bermuda principles”, to enable the assembly of DNA sequencing data. 
However, concerns were raised by Germany and Japan regarding the use of data by 
commercial companies. As a result, Germany and Japan decided not to be compliant with 
the project. Despite the noncompliance issues, over 90% of the funders of the Human 
Genome Project promoted the importance of open data sharing for a “global public good” 
and continued to construct a human reference sequence. Since then, the Bermuda 
principles were considered by many researchers as “an icon of effective open science” and 
was the cornerstone for many initiatives towards scientific data sharing globally (Cook-
Deegan & McGuire, 2017). Since the Bermuda convention, the 2003 HapMap Consortium, 
the 2000 and 2004 Encode Project Consortiums refined the principles and debated the 
rules of open data sharing especially for patent discoveries. The latest initiative of the 
global alliance for genomics and health included more than 400 institutions across 70 
countries and was based on constructing new guidelines to share and regulate the “medical 
information commons” (Cook-Deegan & McGuire, 2017).  
Despite the benefits from data sharing, clinical researchers raised concerns about the 
emergence of “research parasites” who feed on publicly available and shared data (Longo 
& Drazen, 2016a). Longo and Drazen (2016a) described these research parasites as 
“people who had nothing to do with the design and execution of the study but use another 
group’s data for their own ends, possibly stealing from the research productivity planned 
by the data gatherers, or even use the data to try to disprove what the original investigators 
had posited”. They suggested that the shared data be used “symbiotically, not 
parasitically” and recommended that data owners should restrict access to research data. 
They proposed the granting of access to those who request a collaboration in exchange of 
the use of research data. They also suggested data owners should be acknowledged by 
listing their names as co-authors in any publication derived from the data. 
The commentary from Longo and Drazen regarding “research parasite” has sparked further 
debate. Beck supported Longo and Drazen’s concerns and suggested that data owners 
 
 234 
should be addressed and acknowledged appropriately among the research community, 
especially those who establish widely useful shared data (Longo & Drazen, 2016b). In 
addition, Beck suggested that “If data sharing is in the self-interest of whoever collected 
the data, data sharing as a policy will be on better footing”. On other hand, Bergstrom 
argued that researchers should share their scientific discoveries. The restricted access of 
data can slow the pace of discovery and diminish the benefits of public goods (Longo & 
Drazen, 2016b). Bergstorm suggested that “when data can be withheld, researchers can 
have their cake, by hoarding their data, and eat it, too, by claiming public credit”. In 
addition, Embi argued that responsible data sharing should be used to enhance the quality 
of research and “can benefit all stakeholders – patients, secondary researchers, and primary 
researchers”.  
Longo and Dazen replied to the above comments and suggested that their suggested 
collaborative approach was to respect the wishes of patients involved in the primary 
research and to acknowledge the efforts of primary research team in collecting and 
analysing the data (Longo & Drazen, 2016b). They argued that a collaborative approach 
can minimise the misleading statements by independent re-analysts who have inadequate 
information about the data. Furthermore, they argued that sharing data can be against the 
wishes of the consenting study participants and they requested the need to implement safe 
measures and to ensure participants’ privacy. As a result, Harari proposed a few 
recommendations based on Longo and Dazen latest reply: 1) a new consent procedure to 
ensure the approval of participants for data sharing, 2) a software to be added with the 
shared data to enable data sharing, 3) the independent reanalysts, also called the secondary 
researchers, are obliged to inform the primary team with a synopsis of their derived work, 
4) an opportunity should be given to the primary researcher to contribute to any work 
relating to the shared data, 5) secondary researchers can publish their work as a comment 
on the original research in cases of no collaboration agreement, and 6) clear compulsory 
notes should be included with any publication containing shared data describing the terms 
of use (Harari, 2016). The executive officers of the International Society of Computational 
Biology (ISCB) (2016) responded to Longo and Dazen’s comments and argued that 
dividing researchers into “data providers and data analysts is simplistic and gives a 
misleading impression” and that sharing data generated from taxpayers’ money belong to 
the public. They supported the collaborative approach; however, a data-accessibility 
collaboration approach “cannot be contained in professional silos” (Berger et al., 2016). 
 
 235 
To address the concerns of the research community regarding participants concerns, 
Trinidad and colleagues (2010) conducted a focus group survey to identify viewpoints 
about sharing genomic research data across participants. They found wide agreement 
between the participants to support the sharing of de-identified genomic data, and they 
believed that open science is a valuable source for accessible, complete and accurate data 
to the research community. Interestingly, one of the participants viewed sharing the data as 
a “legacy, living on in the lab” and another participant said “It makes me a little less 
mortal”. However, there were few concerns about the privacy of shared data. Some 
participants suggested that it is unethical to claim patency on publicly-based data for a 
“profit-seeking activities” (Trinidad et al., 2010). Interestingly, depositing scientific data is 
becoming a requirement for publication by many high impact journals (Boulton, 2012; 
Denk, 2017; Nelson, 2014). Examples of scientific data repositories include Gene 
Expression Omnibus (GEO is part of NCBI group, website: 
https://www.ncbi.nlm.nih.gov/geo/), The Cancer Genome Atlas (TCGA, website: 
https://gdc.cancer.gov), and ArrayExpress (EBML-EBI group, website: 
https://www.ebi.ac.uk/arrayexpress/). These data repositories are excellent resources for 
scientific genomic and epigenetic data.  
8.2.2 Identification of differentially methylated regions in 450k array analysis 
tools 
Several 450k array analysis tools are available and each tool has its own theme for data 
analysis. As of April 2018, there were 592 tools available for the analysis of 450k array 
data on the OMIC Tools website, 26 of which were designed for the detection of 
differentially methylated regions, and 17 of 592 tools were site-based analysis tools. The 
identification of what can be labelled a “differentially methylated region (DMR)” is not 
standardised between the analysis tools and hence this can lead to contradicting results. 
DMRs were defined as “genomic regions with different methylation statuses among 
multiple samples (tissues, cells, individuals, etc.), and are regarded as possible functional 
regions involved in gene transcriptional regulation” (Neidhart, 2016).  Breton and 
colleagues (2017) found that DMR analysis tools can be classified broadly into two 
groups: 1) CpG site analysis followed by the identification of DMRs, and 2) DMR 
classification followed by methylation analysis of CpG sites. The identification of DMRs 
after the analysis of CpG sites (group one) is a common approach across the available 
DMR-analysis tools (Breton et al., 2017). However, methods for the identification of 
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DMRs vary widely from the customised user-defined regions to pre-defined genomic 
regions. As an example, “minfi” tool (bumphunter and cpgCollapse functions) defines 
DMRs based on the identification of blocks of CpG sites within sliding-windows of 
genomic sequences. Analysis of CpG blocks to adjacent or distant genomic regions can be 
made, such as differences around genomic locations (i.e., gene promoter and gene body) 
(Morris & Beck, 2015). Another example of a DMR identification method can be found in 
the “ChAMP” tool (Probe lasso “champ.lasso” function) which has user-defined, flexible 
windows tailored to the annotated genomic features (i.e., TSS regions and CpG island 
annotations) (Butcher & Beck, 2015). A third example can be seen in the “FastDMA” tool 
which defines DMRs based on predefined or arbitrary regions that have more than two 
CpG sites with significant difference in DNA methylation between the analysed regions 
(Morris & Beck, 2015).  
In comparison, the second type of DMR-analysis (group two) was based on identifying 
DMRs prior to data analysis. An example of this type is found in the “A-clustering” tool 
that used a clustering analysis of closely related CpG sites (Sofer et al., 2013). The authors 
argued that neighbouring CpG sites often have similar methylation features indicating their 
biological significance. The clusters were constructed from user-defined, fixed-windows of 
neighbouring CpG sites. As a result, each cluster of neighbouring CpG sites was 
considered a region. A generalised estimating equation analysis, which assumes equal 
exposure of all CpG sites to any environmental variable, was then applied on all of the 
clusters. Because this approach depends on user input to define the cluster (i.e., number of 
CpG sites in a cluster), results of this approach can vary due to the variable inputs across 
multiple users. 
There is a wide variation between region-based analysis tools on their identification of 
DMRs and this potentially adds more complexity during the identification of biologically 
relevant differentially methylated regions. ABC.RAP, the package that I developed, aimed 
to simplify the analysis process for biologists who would like to capture a methylation 
portrait of their favoured genes, and the captured portrait closely resembles the output of 
the genome browser. To my knowledge, ABC.RAP is the only available tool that defines 
DMRs based on the finding of multiple differentially methylated CpG sites near genomic 
features and then profiles the methylation values for all probes of the identified genes. 
Experimental biologists may find this tool useful to select biologically-relevant DMRs 
based on the methylation profile of the identified genes. In this project, ABC.RAP was 
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useful to identify ALL-methylated genes, a panel of which was easily selected to meet our 
stringent inclusion criteria.  
8.2.3 Selection, evaluation and validation of biomarkers 
ABC.RAP successfully identified a panel of genes that were densely methylated in ALL. 
The selection criteria for the ALL-methylated gene panel was stringent, and the panel was 
validated on many levels. The validation process included: comparison of the DNA 
methylation of the selected panel across nine different ALL cohorts; evaluation of the 
methylation features of the target regions against genome-wide DNA methylation data; 
targeted methylation sequencing using several ALL and control samples; and finally, 
comparison of the sequencing data with the publicly available 450k array methylation 
values. Each step of the validation process added another layer of evidence towards the 
reliability of the selected panel and confirmed their potential use as biomarkers.  
But, what does “validation” mean in the biomarker research context? Brenner and 
Normolle (2007) reviewed the proposed definitions in the literature and found validation 
can be divided into analytical and clinical validations. Analytical validation, also referred 
to as “technical” validation, evaluates the sensitivity and intrinsic errors of the assay. In 
comparison, clinical validation, also referred to as “field” or “epidemiological” validation, 
is about measuring the biological variation when the assay is applied to a population. The 
majority of biomarkers were developed to be used in the clinical settings, and hence issues 
of bias and reliability should be addressed prior to clinical validation (Brenner & 
Normolle, 2007). The first phase of biomarker identification is usually based on analysing 
small number of participants derived from well diagnosed cancer patients matched with 
carefully selected controls. However, the identified biomarker may have poor reliability in 
the clinical setting. This is because of intra- and inter-individual variation between cases 
and controls. As a result, the estimated cutoff values in the clinical settings are 
compromised, affecting the generalisability of the biomarker (Brenner & Normolle, 2007). 
As a result, less than 1% of biomarkers succeed in the clinical setting despite rigorous 
validation attempts by the publishing authors (Kern, 2012). As an example, a gene X may 
be found to be differentially expressed in a tumour condition, technically validated by the 
replicates with a very high correlation analysis and demonstrate perfect concordance on 
the functional proteomic studies; however, the biomarker fails on its initial clinical 
validation attempt (Kern, 2012). Consequently, Pepe and colleagues (2001) suggested five 
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phases to perform validation prior to the application of the biomarker in the clinical 
setting. First, exploring the ability of biomarker to distinguish cancer from control 
samples, Second, testing the biomarker in clinically diverse patients with different 
variables (i.e., gender, age, within and between day assays, etc) to evaluate biomarker 
potential by detecting cancer. Third, evaluating the biomarker assay in asymptomatic 
patients. Fourth and fifth, evaluating the biomarker in a pilot study as a screening test 
followed by a population-wide application (Pepe et al., 2001). 
Do experimental biologists need to go through the layers of validation as described above 
to validate their discovered biomarkers? Chuaqui and colleagues (2002) suggested two 
approaches to validate the identified biomarkers from array-based experiments: “in silico 
analysis and laboratory-based analysis”.  The “in silico” method is based on analysing 
other array-based datasets, either publicly available or privately owned data, or by 
searching the literature for information about the identified genes. This method does not 
require laboratory experiments and the consistency of results provide sufficient evidence to 
validate novel biomarkers (Chuaqui et al., 2002). The laboratory-based validation 
approach includes experimental work, using a new set of samples or using the same 
samples that were used in the array assay (Chuaqui et al., 2002). There are about 16 
potential targeted techniques for the validation of methylation biomarkers, such as bisulfite 
sequencing, pyrosequencing, digital PCR, and padlock probes (Olkhov-Mitsel & Bapat, 
2012). Prior to the emergence of next generation sequencing technology, the clone-based 
bisulfite sequencing technique was the gold standard for the validation of methylation 
biomarkers; however, the technique was expensive and laborious as it requires cloning of 
bisulfite PCR amplicons into E.coli prior sequencing (Olkhov-Mitsel & Bapat, 2012). 
Nowadays, next generation sequencing platforms, such as MiSeq, provides high coverage 
data at single CpG resolution.  
The combined in silico and laboratory-based validation approaches that were used in this 
project to validate the ALL-methylated gene panel provided strong evidence for the 
reliability of the panel as biomarkers and their suitability for a clinical validation as 




8.3 The discovery of an ALL-like cells in healthy newborns 
The uniqueness of this project is that it utilized the ALL-methylated gene panel as 
biomarkers to search for the methylation features of the fetal cell of origin for leukaemia. 
Two of the 11 validated genes (TES and NEFM) showed methylated reads in the blood 
samples of the same healthy babies. In addition, methylated sequence reads of the same 
samples were occasionally detected in KITLG and PAK7 sequences, adding additional 
support for the TES and NEFM results. Methylated reads were detected in 39% of the 
study population (11 cord blood samples had methylated TES and NEFM reads) with a low 
methylation level in mononuclear cells (TES methylation ranged from 0.09% to 12.6%; 
NEFM methylation ranged from 0.24% to 4%). Despite the attempts to maximise the 
enrichment of the ALL-like cells, the methylation level in the sorted subpopulations 
remained low (TES methylation ranged from 0.05% to 0.32%; NEFM methylation ranged 
from 0.06% to 13.11%). The markedly elevated TES methylation values of X9195 (31.7% 
and 55.6% for CD3+ T cells and CD3-CD19- lymphocytes, respectively) were excluded 
from the analysis. This is because of failure of replication compared to the majority of 
methylated TES reads in other cord blood samples and also because of the low NEFM 
methylation levels in this sample (0.32% and 0.06% for CD3+ T cells and CD3-CD19- 
lymphocytes, respectively). Different approaches were used to investigate the reason for 
the high TES methylation level in X9195 subpopulations and technical factors such as 
sample contamination cannot be completely excluded. 
The detection of methylated reads in TES, NEFM, KITLG and PAK7 in 39% of healthy 
newborns suggests the presence of a normal cell lineage that carries distinct DNA 
methylation features similar to acute lymphoblastic leukaemia. To my knowledge, this is 
the first study to suggest the presence of normal ALL-like cells based on the DNA 
methylation features of these cells. This discovery raises many questions about the origin 
of the ALL-like cells and their biological roles.  
8.3.1 Do methylated TES and NEFM reads represent “pre-leukaemic” cells? 
Could the cells containing TES and NEFM DNA methylation be the “pre-leukaemic” cells 
that were described in the literature and occasionally detected in normal cord blood 
samples (see Chapter 1 for details)? It is very unlikely that babies with methylated reads in 
our study had leukaemia. One can argue that these babies could have undetected or 
unreported leukaemia and to rule this possibility out, a review of the medical records for 
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those babies would be needed. However, approximately one of 3000 children gets 
leukaemia, representing a prevalence of 0.03% compared to the high prevalence (39%) in 
this project. In addition, there were methylated reads detected in healthy adult blood 
samples suggesting that the presence of methylated reads does not necessarily mean a 
leukaemic state.  
If the low methylation level in the healthy newborns did not represent leukaemia, what 
about the possibility for the presence of “pre-leukaemic” cells? It is a very unlikely 
possibility. A few studies have detected “pre-leukaemic” cells containing ETV6-RUNX1 
translocation at low level in 0.01% to 1% normal newborns (Brown, 2011). If the 
methylated TES and NEFM reads reflected the presence of these “pre-leukaemic” cells, 
then the prevalence in our study population was at least 39 times higher than the reported 
rate in the literature. In addition, the number of detected “pre-leukaemic” cells in cord 
blood samples or B-ALL cases ranged from 0.00001% to 0.1% (i.e., from 1:1000 to 1:10 
million cells) (Hjalgrim et al., 2002; Mori et al., 2002). Despite the variation in the 
reported numbers of “pre-leukaemic” cells, few of our samples had methylated reads that 
lie within the reported range (three samples had TES methylation level of less than 0.1%). 
The majority of the samples in our study had higher methylation level with a median 
methylation of 0.4% and 0.9% for TES and NEFM, respectively. It can be argued that the 
mononuclear cells enrich for lymphocytes and hence it is excepted that this blood fraction 
will contain higher number of “pre-leukaemic” cells compared to values reported for 
whole blood. Considering that lymphocytes represent about 60% of the whole cord blood 
cells, 0.1% of pre-leukaemic cells in the whole blood could represent about 0.6% of pure 
lymphocytes as the highest possible estimation for the number of “pre-leukaemic” cells 
(i.e., 6:1000 cells). Consequently, it is possible, but very unlikely, that the methylated 
reads of our samples represent the “pre-leukaemic” cells because of the maximum 
methylation level for our samples reached 13% and 4% for TES and NEFM, respectively. 
So far, we do not know if “pre-leukaemic” cells contain methylated TES and NEFM 
epialleles, but we can speculate that “pre-leukaemic” cells possibly carry an ALL-like 
epigenotype and have been sorted, non-specifically, with any of the cord blood 
subpopulations during the enrichment process. As a result, it is expected to identify “pre-
leukaemic” cells in at most 1% of the sequenced neonatal samples (i.e., one of the cord 
blood samples may have “pre-leukaemic” cells) and it is very unlikely to detect “pre-
leukaemic” cells in all of our methylated samples. Based on the above arguments, the 
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methylated reads in our healthy neonatal population are very unlikely to be from “pre-
leukaemic” cells in our healthy newborns.  
8.3.2 Timing of ALL development 
Timing of origin of ALL may provide some clues about the origin of “pre-leukaemic” 
cells. How and when do “pre-leukaemic” cells develop? Fasching (2001) reported that 
“pre-leukaemic” cells arise from B cells that lack “N” nucleotides addition during IGH 
rearrangement. The lack of “N” nucleotide addition was attributed to the lack of TdT 
enzyme, which is a feature of fetal liver B cells at very early gestation (see section 1.4.1 
for more details on TdT role in IGH rearrangement. Briefly, TdT was involved in the 
addition of N nucleotides to the opened DNA strands within the recombinational signal 
sequence (RSS) between the IGH segments). Fasching therefore argued that the “pre-
leukaemic” cells originated during the first weeks of B lymphopoiesis in fetal liver. Based 
on the timing of Fasching’s model, it can be argued that ALL cells arise from only fetal 
stem cells very early in development. These “pre-leukaemic” cells exist in parallel along 
with other fetal cell lineages and can be detected at birth (Figure 8.2).  
 
Figure 8.2. A diagram showing that “pre-leukaemic” cells (derived from a “pre-
leukaemic clone”) can arise from an ALL-like fetal stem cell. Based on Fasching’s 
(2001) model, “pre-leukaemic” clone develop during the first weeks of B lymphopoiesis 
in fetal liver. “Pre-leukaemic” cells then exist in parallel with other fetal cell lineages 




8.3.3 Do methylated TES and NEFM epialleles indicate the presence of fetal 
B-1 cells? 
The existence and identity of a specific fetal cell lineage that gives rise to ALL has been 
the subject of recent literature. One potential candidate is the B-1 B lymphocyte that has 
been discussed and debated heavily in the literature (see Chapter 1 for more details). 
Interestingly, Bueno and colleagues (2016) investigated the number of B-1 B cells at early 
human development and found the highest frequency of B-1 B cells are in embryos at 10 – 
11 weeks, representing 6.1% of B cells (CD20+CD19+CD3-) in fetal liver. The proportion 
of B-1 cells declines to 2.1% and 1.9% in the fetal liver at mid-gestation (20 – 21 weeks) 
and in cord blood, respectively. The reported proportion of B-1 B cells in cord blood 
samples varies widely. Griffin et al. (2011b) reported B-1 cells to be 6% of the B cells 
while others reported about 2% (Descatoire et al., 2011; Perez-Andres et al., 2011). Based 
on our sorted cell subsets, methylated TES reads were not detected in the CD19+ B cells 
suggesting that the fetal ALL-like cells are not always from the B cell lineage. In addition, 
the B-1 B cells that were described in the literature are mature cells circulating in the 
developing embryos. Consequently, we could hypothesise that the ALL-like fetal cells that 
harbour TES and NEFM methylation are the progenitors of the B-1 cells. Progenitors of the 
B-1 cells do not have a known surface markers phenotype. However, methylated NEFM 
reads were detected in B cells (CD19+) and methylated TES reads were detected in B cells 
(CD19+) in one of the premature babies indicating, at earlier development stages, 
methylated B cells can be detected. In addition, few CD19+ sorted B cells samples were 
successfully amplified by TES PCR and hence more samples are needed to fully evaluate 
TES methylation in neonatal B cells. As a result, B-1 B cells or their progenitors are still 
considered potential candidates for the ALL-like fetal B cells that were detected in healthy 
newborns. 
There is agreement in the literature about the fetal origin of B-1 B cells, which can be 
detected at early human embryonic development (about 10 week-gestation, see above). 
The identification of methylated TES epialleles in B cells of a four-week-old, 28 week-
gestation baby highly suggests the presence of an ALL-like fetal B cell lineage. However, 
methylated TES epialleles were not detected in our fetal liver samples (from 6 to 11 weeks’ 
gestation). In addition, fetal liver sequencing results did not show methylated epialleles for 
any of the ALL-methylated gene panel. As a result, one could argue that ALL-like fetal 
cells, including fetal B cell lineage, are undetectable or non-existent at early development. 
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The inability to detect a methylation signal in fetal liver samples does not indicate the non-
existence of ALL-like fetal cells, but instead it might show the limits of the detection 
methods. This is because the methylation signal was most likely diluted out by fetal tissues 
and hepatic cells. The number of fetal hematopoietic cells in the fetal liver slides was 
expected to be about 10% to 20% of hepatic liver tissue. Some of the fetal samples 
contained multiple fetal tissues, reducing fetal liver cells to about 10% of the entire 
sample. Consequently, fetal haematopoietic stem cells were expected to be less than 0.01% 
in these heterogenous fetal tissue samples, and hence limiting our ability to detect the 
methylation signal (see section 6.4 for more details).  
8.3.4 ALL-like fetal cells from T or NK cell lineages 
Sequencing of sorted cell populations showed methylated TES and NEFM reads in T cells 
(CD3+) and non-T, non-B lymphocytes (CD3-CD19-). Based on these results, it is 
possible to hypothesise that the methylation signal could be coming from other lineages 
such as an ALL-like T cells or ALL-like NK cells. But, is there any information in the 
literature about these other lymphocyte lineages in the developing human embryo? 
Mold and colleagues (2010) identified CD3+CD4+CD45RA+CCR7+CD95-CD25- fetal 
naïve T cells in the mesenteric lymph nodes of 18 to 22-week gestation human fetuses. 
These fetal naïve T cells represented more than 15% of the total fetal CD4+ T cells. The 
identified fetal T cells maintain expression of FOXP3 and CD25 upon activation compared 
to transient expression in adult naïve T cells. Interestingly, they found that fetal naïve T 
cells have the potential to transform to T regulatory cells and subsequently can suppress 
proliferation and cytokine production of other immune cells. Principal component analysis 
of the expressed genes showed a difference between the fetal and adult sorted T cell 
subpopulations (both naïve and regulatory cells) (Mold et al., 2010).  
The reported naïve fetal T cells were found to arise from either the CD31+ thymic cells or 
CD31- peripheral cells (Hebel et al., 2014). The CD4+ subset of these fetal naïve T cells 
can then differentiate into different T helper subtypes (such as T helper 1, 2, 9 or 17) or 
effector T regulatory cells secondary to their response to various cytokines or antigens 
(Hebel et al., 2014). Hebel and colleagues (2014) found that the majority of fetal naïve T 
cells isolated from cord blood samples differentiate into T helper 2 cells expressing IL-4 
and GATA3 when stimulated with anti-CD3 and anti-CD28. In addition, they found about 
59% of the fetal CD4+ naïve unstimulated cells express IL-4 compared to 5.4% of the 
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unstimulated naïve adult cells. Differences were also seen with respect to the 8D4-8 
isoform of IL-4. They suggested that fetal naïve T cells differentiate to T helper 2 subtype 
faster than adult naïve T cells indicating their distinct biology from adult type (Hebel et al., 
2014). Based on these studies, it is possible to suggest that methylated TES and NEFM 
reads in our sorted CD3+ T cells were derived from a fetal ALL-like T cell lineage. 
Do Natural Killer (NK) cells also have a fetal cell lineage? Ivarsson and colleagues (2013) 
identified fetal CD7+CD3-CD14-CD19-CD34-CD56+ NK cells comprising 50% to 60% 
of the CD7+ cells in fetal liver, lung and spleen compared to about 20% of CD7+ cells in 
adult blood. Based on CD56 expression, the majority of NK cells in fetal liver and lymph 
nodes were less differentiated than the most differentiated NK cells in the fetal lung. In 
comparison, adult NK cells were found to be highly differentiated when compared to any 
of the fetal NK cells irrespective of their tissue localisation. The self-tolerance of NK cells 
was regulated by the inhibitory binding of killer-cell immunoglobulin-like receptors 
(KIRs) to HLA class I molecules. They found that the number of KIR+ NK cells from the 
fetal liver was similar to those in cord blood and their expression did not change with fetal 
development (15 – 22-week gestations). In comparison, the number of KIR+ NK cells was 
found to be higher in adult blood and in fetal lung than in fetal liver and cord blood 
(Ivarsson et al., 2013). These results suggest that the proliferation of these fetal KIR+ NK 
cells increase postnatally.  
Renoux and colleagues (2015) identified Lin-CD34+CD38+CD123-CD45RA+CD7+ 
CD10+CD127- NK progenitor that were restricted to the NK cell lineage and could be 
isolated from early human fetal liver (6-weeks’ gestation), fetal bone marrow (12-weeks’ 
gestation), cord blood and tonsils. The number of NK progenitors was about 0.12% of 
CD34+ cells in cord blood samples, which was similar to that in adult bone marrow 
(0.10%). Comparing Renoux’s and Ivarsson’s results regarding fetal NK cells in adults, it 
is possible to suggest that the circulating fetal KIR+ NK cells in adult peripheral blood 
have different proliferation kinetics than those in adult bone marrow and this was reflected 
in differences in the number of fetal NK cells in these two compartments (20% and 0.10% 
of the CD34+ cells in adult peripheral blood and bone marrow, respectively). NK cells 
were not specifically investigated in this project and hence it can be hypothesised that TES 
and NEFM methylation signals arise from a fetal NK cell lineage. The majority of our 
ALL-methylated genes, except for TES, had DNA methylation of less than 10% in adult 
blood samples (median methylation ranged between 0.3% to 18%), and this low 
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methylation level in our adult blood samples is closely similar to the reported 20% of fetal 
NK cells in adult peripheral blood samples (Ivarsson et al., 2013). Consequently, the low 
methylation level in adult blood samples could indicate the persistence of ALL-like fetal 
KIR+ NK cells in healthy adults. This is because the methylated reads in our adult blood 
samples potentially reflect the increased number of the KIR+ NK cells in the peripheral 
blood with age, in comparison to the lower numbers in fetal liver and cord blood samples.  
8.3.5 A proposed model for the presence of different ALL-like fetal cell 
lineages 
Based on the discussion above, methylated TES and NEFM epialleles were detected in B 
cells (CD19+) suggesting the presence of an ALL-like fetal B cell lineage, possibly a fetal 
B-1 cell lineage. In addition, fetal NK cells lack the expression of CD3+ and CD19+ 
surface markers suggesting that methylated TES and NEFM reads in the CD3-CD19- 
lymphocytes could be from fetal NK cell lineage. Methylated signals in the CD3+ T cell 
population suggest the presence of a committed ALL-like fetal T cell lineage, possibly 
fetal naïve T cells. As a result, it is plausible to construct a model based on methylated TES 
and NEFM epialleles (Figure 8.3). The model proposes the presence of B, T and NK fetal 
cell lineages that carry an ALL-like epigenotype and that each can be detected at birth. The 
common epigenotype suggests the common source of an ALL-like fetal stem cell that had 
differentiated early in gestation and was committed to different fetal cell lineages. The 
same fetal stem cell can transform to a pre-leukaemic clone at very early developmental 
stages. 
The literature describes Lin-Sca1+Kit- (LSK-) multipotent lymphoid-myeloid progenitors, 
that express FLT3 and IL-7R and that are distinctly different from the common lymphoid 
progenitors (Kumar et al., 2008). In the presence of myeloid colony stimulating factor (M-
CSF), the LSK- progenitors have the potential to differentiate into myeloid (e.g. 
monocytes) and lymphoid (i.e., B, T and NK) cell lineages (Kumar et al., 2008). Adolfsson 
and colleagues (2005) found that the committed FLT3+ LSK- progenitors lose their 
potential to differentiate to megakaryocytes and erythrocytes but retain their differentiation 
to lymphocytes and other myeloid cells, especially granulocytes and monocytes. They 
proposed that the FLT3+ LSK- cells differentiate into common lymphoid progenitor and 
common myeloid progenitors, which can then commit into their restricted cell lineages. 
Since methylated TES, NEFM and KITLG epialleles were detected in CD19- mononuclear 
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cells of two cord blood samples, it is possible that the methylation signal could be from an 
ALL-like fetal FLT3+ LSK- multipotent lymphoid-myeloid progenitor or from an ALL-
like fetal myeloid cell lineage (Figure 8.3).  
This model raises questions about the identity of the ALL-like fetal stem cell and methods 
for its identification. Recently, two studies have identified FEV and IL-7R surface markers 
for the identification of human fetal stem cells. The following discussion will focus on 
these two markers and evaluate their potential use for future experiments. 
 
Figure 8.3. A diagram showing a model for the development of fetal cell lineages with 
an ALL-like epigenotype. Fetal cell lineages develop during very early development 
from an ALL-like fetal stem cell that can also transform to a pre-leukaemic clone in few 
babies. 
 
8.3.6 FEV as a potential surface marker for the ALL-like fetal stem cell 
It can be hypothesised that the methylated sequence reads represent the presence of a 
unique ALL-like fetal stem cell that is capable of transformation to leukaemia. This 
hypothesis incorporates the potential features of the fetal cells and does not exclude the 
possibility of their regression or disappearance with development, which can be 
hypothesised to be their common fate. Recently, the identity of the fetal cell of origin for 
leukaemia has been a focus for a number of publications. In addition, the search for surface 
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markers, such as FEV and IL-7R, to characterise the fetal stem cells was the subject of a 
few recent studies. 
What do we know about FEV expression in fetal stem cells? Liu and colleagues (2017) 
found high FEV expression in zebrafish embryos at 10-somite stage and the expression 
continued in the aorta-gonad-mesonephros (the earliest site of haematopoiesis). In 
addition, they found FEV expression in the Lin- haematopoietic cells at 14.5-day post-
fertilization in murine fetal liver and the expression declined gradually after birth. 
Interestingly, FEV expression was also detected in human CD34+ cells sorted from fetal 
liver and cord blood samples; however, FEV expression was not detected in bone marrow 
samples. They knocked down FEV by treating the Lin-CD34+CD38- cell sorted 
subpopulation from human cord blood samples with siRNA and found that the cells failed 
to proliferate in the colony formation assay. They also engrafted the FEV knockdown cells 
into NOD/SCID mice and they found, at 12 weeks post-transplantation, the number of 
CD34+ and CD38- cells were significantly reduced by 14-fold compared to the control 
cells. They speculated that FEV expression has a self-renewal regulatory role in fetal 
haematopoietic cells before birth.  
Based on Liu’s results, do our TES and NEFM methylated cells correspond to these fetal 
stem cells that express FEV? It is possible that FEV+ fetal stem cells could harbour TES 
and NEFM methylation. However, Liu’s study lacks details about the proportion of FEV+ 
cells in the cord blood samples which limits our ability to compare our results to theirs. Liu 
and colleagues found that 96% and 97% of infantile (KMT2A rearrangement) and 
childhood leukaemia cases (53 and 193 cases, respectively) had high FEV expression 
similar to the expression level of cord blood samples. This suggests that leukaemic cells 
with high FEV expression were derived from a fetal FEV+ stem cell, indicating the 
prenatal origin of the disease. They also found consistently high FEV expression in acute 
lymphoblastic leukaemia samples suggesting its potential use as a biomarker for ALL.  
8.3.7 IL-7R is another potential surface marker for the ALL-like fetal stem cell 
As discussed previously (see Chapter 1), B-1 progenitors have a high potential to 
transform into B-ALL in mice (Gough et al., 2017; Montecino-Rodriguez et al., 2014). 
These B-1 progenitors were characterised by their expression of Lin-CD93+CD45Rlow/-
CD19+ surface markers in day-11 fetal liver (Montecino-Rodriguez et al., 2006). To 
understand the biology of B-1 progenitors, Kristiansen and colleagues (2016) used a 
 
 248 
unique barcoding system to label Lin-Sca1+cKit+ haematopoietic stem cells (LSK HSCs) 
extracted from mice fetal liver (E14.5 stage) that were engrafted into irradiated recipient 
mouse. The lentiviral barcoding library contains a GFP vector for FACS enrichment 
experiments. To retrieve the barcodes from the differentiated cells, GFP+ cells were sorted 
to CD19+B220low/-CD5+CD11blow/+CD43+CD23- B-1a cells from peritoneal cavity, 
CD19+B220+CD93-CD1d-CD23+CD43-CD5- B-2 cells from splenic follicles and B220-
CD3-Ter119-CD71-F4/80-Gr1+CD11b+ granulocytes from spleen. Genomic DNA was then 
extracted from the collected cells and PCR amplified for targeted deep sequencing to 
analyse barcode sequences. Interestingly, they found 108 common unique barcodes shared 
between B-1a and B-2 cells, 27 of which were also found to be shared with granulocyte 
population indicating that B-1a, B-2 and granulocytes developed from a common FLT3+ 
LSK- multipotent lymphoid-myeloid progenitor. In addition, they speculated that FLT3+ 
LSK- cells gradually decline with development from 2 days to 16-20 weeks post-
transplantation. Cells with the 27 unique barcodes were found in 52% of B-1a cells, 79% 
of B-2 cells and 85% of granulocytes indicating the high proliferation feature of the 
FLT3+ LSK- lymphoid-myeloid progenitor (Kristiansen et al., 2016).  
In line with the results from Kristiansen et al., Boiers and colleagues (2018) hypothesised 
that these B-1a/B-2/granulocyte FLT3+ LSK- progenitors (also called LMPPs) express IL-
7R and can be detected in the first trimester of human embryos. They detected a small 
population (<0.5%) of CD45+CD34+CD19+ cells at day 41 post-fertilisation in three of 
four fetal liver samples demonstrating the early development of fetal B cells. At about day 
50 post-fertilization, they detected about 4% of CD45+CD19+CD34- pre-B cells, the 
majority of which expressed IL-7R (60% to 88% of the cells). In addition, the majority of 
pro-B cells in fetal liver expressed IL-7R. The expression of IL-7R in these cells was 
consistent to the expression of other fetal pro-B markers, such as KIT and LIN28B. 
Interestingly, the majority of the immature CD19+ B cells in human fetal liver were found 
to express IL-7R, suggesting that IL-7R is expressed in a fetal B cell progenitor. They 
found IL-7R expression in primitive LIN- cells which also express KIT, CD45RA and 
CD38. These LIN-CD19-CD34+CD38+CD45RA+IL-7R+KIT+ fetal liver cells (hereafter 
referred to “IL-7R progenitors”) declined with development from day 41 post-fertilisation 
to birth by 7 to 10-fold. When IL-7R progenitors were cultured in-vitro, IL-7R progenitors 
differentiated to CD19+ B cells and to monocytes (a myeloid cell lineage). Interestingly, 
the majority of IL-7R progenitors in fetal liver expressed myeloid genes at day 41 post-
 
 249 
fertilisation (high expression of CSF1R and LIN28B) and then by about day 50, lymphoid 
and B lineage gene expression started to emerge. The combined myeloid/lymphoid 
expression signature was found to be restricted to about day 50 post-fertilisation and these 
cells did not exist in other developmental stages. In comparison, the majority of IL-7R 
progenitors in cord blood and adult bone marrow samples showed a lymphoid gene 
expression signature. 
Based on Kristiansen’s and Boiers’ results, could the methylated TES and NEFM reads 
reflect FLT3+LSK-IL-7R+ B-1a/B-2/granulocyte progenitors? IL-7R progenitors represent 
about 2.5% and 1% of the total CD45+CD34+ cells in 8-week gestation fetal liver and in 
cord blood samples, respectively (Boiers et al., 2018). As discussed above, these cells 
express predominantly lymphoid genes after day 50 post-fertilization (i.e., after 7-weeks 
gestation). As a result, the detection of IL-7R progenitors, which were estimated to be 
2.5% of CD45+CD34+ sorted cells in 8-week gestation fetal liver, can be beyond the 
detection limits of our sequencing technology. As described previously, some of our fetal 
samples contained about 10% of fetal liver tissue and the haematopoietic stem cells 
represent about 10% to 20% of fetal liver cells. Failure to detect TES and NEFM 
methylated reads in fetal liver samples might be attributed to the dilution of IL-7R 
progenitors in other fetal cells and tissues. 
Is it possible to detect IL-7R progenitors in cord blood samples? This is a possibility and 
can be explained by the following: First, the analysed cord blood samples in this project 
contained cells from mononuclear cells, which enhanced the representation of 
lymphocytes, and subsequently increased the detection rate of the IL-7R progenitors in 
cord blood samples. Second, IL-7R progenitors do not express CD19 antigens which can 
explain the lack of methylated TES epialleles in CD19+ sorted B cells. Since the majority 
of methylated TES epialleles were detected in T cells and CD3-CD19- lymphocytes, it can 
be speculated that IL-7R progenitors were sorted into these two subpopulations. However, 
IL-7R progenitors express CD34 and methylated TES reads were not detected in CD34+ 
sorted cells. Unfortunately, TES methylation sequencing results of CD34+ sorted cells 
were suboptimal because of low cell numbers, limiting our ability to make a clear 
conclusion about TES DNA methylation in this subpopulation (six out of 20 samples had 
TES sequencing results for CD34+ cells, see Chapter 7). As a result, we can hypothesise 
that methylated TES and NEFM reads are methylation signals from IL-7R progenitors. To 
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test this hypothesis, cell sorting experiments specifically enriching for IL-7R progenitors 
could be used to evaluate the methylation of leukaemia biomarker genes. 
Does the low methylation level in adult blood samples represent ALL-like fetal cells? As 
discussed in Chapter 5, the ALL-methylated gene panel show a low level of methylation in 
the majority of adult blood samples with a median methylation ranging between 0% to 
18%. Interestingly, TES was the only unmethylated gene in adult blood samples, in 
contrast to MARCH11 and SYBU that were methylated. We hypothesised in Chapter 5 that 
the low methylation in adult blood was related to aging, mostly due to the acquisition of 
DNA methylation by the immune cells. As discussed above, Boiers et al., (2018) found a 
small proportion of IL-7R progenitors in adult bone marrow samples indicating the 
presence of these progenitors in adulthood. Based on these findings, it is plausible that the 
low methylation level in adult blood samples may reflects weak signals from the 
circulating ALL-like IL-7R progenitors. To explore this further, FACS sorting experiments 
could be conducted based on IL-7R expression to evaluate TES and NEFM methylation in 
the ALL-like fetal cells. 
8.4 Limitations 
8.4.1 Samples 
Since ALL-like methylated sequences were detected only in a minority of samples, it was 
difficult to pre-select positive samples for cell sorting. In addition, some of the cord blood 
samples had small blood volumes (about 2 mL) that affected the number of cell sorted 
subpopulations. As a result, three cord blood samples failed the sorting experiments (blood 
volumes were 1.5, 2.5 and 3 mL).  
FACS sorted fetal liver samples would be highly valuable for this project. Unfortunately, 
some of the fetal liver samples used in this project contained a heterogenous mixture of 
fetal tissues, diluting out the methylation signal from fetal haematopoietic cells. Ideal 
sorting experiments would require the use of fresh fetal liver samples. 
8.4.2 Sequencing assay 
There is a possibility that some of our sequence reads for each amplified gene may have 
been derived from technical variables, such as non-specific PCR amplification bias. The 
use of unique sequence barcodes for each bisulfite-converted DNA can minimise the 
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random effects of technical variables in our sequencing assays. Unique sequence barcodes 
can be used to identify PCR amplification as each unique barcode represents a single DNA 
template (see section 8.5.3 for more details). 
8.5 Future directions 
This project raised many potential ideas for more comprehensive research in the future. 
These include detailed investigation of the cells that have TES and NEFM methylation to 
identify their phenotypic features, search for other potential surface markers to maximise 
the detection of the ALL-like fetal cells and the addition of features to upgrade the current 
ABC.RAP package.  
8.5.1 Characterising the fetal ALL-like cells and understanding their biology. 
One of the remarkable achievements of this project is the discovery of cells with an ALL-
like methylation pattern in healthy newborns. These cells are unlikely to be “pre-leukaemic 
clones” but rather represent unique normal fetal cell lineages. I attempted to increase the 
enrichment of these cells using FACS sorting; however, the cell sorted subpopulations did 
not enrich for TES and NEFM methylation.  
To purify the ALL-like cells, a new FACS sorting strategy could be designed to 
incorporate the candidate cell population that were described above (Figure 8.4). 
Specifically, IL-7R+ cells are strong candidates and a future strategy could explore the 
utility of IL-7R expression to detect cells with an ALL-like methylation pattern. Since TES 
is methylated in the ALL-like cells, enriching for TES negative cells will maximise the 
chances to purify the ALL-like cells. TES positive cells will also be sorted for comparisons 
and as intrinsic controls. As discussed above, B-1 cells and IL-7R progenitors are potential 
candidate cells for our ALL-like TES- and NEFM-methylated cells. Consequently, the TES 
negative and positive cells would also be analysed for IL-7R expression and for the B-1 
surface markers (Figure 8.4). The following plan has been designed to test cord and adult 




Figure 8.4. Sorting plan to enrich for ALL-like TES- expression cells. TES positive and 
negative cells will be sorted and the cells will also be analysed for the expression of IL-
7R and the expression of B-1 surface markers.  
 
Once at least 80% of TES methylation is detected in the purified ALL-like cells, then 
further detailed studies could be carried out, such as whole genome bisulfite-sequencing 
and gene expression analysis. In addition, it will be of interest to study these cells further 
by detailed phenotypic flow cytometry experiments to characterise their surface marker 
expression. Furthermore, other experiments like studying the growth kinetics of these cells 
in different culture assays and investigating their potential to develop into leukaemia can 
be performed. Future experiments may also include exposing the ALL-like cells to a panel 
of drugs that can be used to eradicate these cells from high risk children before the ALL 
development. 
8.5.2 Identifying a differentially expressed surface marker for the ALL-like 
cells 
The above plan to enrich for the ALL-like fetal cells may have limitations. This is because 
the enrichment depends on the specificity of the TES antibody. Based on previous 
experience with anti-CTGF antibodies, proper evaluation and validation of antibodies is 
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crucially important (Alsaleh, 2014). As a result, publicly available transcriptome datasets 
(gene expression microarray or RNA-seq datasets) can be analysed to search for 
differentially expressed gene in leukaemia that can be used to enrich for an ALL-like fetal 
cell population. The ideal gene would be expressed on the surface of the cells with a high 
antigen density and have a commercially available labelled antibody. The analysis of 
transcriptomic data would involve a thorough search through the data depository for ALL 
datasets. Then, data analysis would be used to search for an ALL-expressed gene panel to 
use for sorting experiments (i.e., a similar approach to the ALL-methylated genes). Some 
of the 450k array cohorts contain gene microarray data which can be useful to perform a 
methylation-expression correlation analysis (see Chapter 4). 
8.5.3 Development of a barcoded sequencing method 
As mentioned above, the use of barcodes in the sequencing assay can minimise technical 
variation and enhance specificity. We can construct a barcoded sequencing method based 
on the PBAT principal (Miura et al., 2012). Briefly, gene-specific primers can be designed 
with unique barcodes and Illumina tag sequences added at their tails. Reverse primers can 
be customised to have biotin molecules (Figure 8.5). The method involves three 
amplification steps. The first amplification was to synthesise targeted biotinylated DNA 
fragments from the bisulfite-converted DNA using the biotinylated gene-specific reverse 
primers. This is a single cycle amplification step based on annealing and extension of the 
reverse primers using KAPA HiFi HotStart Uracil+ ReadyMix kit. The annealing 
temperatures can be optimised for each amplified gene. Then, the amplified biotinylated 
DNA fragments can be purified using AMPure XP beads for the removal of excess primers 
and then the biotinylated DNA can be captured using streptavidin beads. The second 
amplification step is a single cycle amplification and is based on the use of gene-specific 
forward primers to specifically define the target region for sequencing. The amplified 
second strand contains unique barcodes and Illumina tag sequences at both ends. Finally, 
the third amplification step is based on the PCR amplification of the second strand DNA 
fragment using Illumina index primers. PCR products can then be checked on the agarose 
gel to confirm the successful amplification of target regions. PCR products can then be 
pooled, purified, and quantified prior to MiSeq sequencing as described previously (see 








Figure 8.5. A proposed method for the addition of unique barcode sequences to the 
amplified bisulfite-converted DNA. The method was based on PBAT principles and 




8.5.4 Upgrading ABC.RAP R package 
ABC.RAP analysis was used on several projects, for which I performed 450k array 
methylation data analysis. These projects include identifying biomarkers for pre-
ecclampsia; identifying methylation biomarkers to detect tumour circulating DNA in 
plasma cell myeloma; identifying densely methylated genes in HL60 cell line for targeted 
methylation sequencing assay; analysing RASSF1 and PCDHGA12 methylation in 
decitabine treated leukaemia cell lines; profiling TNFRSF12A methylation in breast 
cancer; and global methylation analysis and TRIM28 methylation in Wilms tumour and 
hepatocellular carcinoma. The analysis involved searching for 450k array methylation 
datasets, normalising the beta values and then using ABC.RAP analysis.  
The application of ABC.RAP on other projects demonstrated the role of the tool in 
utilising the publicly available data. However, ABC.RAP requires more features to 
enhance its utility. As an example, ABC.RAP cannot provide a list of densely methylated 
genes in a single group of samples as the package was designed to compare two groups. In 
addition, two groups of samples are needed to profile any gene in the dataset and it is not 
possible to study a single gene without the comparison process. As a result, a number of 
features are planned such as identification of densely methylated genes in any sample or 
group of samples and profiling any gene without the need to compare cases to controls. In 
addition, additional features are planned to maximise the utility of ABC.RAP to analyse 












This project utilised the publicly available human 450k array datasets to search for genes 
that could be used as methylation biomarkers. The exploration and data analysis process 
lead to the development of a 450k array ABC.RAP analysis tool and subsequently 
identified a list of ALL-methylated genes that were consistently methylated in leukaemia 
samples. A panel of 11 genes were selected to be used for a targeted DNA methylation 
sequencing assay and were validated by sequencing blood samples from healthy adults and 
neonates, and different B and T leukaemia xenografts and cell lines samples. The 
sequencing analysis showed low level methylation in adult blood samples and dense DNA 
methylation in leukaemia cases. The ALL-methylated gene panel was then used to search 
for ALL-like cells in healthy newborns. About 39% of the study population showed low 
level methylation in TES, NEFM, PAK7 or KITLG. The discovery of TES and NEFM DNA 
methylation in newborns is remarkable, indicating that cells with an ALL-like methylation 
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Appendix 2 ABC.RAP manual 
This manual was published on the CRAN website and can be accessed on the following 
link: https://cran.r-project.org/web/packages/ABC.RAP/vignettes/ABC.RAP.html  
Array Based CpG Region Analysis Package (ABC.RAP) - 
manual 
Abdulmonem A. Alsaleh, Robert J. Weeks, Ian M. Morison. Department of Pathology, 
Dunedin School of Medicine, University of Otago, Dunedin, New Zealand 
2018-06-14 
 
ABC-RAP package was developed to analyse human 450k DNA methylation array data 
and to identify candidate genes that have significant differences in DNA methylation 
between cases and controls. The following example analysis is based on a small sample 
dataset "test_data" (included) containing 10,000 probes for 2 B-ALL cases and 2 controls 
from Busche et al (2013). 
Busche S, Ge B, Vidal R, etc. Integration of high-resolution methylome and transcriptome 
analyses to dissect epigenomic changes in childhood acute lymphoblastic leukaemia. 
Cancer Research 2013; 73(14); 4323-4336. 







Summary of the workflow 
The package offers a choice of two workflows: 
1. Step by step as follows 
2. Using a single script (see "using one script" section) 




Filtering the nonspecific probes: 
test_data_filtered <- filter_data(test_data) 
Annotation based on "UCSC platform": 
test_data_annotated <- annotate_data(test_data_filtered) 
 
Browsing the data 
This function provides a general overview for the DNA methylation between cases and 
controls. It produces 4 plots: the upper 2 plots show DNA methylation (distribution) for 
cases (left) and controls (right). The left bottom plot compares the DNA methylation 
between cases and controls, and the right bottom plot represents the difference in DNA 
methylation between cases and controls (cases minus controls). Also, summary statistics 
for the difference in mean DNA methylation between cases and controls is produced. 
 
Function arguments: 
x = the filtered 450k probes from filter_data() function. In this example, it is 
"test_data_filtered". 
cases_column_1 = the first column (column number) for cases in the filtered dataset. In 
this example, it is column 1. 
cases_column_n = the last column (column number) for cases in the filtered dataset. In this 
example, it is column 2. 
controls_column_1 = the first column (column number) for controls in the filtered dataset. 
In this example, it is column 3. 
controls_column_n = the last column (column number) for controls in the filtered dataset. 
In this example, it is column 4. 




##      Min.   1st Qu.    Median      Mean   3rd Qu.      Max.  
## -0.881051 -0.171903 -0.038127 -0.041154  0.004206  0.774296 
 
Applying t-test 
This function applies a "two.sided", unequal variance t-test analysis, then selects p-values 
that are less than or equal to the cutoff value entered. For this example, a cutoff value of 
1e-3 is used: 
test_data_ttest <- ttest_data(test_data_filtered, 1, 2, 3, 4, 1e-3) 
Checking number of rows from t-test output: 
nrow(test_data_ttest) 
## [1] 156 
 
Delta beta analysis 
This function calculates the difference between the beta values of cases and controls. It 
requires the minimum desired difference in proportion of DNA methylation for cases 
minus controls (delta_meth) and for controls minus cases (delta_unmeth). In this example, 
delta_meth is 0.5 and delta_unmeth is -0.5 which are based on the values from summary 
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statistics from plot_data() function. Also it provides the option to specify probes where the 
average beta value of the cases or controls is greater than a cutoff value (e.g. 0.94) or less 
than a cutoff value (e.g. 0.06). 
test_delta_beta <- delta_beta_data(test_data_filtered, 1, 2, 3, 4, 0.5, -0.5, 0.94, 0.06) 
Checking the number of rows from delta beta analysis: 
nrow(test_delta_beta) 
## [1] 187 
 
Overlapping t-test and delta beta outputs 
The following function overlaps the results of the previous 2 analyses: 
test_overlapped_data <- overlap_data(test_data_ttest, test_delta_beta) 
Checking the number of rows (CpG sites) that are overlapping between the two analyses: 
nrow(test_overlapped_data) 
## [1] 26 
 
Identifying genes for which multiple CpG sites show significant methylation 
differences: 
test_CpG_hits <- CpG_hits(test_overlapped_data) 
Gene names and their number of significantly different CpG sites: 
test_CpG_hits 
##         Var1 Freq 
## 5160   DACH2    2 
## 10191 KLHL34    2 






Investigating candidate genes: 
"plot_gene" function generates four plots for any investigated gene: plot 1 (top left) shows 
the difference in beta values between cases and controls for each probe; plot 2 (top right) 
shows the mean methylation level for cases (red circles) and controls (blue triangles); and 
plots 3 and 4 (bottom plots) show the distribution of DNA methylation for each probe, for 
cases and controls, respectively. Also, an annotation table for all probes arranged from 5' 
to 3' is generated with the following columns: probe names, gene name, distance from 
transcription start site (TSS), mean methylation for cases, mean methylation for controls, 
delta beta (cases minus controls), and t-test p.value. KLHL34 is used as an example: 
 
Function arguments: 
x = the filtered and annotated 450k probes. In this example, it is "test_data_annotated" 
b = gene name between quotation marks. In this example, "KLHL34" is used. 
KLHL34 <- plot_gene(test_data_annotated, "KLHL34", 1, 2, 3, 4) 
 
##              Gene Chr      Distance Relation_to_CGI cases_mean 
## cg15383633 KLHL34   X       1stExon          Island  0.5987974 
## cg10607675 KLHL34   X       1stExon          Island  0.3515215 
## cg01640808 KLHL34   X       1stExon          Island  0.5543636 
## cg01563671 KLHL34   X       1stExon          Island  0.6671249 
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## cg04488527 KLHL34   X       1stExon          Island  0.5962242 
## cg02812399 KLHL34   X 5'UTR;1stExon          Island  0.5318288 
## cg14232291 KLHL34   X        TSS200          Island  0.6795550 
## cg01891172 KLHL34   X        TSS200          Island  0.6641148 
## cg01828474 KLHL34   X        TSS200          Island  0.7895418 
## cg20312916 KLHL34   X        TSS200          Island  0.6329774 
## cg12423482 KLHL34   X       TSS1500          Island  0.5615458 
## cg06775759 KLHL34   X       TSS1500          Island  0.6194449 
## cg21655480 KLHL34   X       TSS1500          Island  0.6740254 
##            controls_mean delta_beta ttest_p.value 
## cg15383633    0.34515336  0.2536440  0.1789289595 
## cg10607675    0.20330812  0.1482134  0.0828907511 
## cg01640808    0.27025886  0.2841047  0.0220891395 
## cg01563671    0.52643590  0.1406890  0.0085029358 
## cg04488527    0.40282047  0.1934037  0.0560646542 
## cg02812399    0.32363093  0.2081978  0.2553849825 
## cg14232291    0.15033859  0.5292164  0.0008604134 
## cg01891172    0.03948140  0.6246334  0.0047339375 
## cg01828474    0.02328138  0.7662605  0.0006825483 
## cg20312916    0.02726248  0.6057149  0.0009448970 
## cg12423482    0.12302873  0.4385171  0.0825854228 
## cg06775759    0.11546027  0.5039846  0.0016310962 
## cg21655480    0.16096001  0.5130654  0.0152313076 
 
Using one script: 
Here is one script that applies all the previous scripts and produce plots for candidate genes 
automatically. The function exports two files onto the current working directory: 1. 
"process.ABC.RAP.plots.pdf" containing plots for all the candidate genes, and 2. 
"process.ABC.RAP.tables.txt" containing the annotation tables for the candidate genes. 
Function arguments on the following order: 
x = The normalised beta values in a data matrix format, where conditions are arranged in 
columns and cg probes are arranged in rows. In this example, it is "test_data". 
cases_column_1 = the first column (column number) for cases in the filtered dataset. In 
this example, it is column 1. 
cases_column_n = the last column (column number) for cases in the filtered dataset. In this 
example, it is column 2. 
controls_column_1 = the first column (column number) for controls in the filtered dataset. 
In this example, it is column 3. 
controls_column_n = the last column (column number) for controls in the filtered dataset. 
In this example, it is column 4. 
ttest_cutoff = the cutoff level to filter insignificant p-values. In this example, a cutoff value 
of 1e-3 is used. 
 
 287 
meth_cutoff = the cutoff level for the methylation difference between cases and controls 
(cases minus controls). In this example, a cutoff value of 0.5 is used. 
unmeth_cutoff = the cutoff level for the methylation difference between controls and cases 
(cases minus controls), consequently it is a negative value. In this example, a cutoff value 
of -0.5 is used. 
high_meth = the upper margin for the desired highly methylated probes. In this example, a 
value of 0.94 is used. 
low_meth = the lower margin for the desired highly unmethylated probes. In this example, 
a value of 0.06 is used. 
























Appendix 3 Profiling DNA methylation for a list of differentially 
methylated genes in paediatric B and T cell leukaemias 
The following section contains methylation features of the 36 ALL-methylated genes that 
have consistent DNA methylation in at least three leukaemia datasets (see section 4.6 and 
Table 4.3). In this section, methylation features of the ALL-methylated genes were 
extracted from Busche’s (B-ALL) and Borssén’s (T-ALL) human DNA methylation 450k 
array dataset to evaluate the distribution of DNA methylation in leukaemia cases and 




##              Gene Chr      Distance Relation_to_CGI cases_mean 
## cg03829734 Mar-11   5          Body            <NA>  0.6558236 
## cg11584519 Mar-11   5          Body         N_Shelf  0.5910441 
## cg03477332 Mar-11   5          Body         N_Shore  0.4105857 
## cg17507952 Mar-11   5          Body         N_Shore  0.5273092 
## cg06782035 Mar-11   5          Body          Island  0.6011379 
## cg03705912 Mar-11   5       1stExon          Island  0.6204744 
## cg23479922 Mar-11   5       1stExon          Island  0.6241594 
## cg09017434 Mar-11   5       1stExon          Island  0.5661974 
## cg15015920 Mar-11   5 1stExon;5'UTR          Island  0.5064650 
## cg25092681 Mar-11   5        TSS200          Island  0.4734222 
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## cg00339556 Mar-11   5        TSS200          Island  0.5524020 
## cg01791874 Mar-11   5        TSS200          Island  0.5408633 
## cg17030173 Mar-11   5        TSS200          Island  0.5790099 
## cg17712694 Mar-11   5        TSS200          Island  0.5875042 
## cg16150752 Mar-11   5        TSS200          Island  0.5952839 
## cg21901718 Mar-11   5        TSS200          Island  0.5225815 
## cg18325622 Mar-11   5       TSS1500          Island  0.5216400 
## cg23065934 Mar-11   5       TSS1500          Island  0.5854932 
## cg11452391 Mar-11   5       TSS1500          Island  0.4591654 
## cg12456714 Mar-11   5       TSS1500          Island  0.5281783 
## cg16182986 Mar-11   5       TSS1500          Island  0.4964343 
## cg21582253 Mar-11   5       TSS1500         S_Shore  0.6200630 
##            controls_mean   delta_beta ttest_p.value 
## cg03829734    0.79011816 -0.134294608  1.677339e-11 
## cg11584519    0.73891970 -0.147875650  4.491824e-11 
## cg03477332    0.41539240 -0.004806749  8.433956e-01 
## cg17507952    0.20985680  0.317452444  9.805520e-29 
## cg06782035    0.06474386  0.536394012  1.737044e-36 
## cg03705912    0.16526935  0.455205061  5.604057e-41 
## cg23479922    0.05070440  0.573454990  2.944003e-58 
## cg09017434    0.05789438  0.508303028  1.129199e-47 
## cg15015920    0.06679511  0.439669850  9.607115e-26 
## cg25092681    0.04392753  0.429494648  1.144188e-21 
## cg00339556    0.03079502  0.521606948  5.380179e-27 
## cg01791874    0.04245148  0.498411793  6.580556e-27 
## cg17030173    0.06630553  0.512704377  1.231339e-27 
## cg17712694    0.04044403  0.547060162  4.623866e-27 
## cg16150752    0.03143170  0.563852217  1.166470e-27 
## cg21901718    0.02755736  0.495024155  3.256540e-23 
## cg18325622    0.06051364  0.461126330  1.334624e-28 
## cg23065934    0.04158348  0.543909756  1.408888e-31 
## cg11452391    0.03873924  0.420426169  1.492181e-26 
## cg12456714    0.07205803  0.456120303  3.826950e-25 
## cg16182986    0.17588343  0.320550860  9.948457e-24 





##              Gene Chr      Distance Relation_to_CGI cases_mean 
## cg03829734 Mar-11   5          Body            <NA>  0.8992635 
## cg11584519 Mar-11   5          Body         N_Shelf  0.8002830 
## cg03477332 Mar-11   5          Body         N_Shore  0.5288176 
## cg17507952 Mar-11   5          Body         N_Shore  0.6911215 
## cg06782035 Mar-11   5          Body          Island  0.6893817 
## cg03705912 Mar-11   5       1stExon          Island  0.6839878 
## cg23479922 Mar-11   5       1stExon          Island  0.6803142 
## cg09017434 Mar-11   5       1stExon          Island  0.6339988 
## cg15015920 Mar-11   5 1stExon;5'UTR          Island  0.5638591 
## cg25092681 Mar-11   5        TSS200          Island  0.5653638 
## cg00339556 Mar-11   5        TSS200          Island  0.6019743 
## cg01791874 Mar-11   5        TSS200          Island  0.6088933 
## cg17030173 Mar-11   5        TSS200          Island  0.6810216 
## cg17712694 Mar-11   5        TSS200          Island  0.6782042 
## cg16150752 Mar-11   5        TSS200          Island  0.6751433 
## cg21901718 Mar-11   5        TSS200          Island  0.5940712 
## cg18325622 Mar-11   5       TSS1500          Island  0.6687588 
## cg23065934 Mar-11   5       TSS1500          Island  0.7102811 
## cg11452391 Mar-11   5       TSS1500          Island  0.5707480 
## cg12456714 Mar-11   5       TSS1500          Island  0.6624979 
## cg16182986 Mar-11   5       TSS1500          Island  0.6292908 
## cg21582253 Mar-11   5       TSS1500         S_Shore  0.8338199 
##            controls_mean  delta_beta ttest_p.value 
## cg03829734   0.861480798  0.03778273  2.313262e-03 
## cg11584519   0.914438845 -0.11415582  9.645917e-06 
## cg03477332   0.567163090 -0.03834551  4.089740e-01 
## cg17507952   0.195742552  0.49537893  4.487314e-28 
## cg06782035   0.048061314  0.64132037  2.132044e-32 
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## cg03705912   0.118416110  0.56557171  4.948663e-28 
## cg23479922   0.022267736  0.65804644  1.771772e-39 
## cg09017434   0.038270911  0.59572787  7.427252e-36 
## cg15015920   0.103244226  0.46061486  4.783188e-20 
## cg25092681   0.016453770  0.54891004  2.347299e-25 
## cg00339556   0.003919504  0.59805476  1.052712e-25 
## cg01791874   0.008396659  0.60049668  8.474229e-27 
## cg17030173   0.061709554  0.61931204  8.268242e-31 
## cg17712694   0.022250197  0.65595398  8.567512e-29 
## cg16150752   0.011455593  0.66368771  2.024262e-28 
## cg21901718   0.008741432  0.58532982  4.032493e-25 
## cg18325622   0.087344247  0.58141458  4.785514e-28 
## cg23065934   0.025469431  0.68481169  1.600849e-34 
## cg11452391   0.024543183  0.54620477  4.153417e-28 
## cg12456714   0.093569586  0.56892830  1.337669e-23 
## cg16182986   0.140041057  0.48924976  1.113773e-21 























































































































































































































































































Appendix 4 Validating the ALL-methylated gene panel using four 
leukaemia cohorts 
This section compares the DNA methylation profile of the ALL-methylated gene panel 
across four leukaemia “validation” cohorts (see section 4.3). These cohorts are: Lee’s (B-
ALL subgroups; 450k array), Gabriel’s (B-ALL subgroups; 450k array), Hogan’s (ALL; 
27k array) and Wong & Bhadri’s (primary and xenograft ALL; 27k array) datasets.  
A4.1 Lee’s dataset (B-ALL subgroups; 450k array): 
Lee’s dataset has 73 cases of hyperdiploidy (plot: A), 52 cases of ETV6-RUNX1 
translocation (plot: B), six cases with TCF3-PBX1 translocation (plot: C), two cases with 
mixed lineage leukaemia (MLL) (plot: D), 73 cases with other cytogenetic mutations (plot: 
E) and 21 cases with unknown cytogenetics (plot: F). The plots show the distribution of 















































A4.2 Gabriel’s dataset (B-ALL subgroups; 450k array): 
Gabriel’s dataset contained ten cases of hyperdiploidy (plot: A), ten cases of ETV6-RUNX1 
translocation (plot: B), three cases with TCF3-PBX1 translocation (plot: C), and three 
cases with dic(9;20)  (plot: D). The plots show the distribution of DNA methylation for 








































A4.3 Hogan’s dataset (ALL; 27k array): 
Hogan’s dataset is a 27k array, which contained 35 cases of B-ALL and 33 control 
samples. The following plots were from ABC.RAP package using plot_gene function. The 
function produces four plots for each gene: the top left shows the difference in beta values 
between cases and controls for each gene probes arranged in 5’ to 3’ direction; the top 
right shows the mean methylation level for cases (red circles) and controls (blue triangles); 





difference in DNA methylation of cases minus controls for ^TES$




































mean DNA methylation for ^TES$
red circles = cases, blue triangles = controls




















^TES$ :DNA methylation for cases




















^TES$ :DNA methylation for controls














difference in DNA methylation of cases minus controls for NEFM


































mean DNA methylation for NEFM
red circles = cases, blue triangles = controls




















NEFM :DNA methylation for cases




















NEFM :DNA methylation for controls








difference in DNA methylation of cases minus controls for KITLG

































mean DNA methylation for KITLG
red circles = cases, blue triangles = controls




















KITLG :DNA methylation for cases




















KITLG :DNA methylation for controls














difference in DNA methylation of cases minus controls for KCNA4






































mean DNA methylation for KCNA4
red circles = cases, blue triangles = controls




















KCNA4 :DNA methylation for cases




















KCNA4 :DNA methylation for controls








difference in DNA methylation of cases minus controls for PAK7


































mean DNA methylation for PAK7
red circles = cases, blue triangles = controls




















PAK7 :DNA methylation for cases




















PAK7 :DNA methylation for controls














difference in DNA methylation of cases minus controls for ISL1































mean DNA methylation for ISL1
red circles = cases, blue triangles = controls




















ISL1 :DNA methylation for cases




















ISL1 :DNA methylation for controls







cg26059153 cg23751724 cg23127998 cg26082838
difference in DNA methylation of cases minus controls for MACROD2

































mean DNA methylation for MACROD2
red circles = cases, blue triangles = controls




















MACROD2 :DNA methylation for cases




















MACROD2 :DNA methylation for controls









A4.4 Wong & Bhadri’s dataset (primary and xenograft ALL; 27k array): 
Wong & Bhadri’s dataset is a 27k array containing ten B-ALL cases (plot: A) and ten 
leukaemia xenograft samples (B). The plots show the distribution of DNA methylation for 
CpG sites arranged from 5’ to 3’ direction. 
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